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ABSTRACT
Coronaviruses (CoVs) are positive-sense RNA viruses that can emerge from endemic
reservoirs and infect zoonotically, causing significant morbidity and mortality. CoVs encode an
endoribonuclease (EndoU) that cleaves RNA in biochemical assays, but the target and function
of EndoU activity during viral replication was not known. My work focused on characterizing
the functions of EndoU during infection. I report that EndoU is an innate immune antagonist. To
function as an immune antagonist, EndoU cleaves the 5’-Poly-Uridines from Negative-sense
viral RNA, termed PUN RNA, which is the product of polyA-templated RNA synthesis. Using a
virus containing an EndoU catalytic-inactive mutation, I detected a higher abundance of PUN
RNA in the cytoplasm of infected cells compared to wild type CoV-infected cells. Furthermore,
we found that transfecting PUN RNA into cells stimulates a robust, MDA5-dependent interferon
response, and that removal of the polyU-extension on the RNA dampens the response. Overall,
the results of this study reveal the PUN RNA to be a novel CoV MDA5-dependent pathogenassociated molecular pattern (PAMP). We also establish a mechanism for EndoU activity to
cleave and limit the accumulation of this novel PAMP. Since EndoU activity is highly conserved
in all coronaviruses, inhibiting this activity may serve as an approach for therapeutic
interventions against existing and emerging CoV infections.
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CHAPTER ONE
INTRODUCTION
The Biology of Coronaviruses
Overview and Classification
Coronaviruses (CoVs) are enveloped, positive-sense ribonucleic acid (RNA) viruses in
the taxonomic order Nidovirales. The Coronaviridae family is divided into two subfamilies:
Letovirinae, which contains the Alphaletovirus genus, and Orthocoronavirinae, which contains
four main genera: Alphacoronaivrus, Betacoronavirus, Deltacoronavirus, and
Gammacoronavirus (Lefkowitz et al., 2018). CoVs infect a wide range of avian and mammalian
species with most infections resulting in respiratory or gastrointestinal disease.
Viruses in the Nidovirales order are organized based on the phylogenetic similarity of the
genome structure. All nidoviruses have large positive-sense RNA genomes, with CoVs
containing genomes of 27 to 32 kilobases (kb) in length. The nidoviruses were aptly named due
to their ability to produce nested sets of RNA during infection. Nido means “nest” in Latin. CoVs
produce 7-9 nested, subgenomic RNAs (sgRNAs), which amplify the 3’ end of the genome
(Masters, 2006). Another common feature among nidoviruses is that the genomic organization is
conserved with a large replicase gene at the 5’ end of the genome, followed by structural and
accessory proteins at the 3’ end of the genome. The major differences in the nidoviruses derive
from the size, number, and type of structural proteins, which significantly alter the structure and
morphology of the virions (Fehr and Perlman, 2015).
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Genome Organization
CoVs carry non-segmented, single-copy, single-stranded, positive-sense RNA genomes,
which are about 30 kb in length. The viral genome has a similar appearance to host messenger
RNA (mRNA) since the genomic RNA (gRNA) is capped at the 5’end with a guanine residue
methylated at the N7 position, while the 3’ end of the genome contains a poly-adenosine (polyA)
tail. Since the viral RNA mimics host mRNA, the viral genome can be translated by host
ribosomes after insertion of the viral genome into the cytoplasm of cells (Fehr and Perlman,
2015; Masters, 2006).
The 5’ end of the genome contains an untranslated region (5’ UTR) with a small leader
(L) sequence. The 5’ UTR is highly structured with seven stem-loops being experimentally
determined to be critical for viral replication (Brown et al., 2007; Guan et al., 2011; Yang and
Leibowitz, 2015). The leader sequence includes the first 70-100 nt of the genome and a 6-8 nt
transcription-regulating sequence (TRS) (Baric et al., 1983; Lai et al., 1984, 1983). Each sgRNA
also contains identical TRS segments at the 5’ end of the RNA, which act as cis-acting
regulatory elements and are critical for the discontinuous transcription that occurs during sgRNA
replication (Budzilowicz et al., 1985; Sawicki et al., 2007; Sola et al., 2015). The 3’ end of the
CoV genome contains an untranslated region (3’ UTR) between 270 to 500 nt in length that
precedes the polyA tail. The 3’ UTR is also highly structured, containing an RNA pseudoknot
and several cis-acting elements essential for RNA replication (Goebel et al., 2004b, 2004a; Yang
and Leibowitz, 2015).
The remaining CoV genome can be divided into two major regions, with the first two
thirds of the genome coding for the replicase polyproteins and the last third of the genome
encoding structural and accessory proteins (Fig. 1B). Translation of the first two open reading
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frames (ORF), ORF1a and ORF1b, produces two replicase polyproteins, polyprotein 1a (pp1a)
and polyprotein 1ab (pp1ab)(Lai et al., 1994). While ORF1a is translated directly into pp1a,
pp1ab is produced by a -1 nt ribosomal frameshift (RFS) that occurs at a pseudoknot-slippery
sequence in ORF1. The slipping of the ribosome allows for continuation of translation through
ORF1b, producing pp1ab (Bredenbeek et al., 1990; Brierley et al., 1987). Both pp1a and pp1ab
are subsequently cleaved by viral proteases to generate 16 nonstructural proteins (nsp1-16),
which have a wide-range of activities. These activities include altering the host cell endoplasmic
reticulum (ER) membranes to form the replicase-transcriptase complex (RTC), replicating the
viral genome, and altering host innate immune signaling. The remaining third of the genome
contains multiple ORFs that encode for structural and accessory proteins. CoV structural proteins
include the envelope (E), membrane (M), nucleocapsid (N), and spike (S) proteins (Fehr and
Perlman, 2015; Masters, 2006). A subset of Betacoronaviruses also encode a hemagglutininesterase (HE) which is incorporated in the virion (Cornelissen et al., 1997; Kazi et al., 2005;
Klausegger et al., 1999). ORFs for accessory proteins are spread among the structural protein
ORFs. These accessory proteins differ for each CoV species and are generally dispensable for
viral replication. Many of the accessory proteins provide a selective pathogenic advantage to the
specific CoV species (Fehr and Perlman, 2015). This dissertation is focused on the murine CoV
mouse hepatitis virus, strain A59 (MHV-A59), which is a Betacoronavirus. The genome of
MHV-A59 contains 7 distinct viral mRNAs: 1 genomic full-length RNA and 6 sgRNAs. MHVA59 encodes the replicase and structural proteins as well as four distinct accessory proteins: ns2,
ns4a, ns4b, and ns5a (Masters, 2006). The functions of these proteins are discussed below.
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Figure 1. CoV Virion and Genome Structures. (A) Cartoon representation of mature CoV
virion. A host membrane that contains S, E, M, and HE proteins surround the viral (+) sense,
genomic RNA. The genomic RNA is coated with N protein. (B) Cartoon representation of the
CoV genome. The genome can be divided into two large segments, the replicase nonstructural
proteins and the structural/accessory proteins. The first two/thirds of the genome encodes a large
polyprotein that is cleaved into 16 nonstructural proteins (nsp1-16). The last third of the genome
encodes for the structural proteins, S, E, M, N, and HE, as well as multiple accessory proteins.
For MHV-A59, there are four known accessory proteins, ns2, ns4a, ns4b, and ns5a.
Virion Structure
Coronavirus virion. CoVs are spherical virions with diameters of approximately 125 nm
(Bárcena et al., 2009; Neuman et al., 2006). CoVs have a distinct corona or crown of proteins
extending from the virion like rays from a sun, hence the name “corona”-virus. This prominent
feature of the enveloped virus are the large trimeric, club-like S proteins projecting out from the
virion (Masters, 2006). The rest of the virion is contained within a host membrane-derived lipid
envelope. The virus particle contains 4 main structural proteins: S, E, M, and N proteins (Fig.
1A).
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Spike. The spike (S) protein is the main determinant host range and tissue tropism since
the virus uses S protein for cell attachment and entry. The S protein is about 150 kilodaltons
(kDa) in size and is heavily N-linked glycosylated. S protein utilizes an N-terminal sequence to
associate with endoplasmic reticulum (ER) membranes and become incorporated into the virion
(Neuman et al., 2006). For entry, the S protein is a class 1 fusion protein (Bosch et al., 2003;
Collins et al., 1982; Walls et al., 2019). S protein forms a homotrimer that can engage with host
cell surface proteins and/or sugars. For MHV-A59, the cellular protein receptor is
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1)(Holmes et al., 1990).
The spike protein can be divided into two subunits, S1 which is involved in receptor binding and
S2 which contains the stalk region of spike protein (Abraham et al., 1990; Luytjes et al., 1987).
Some coronaviruses also require cleavage by host cell furin-like protease to separate S1 and S2
subunits of spike to mediate fusion and entry into cells.
Envelope. The envelope (E) protein is an 8-12 kDa transmembrane protein that is present
in small quantities in the virion (Raamsman et al., 2000). The E protein encodes a predicted ion
channel, but the function of the protein is still yet to be determined. For example, deleting the E
protein is not always lethal to virus replication. In SARS-CoV, the ion channel function is not
necessary for viral replication, but is necessary for the pathogenesis of the virus in vivo
(Boscarino et al., 2008; Corse and Machamer, 2000; Fischer et al., 1998; Nieto-Torres et al.,
2014; Verdiá-Báguena et al., 2012; Ye and Hogue, 2007).
Membrane. The membrane (M) protein is the most abundant structural protein in the
virion. This small 25-30 kDa protein contains three transmembrane domains, with a small Nterminal glycosylated ectodomain and a larger endodomain. When present in the virion, the M
protein promotes membrane curvature and ultimately drives the shape of the virion (Neuman et
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al., 2011). The M protein is hypothesized to form a dimer, but likely utilizes multiple
conformations to function as a membrane altering protein (de Haan and Rottier, 2005; Fehr and
Perlman, 2015; Masters, 2006).
Nucleocapsid. The nucleocapsid (N) protein binds to the viral RNA. The 43-50 kDa N
protein contains two RNA binding domains, NTD and CTD (Chang et al., 2006; Hurst et al.,
2009). The N protein can be highly phosphorylated, which is hypothesized to trigger structural
changes and alter the affinity of RNA binding (Stohlman and Lai, 1979). The N protein has a
high binding affinity for the TRSs and packaging signal in the viral RNA (Molenkamp and
Spaan, 1997; Stohlman et al., 1988). N protein also interacts with nsp3 and the M protein, with
the M protein interaction driving packaging of the viral RNA into the virion (Sturman et al.,
1980). The N protein is found in the core of the virion, encompassing the genomic RNA.
Hemagglutinin-esterase. A subset of Betacoronaviruses also encode a hemagglutininesterase (HE) protein (King et al., 1985). The HE protein binds to sialic acids and contains acetyl
esterase activity (Cornelissen et al., 1997). The HE protein is predicted to enhance the
attachment of the S protein to host protein receptors and promote the spread of the virus through
mucosa. Interestingly, the HE protein is selected against during passage of the virus in cell
culture (Lissenberg et al., 2005).
Replication Cycle
Overview. CoV replication begins with the S protein binding to the cellular receptor. The
virion membrane can fuse with the cell surface or be incorporated into intracellular vesicles
through receptor-mediated endocytosis (Gallagher and Buchmeier, 2001; Millet and Whittaker,
2015). After a membrane fusion event, the single-stranded, positive-sense genome is released
into the cytoplasm of cells. This positive-sense RNA resembles host mRNA so the viral mRNA
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is translated by host ribosomes to produce the replicase polyproteins, pp1a and pp1ab. Pp1a and
pp1ab are then cleaved by viral proteases to produce sixteen nonstructural proteins (nsps)
involved in viral replication (Baker et al., 1993; Kanjanahaluethai et al., 2003; Masters, 2006;
Schiller et al., 1998). The functions of each nsp are diverse, but nsps are functionally conserved
between every coronavirus (Gorbalenya et al., 1989). For example, nsp12 encodes an RNAdependent, RNA polymerase (RdRp) for each coronavirus. Nsp3, Nsp4, and Nsp6 alter host
membranes to form convoluted membranes (CMs) and double-membrane vesicles (DMVs) to
generate the replicase-transcription complexes (RTCs) (Angelini et al., 2013). CoV RTCs have
two main functions. First, RTCs replicate full-length genomic RNA to be package into newly
synthesized virions to infect new cells. Second, RTCs produce sgRNAs through discontinuous
transcription to enhance production of structural and accessory proteins. Structural proteins are
translated, inserted into the ER membrane, trafficked to the ER-Golgi intermediate compartment
(ERGIC), and finally assembled into complete virions. N protein binds to newly synthesized
genomic RNA, which then buds into ERGIC membranes containing the remaining structural
proteins (Fehr and Perlman, 2015; Masters, 2006). These budded virions are then trafficked in
vesicles to the cell surface, where the new infectious virions are released from the cell (Fig. 2).
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Figure 2. Diagram of CoV Replication Cycle. The infectious virion binds to the cell surface
receptor. The virion either fuses at the cell surface or is endocytosed and fused to the cell
membrane in the endosome. Upon fusion, the genomic (+) RNA is released. The (+) RNA is
translated into replicase polyproteins, which are proteolytically cleaved into individual
nonstructural proteins (nsps). The replication proteins generate replicative membranes
(convoluted membranes and DMVS) from the ER and replicate the viral (+) RNA into (-) gRNA
and (-) sgRNAs. The (-) gRNA and (-) sgRNAs act as templates for (+) gRNA and (+) sgRNAs.
These (+) RNAs then are translated into structural proteins in the ER. The gRNA interacts with
structural proteins and virions bud into the ERGIC. The fully formed virions are then released
from the cell by exocytosis.
Attachment and entry. The initial attachment of the virion to the host cell is initiated by
the S protein binding to its receptors. Recent studies have shown the not only does S protein
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interact with a host protein receptor, but also contains a sialic acid binding domain that facilitates
cell entry (Qing et al., 2020). The interaction between the S protein and host receptor is the
primary determinant for what host species and tissues the virus can infect (Fehr and Perlman,
2015). Many Alphacoronaviruses utilize aminopeptidase N (APN) as their receptor, where
Betacoronaviruses have a range of host protein receptors. SARS-CoV and HCoV-NL63 utilize
angiotension-converting enzyme 2 (ACE2), whereas MERS-CoV uses dipeptidyl-peptidase 4
(DPP4)(Li et al., 2003; Raj et al., 2013; Wan et al., 2020). For MHV-A59, the cell receptor that S
protein binds to is murine CEACAM-1, but MHV can infect cell lines from multiple species
including monkey, feline, hamster, swine, and human cells (Schickli et al., 1997). Recent
structural studies have shown that S protein may “breath.” The S1a domain of the S protein has
two conformations, which open and close the receptor binding domain. Once the receptor binds
to the S protein, then the S1a domain is locked into the open state (Tortorici and Veesler, 2019).
Many CoVs also utilize other host proteins for cell entry. Recently the role of
tetraspanins and peptidases have been implicated in enhancing CoV entry into cells. Studies
show that many CoVs utilize peptidases to cleave the S protein to expose the fusion peptide to
the host membrane and facilitate fusion. The density and presence of host peptidases also alters
the tropism for CoV and can facilitate zoonotic shifts (Belouzard et al., 2012, 2009; Millet and
Whittaker, 2015). The cleavage is generally accomplished by acid-dependent proteolytic
cleavage by cathepsin, transmembrane protease, serine 2 (TMPRRS2), or another protease,
which then triggers cell fusion. S protein cleavage separates the receptor binding domain from
the fusion domain, freeing the fusion peptide to insert into host membranes (Earnest et al., 2017;
Glowacka et al., 2011; Park et al., 2016). Tetraspanins have been implicated in arranging host
receptors and peptidases into lipid rafts. The tetraspanin, CD9 drives the formation of protein
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rich domains on the cell surface, which is hypothesized to increase the interactions of the
receptor-bound S protein with a host peptidase, thus enhancing viral entry (Earnest et al., 2017).
Interestingly, there are interferon induced tetraspanins that can decrease cellular entry by CoVs,
suggesting a inhibitory role for some tetraspanins (Hantak et al., 2019).
Upon insertion of the fusion peptide into the host membrane, the S protein undergoes a
conformation shift indicative of class 1 fusion proteins. The S protein extends into the outer
leaflet of the host membrane then folds into an anti-parallel six-helix bundle, pulling the cell and
virion membranes into contact (Bosch et al., 2003). After formation of the bundle, the viral and
cellular membranes begin mixing forming a hemi-fusion state. Ultimately, the membranes will
completely fuse and release the viral genome into the cytoplasm of the cells (Fehr and Perlman,
2015).
Replicase protein translation. Upon release of the viral genomic mRNA into the
cytoplasm of the cell, host ribosomes will begin translation of the replicase polyproteins. The
replicase proteins are translated as two major polyproteins, pp1a and pp1ab. Pp1ab is generated
through a pseudoknot and slippery sequence causing a frameshift to occur during ribosome
translation. The RNA pseudoknot causes the ribosome to stall and shift -1 nt along the slippery
sequence (5’-UUUAAAC-3’). This frameshift causes the reading of the ORF to change and skip
the pp1a stop codon, allowing for the remaining pplab to be translated. A majority of the time,
the ribosome will unravel the pseudoknot and translate only ppla, but as high as 25% of the time,
the frameshift will allow for all of pp1ab to be translated (Lai et al., 1994). This frameshifting is
present in all nidoviruses and is hypothesized to control the replicase protein expression in a
precise ratio. Another hypothesis is that the frameshift delays the production of the 1b proteins
until a suitable replication membrane structure has been formed.
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After translation, ppla and pp1ab are cleaved by viral proteases into individual
nonstructural proteins. Pp1a is cleaved into nsp1-11 while pp1ab is cleaved into nsp1-16. CoVs
contain either two or three proteases for polyprotein cleavage. While most coronaviruses encode
two papain-like proteases (PLP1 and PLP2) within nsp3, Betacoronaviruses, SARS-CoV, and
MERS-CoV only contain one domain designated PLpro. All coronavirus encode a 3C-like
protease (3CLpro) in nsp5. The PLpros cleave between nsp1/2, nsp2/3, and nsp3/4 at a
conserved LXGG/X motif (Baker et al., 1993; Kanjanahaluethai et al., 2003). 3CLpro cleaves the
remaining 11 cleavage sites at a LQ/S motif to produce the individual nsps (Baker et al., 1989;
Gorbalenya et al., 1989). The known and predicted functions of all of the nsps are listed in Table
1.
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Table 1. Predicted Functions of Nonstructural Proteins. Listed are the functions that are
associated with each nonstructural protein (Nsp) and the studies that determined these functions.
Adapted from Fehr and Perlman 2015.
Protein
Nsp1
Nsp2
Nsp3

Nsp4
Nsp5
Nsp6
Nsp7
Nsp8
Nsp9
Nsp10
Nsp11
Nsp12
Nsp13
Nsp14
Nsp15
Nsp16

Function(s)

References

Inhibit host translation; Degrade host
mRNA; Block Innate Immune
Signaling
Binds prohibitin proteins
Multi-Domain: DMV formation
(Macrodomain): IFN antagonist
(PLPros): LXGG-specific protease;
Deubiquitinase; DeISGylase
(DPUP, Ubl2, NAB, G2M, SUD, Y):
Unknown Functions
DMV Formation
3CL-protease
DMV Formation
Hexadecameric complex with nsp8
Helicase for RdRp (nsp12)
Hexadecameric complex with nsp7;
Helicase for RdRp (nsp12); Potential
Primase; Adenyltransferase
RNA binding protein
Cofactor for nsp14 and nsp16
Promotes 2’-O-MT and ExoN activities
Unknown function
RNA-dependent RNA polymerase
DNA/RNA helicase

(Huang et al., 2011; Kamitani et al., 2009, 2006; Tanaka
et al., 2012)

N7 Methyltransferase
Exoribonuclease: RNA proofreading
activity
Endoribonuclease of Uridines; IFN
antagonist
2’-O-Methyltransferase (2’-O-MT);
IFN Antagonist

(Cornillez-Ty et al., 2009; Graham et al., 2005)
(Angelini et al., 2013; Baker et al., 1993; Chatterjee et
al., 2009; Fehr et al., 2015; Frieman et al., 2009; Mielech
et al., 2014; Niemeyer et al., 2018)

(Clementz et al., 2008; Gadlage et al., 2010)
(Lu et al., 1995)
(Oostra et al., 2008)
(Zhai et al., 2005)
(Imbert et al., 2006; Tvarogova et al., 2019; Zhai et al.,
2005)
(Egloff et al., 2004)
(Bouvet et al., 2014; Decroly et al., 2011)
(de Haan and Rottier, 2005)
(Brockway et al., 2003)
(Konstantin A Ivanov et al., 2004; Ivanov and Ziebuhr,
2004)
(Denison et al., 2011; Eckerle et al., 2007; Minskaia et
al., 2006)
(Bhardwaj et al., 2004, 2006; Deng et al., 2017, 2019; K.
A. Ivanov et al., 2004; Kindler et al., 2017)
(Chen et al., 2011; Decroly et al., 2008)

Replication complex structure. During replication, CoVs utilize host membrane to
derive replicative membrane structures. The two major structures generated during most CoV
replication are double membrane vesicles (DMVs) and convoluted membranes (CMs)(Gosert et
al., 2002; Knoops et al., 2008; Prentice et al., 2004; Shi et al., 1999; van der Meer et al., 1999).
In the nidovirus family, certain replicative structures are conserved. For example, coronaviruses
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and arteriviruses all form DMVs in some capacity. Interestingly, some nidoviruses do not
contain convoluted membranes, but instead alter membranes to produce paired membranes or
spherules from the ER (van der Hoeven et al., 2016). Since all nidoviruses alter host membranes,
the process is hypothesized to be crucial for viral replication and pathogenesis. Studies have
shown that DMVs contain newly synthesized RNA during MHV infection, again implicating the
necessity of the replication structures (Gosert et al., 2002).
Interestingly, nidoviruses contain a conserved region of the replicase polyprotein that
drives the rearrangement of host membranes. For CoVs, the proteins necessary for membrane
rearrangement is nsp3, nsp4, nsp5, and nsp6. Studies have shown that nsp3, 4, and 6 can
rearrange membranes during expression in cells, absent of viral RNA synthesis and replication
(Angelini et al., 2013; Clementz et al., 2008). Nsp5 is the main protease necessary for cleavage
of nsp4 and nsp6 from the polyprotein. Nsp3 contains many functional domains and upon
expression in cells, nsp3 will drive formation of perinuclear clusters of large multilamellar
vesicles and membrane bundles. Nsp4 and nsp6 do not have any known enzymatic activity, but
alter membrane rearrangement. Nsp4 shows reticular localization, but does not induce
membrane rearrangements on its own. When nsp3 and nsp4 are paired, maze-like bodies of
tubular membranes are formed inside the cells. When nsp6 is expressed, single-membrane
vesicles accumulate around microtubule organization centers. It is hypothesized that the
membrane pairing activity of nsp3 and nsp4 and the vesicle induction by nsp6 ultimately leads to
the formation of DMVs and CMs in cells. (Gosert et al., 2002; Knoops et al., 2008; Neuman et
al., 2014).
RNA replication and transcription. Following the translation, cleavage, and assembly
of the replication complex proteins and structures, viral RNA synthesis occurs. RNA synthesis
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generates new gRNA as well as sgRNA. SgRNA serves as mRNA for structural and accessory
proteins. All positive-sense (+) sgRNAs are produced 3’ co-terminal with the sgRNAs being
nested within each other. To generate more gRNA and sgRNA, the positive-sense RNA is first
replicated into negative-sense (-) gRNAs and sgRNAs, which then acts as a template for
positive-sense RNA synthesis. The negative-sense RNAs are about a 0.1% as abundant as
positive-sense RNA and contain a poly-uridylate and anti-leader sequences (Masters, 2006; Sola
et al., 2015).
Viral RNA replication begins with synthesis of negative-sense gRNA and sgRNA. The
transcription is completed by nsp12, the RNA-dependent, RNA polymerase (RdRp). Also nsp7
and nsp8 are hypothesized to be necessary for RNA synthesis. Nsp7 is predicted to form a
helicase for RNA binding, while nsp8 is a predicted primase. In fact, the structure of the nsp7nsp8-nsp12 complex has been solved by cryo-EM (Kirchdoerfer and Ward, 2019). The current
model for RNA synthesis is through two steps, continuous replication of genomic RNA and
discontinuous transcription of sgRNA. RNA structure and sequence at the 3’ UTR of the (+)
RNA recruits the replication proteins to the end of the genome. Nsp8 will generate a short RNA
primer, which then binds in the polyA tail of the positive sense, forming the beginning of the (-)
RNA. Nsp12 then synthesizes the remaining genomic (+) RNA is a continual transcription
process (Masters, 2006; Sola et al., 2015).
Interestingly, each (+) sgRNA contains a short leader sequence (about 100 nt) at the 5’
end of the RNA similar to the full-length genomic RNA. The “attachment” of the leader
sequence is hypothesized to occur during (-) sgRNA synthesis though a mechanism of
discontinuous transcription (Sawicki et al., 2007; Sola et al., 2015)(Fig. 3). CoVs contain
multiple transcription regulatory sequences (TRS) in the beginning of each sgRNA. The TRS
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within the leader sequence (TRS-L) binds to TRSs in the body (TRS-B) which precede each
sgRNA. The TRS has a conserved core sequence which is 6-7 nt in length. Since the core
sequence is identical between the TRS-L and TRS-B sites, the TRS-L can basepair with a
nascent (-) sense TRS-B. This base pairing drives the template to switch from the nascent RNA
to the leader sequence and transcription continues through the leader to the end of the RNA.
This process generates (-) sgRNA that contains the TRS sequence with an anti-leader sequence
attached. The attachment of leader sequences implies a premature termination of synthesis and a
template switch to the leader sequence, which would require long-distance RNA-RNA
interactions. After the replication of the (-) gRNA and sgRNAs, these (-) sense RNAs act as
templates for (+) mRNA synthesis. RNA secondary structure and sequences in the anti-leader
sequence recruits the replication machinery. The replication machinery then begins transcription
of the leader sequence and ORFs. Interestingly, longer sgRNAs can produce the smaller, nested
sgRNAs as well.
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Figure 3. Model of Discontinuous RNA Transcription during CoV Replication. This
diagram represents the hypothesis that the (-) sense, sgRNAs obtain leader sequences through
discontinuous transcription. Upon infection, the (+) sense, genomic RNA is released into the
cytoplasm and replication complex proteins are translated. 1) Viral proteins will bind to the
genomic RNA and form an RNA/Protein complex. Proteins will interact with the transcription
regulatory sequences (TRS) at the leader region (TRS-L) or body (TRS-B) of the genomic RNA.
The proteins will then facilitate long distance RNA interactions between the TRSs. 2) The RdRp
will begin transcription of the (-) sense RNA starting in the polyA tail. 3) Upon transcription, the
RdRp will continue to transcribe new (-) sense RNA. 4) After reaching a TRS, occasionally the
RdRp will switch templates from the TRS-B to the TRS-L. This results in the RdRp to now
transcribe the leader sequence to the end of a shortened (-) sense RNA, generating the (-) sense
sgRNA. 5) Upon reaching the terminal end of the leader sequence, the newly transcribed (-)
sense, sgRNA is released.
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After transcription of the (+) gRNA and sgRNAs, the RNA is processed by numerous
viral proteins to prevent host RNA sensor recognition. To pass as mRNA, viral RNAs are
capped at the 5’end by a canonical 4-step capping mechanism of: 1) RTPase activity, encoded by
nsp13 helicase, which hydrolyzes the gamma-phosphate of the mRNA; 2) guanylyltransferase
activity to add GMP to the 5’-diphosphate RNA, which has yet to be assigned to an nsp; 3) N7MTase activity, encoded by nsp14, which methylates the guanosine, leading to a cap-0 structure;
and 4) 2’-O-methyltransferase activity, encoded by nsp16, carrying out further methylations and
producing to cap-1 and cap-2 structures. Thus CoV RNA appears like cellular mRNAs, which
allows them to escape host detection (Chen and Guo, 2016; Sawicki et al., 2007; Sola et al.,
2015). The 3’ end of the genome also contains a long polyA tail, similar to host mRNA. This
tail has recently been proposed to be attached through a non-canonical cytoplasmic adenylation
signal that is encoded within the 3’UTR. Briefly host cleavage and polyadenylation specificity
factor (CPSF) binds to an AGUAAA signal which recruits host proteins such as polyA binding
protein (PABP). These host proteins will cleave at a cytidine residue and synthesize a new
polyA tail on the RNA (Peng et al., 2016). Also, a study has determined that nsp8 contains 3’terminal adenylyltransferase activity, which could add a polyA tail onto the end of the RNA
(Tvarogova et al., 2019).
Since coronaviruses have a long RNA genome, the viruses also encode a proofreading
system to maintain sequence fidelity. Nsp14 encodes an exonuclease (ExoN) as well as the N7MTase, which upon ExoN mutation leads to a 15- to 20-fold increase in mutation accumulation
(Eckerle et al., 2007; Minskaia et al., 2006). The removal of ExoN activity also increases the
susceptibility of CoVs to mutagens such as ribavirin and 5-fluorouracil (Denison et al., 2011).
Interestingly nsp10 has been linked to ExoN and nsp16 methyltransferase activities (Bouvet et
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al., 2014; Decroly et al., 2011). Nsp14 and Nsp16 bind to nsp10 in overlapping sites on nsp10
which suggests a molecular switch, mediating interactions between RNA for proofreading and
mRNA capping machineries.
Virion assembly and release. Following viral mRNA transcription, viral structural
proteins are translated and the S, E, and M proteins are inserted into the endoplasmic reticulum.
The proteins are trafficked to the ER-Golgi intermediate compartment (ERGIC). The genomic
mRNA is encapsidated by N protein, which then binds to M protein in the ERGIC and buds into
a new virion (Krijnse-Locker et al., 1994; Tooze et al., 1984). While M protein directs the
protein-protein interactions for virion formation, E protein is also necessary for viral particles to
form. S protein is involved in this step but is not required for packaging. The interaction site
between N protein and M protein has been mapped to the C-terminus of the endodomain of M
protein and the CTD of the N protein, however it is unclear how the nucleocapsid traffics to the
ERGIC with viral RNA in tow. It is also unknown how only (+) sense RNA is packaged. MHV
contains a packaging signal in the nsp15 coding sequence but mutating this signal does not affect
virus production. Also, most coronaviruses do not contain a similar packaging signal, so this
may be MHV specific (Fehr and Perlman, 2015; Masters, 2006).
After mature virions bud from the ERGIC, the virions are trafficked to the cell surface in
vesicles and released by exocytosis. Additionally, S proteins that are not packaged into virions
are transported to the cell surface where they function as cell-cell fusion proteins. Briefly, S
proteins will interact with receptors on neighboring cells, causing fusion of cell membranes and
formation of multinucleated syncytia. This allows the virus to spread cell to cell without
exposure to extracellular factors like neutralizing antibodies.
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Innate Immune Responses to RNA Virus Infection
Overview
The host immune system is constantly encountering and combatting pathogen invasions.
Due to the presence of pathogens, innate and adaptive immune systems have evolved to detect
and suppress the growth of invading pathogens. For viral infections, the innate immune system
provides the initial immune response. The innate immune system senses viral particles, viral
proteins, and viral nucleic acids and signals for an appropriate immune response to impair the
growth and disease caused by the virus. The sensing of the viral infection is accomplished by
pattern recognition receptors (PRRs). PRRs will recognize pathogen-associated molecular
patterns (PAMPs), which will activate the PRR to signal for an anti-viral state in cells. One
major antiviral signal produced during innate immune activation is Type I Interferon (IFNα and
IFNβ). IFNs are cytokines that activates multiple interferon-stimulated genes (ISGs), which in
turn have multiple antiviral functions to inhibit viral replication. Through autocrine and
paracrine signaling, IFN binds to IFN receptors on the cell surface to signal the upregulation of
hundreds of ISGs, which then induce an anti-viral state (Müller et al., 1994; Trinchieri, 2010).
Pathogen-Associated Molecular Patterns (PAMPs)
In order to stop viral replication, cells must first recognize that it has been infected with
the virus. Cells initiate the innate immune response by detecting fragments or characteristics of
the virus replication cycle. PAMPs are pathogen-derived molecular signals that are recognized as
“non-host” by host sensors. PAMPs can be proteins, lipids, nucleic acids, or small molecules,
but are not naturally produced by host cells absent of infection. PRRs will recognize and bind to
a unique PAMP, which leads to activation of specific cellular pathways. For this document,
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specific RNA PAMPs and PRRs will be discussed, specifically RNA PAMPs during CoV
infection and RNA-specific PRRs (Kato et al., 2006).
RNA PAMPs. RNA PAMPs are ribonucleic acids that are recognized as non-cellular
RNA. Usually RNA PAMPs contain unique secondary structures or are “missing” cellular RNA
modifications. To understand how viral RNAs can differ from host RNA, it is first important to
know what cellular RNAs look like.
Generally cellular RNA is generated in the nucleus or mitochondria of cells, then is
transported to the cytoplasm, where the RNA is most active. Host RNA polymerases (Pol-I, PolII, and Pol-III) transcribe different types of RNAs. Pol-I transcribes ribosomal RNAs, Pol-II
transcribes mRNA, and Pol-III transcribes tRNA. These polymerases generate a precursor
transcript with a 5’ triphosphate on the RNA. Before translocation out of the nucleus or
mitochondria, the RNA is then modified by host proteins to remove the 5’ triphosphate.
Ribosomal RNA is cleaved by a phosphatase to remove the triphosphate. mRNA is capped
through N7-guanosine methylation. Host tRNAs are cleaved to remove the triphosphate or
methylated to prevent detection. The 3’-end of mRNA also contains a poly-adenosine (polyA)
tail that is attached through host polyadenylation factors. Host RNAs also contain internal
modifications. ADAR1 deaminates adenosine residues to inosines, which destabilize RNA stem
loop structures. This is used to prevent Alu elements in certain mRNAs from forming dsRNA
stem loops that are immunostimulatory. Host tRNAs are modified by ribose 2’O methylation of
internal guanosines, which dampens immune stimulation by the tRNAs (Bouvet et al., 2014;
Brocard et al., 2017; Ramanathan et al., 2016). If viral RNAs do not mimic host RNA structures
and modifications, then they may activate innate immune sensors.
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Two predominant viral RNA signals that activate host sensors are a 5’ triphosphate on
RNA and dsRNA. Since most viruses use relatively simple replication machinery, the viral
RNAs resemble premature cellular RNAs and contains 5’ triphosphate ends. CoV (+) sense RNA
actually lacks the 5’ triphosphate due to the viral proteins that cap the RNA (Kindler and Thiel,
2014). The RNA that activates innate immunity during CoV infection was thought to be dsRNA
(Deng et al., 2017; Kindler et al., 2017; Roth-Cross et al., 2008). Since CoVs replicate through
long strands of complement RNA, there are dsRNA species formed from the gRNA and each
sgRNA that are thousands of basepairs long (Lai et al., 1982; Sethna et al., 1991). Long
complemented dsRNA species do not normally exist in host cells, so these long dsRNA are
detected as PAMPS by host sensors. Previous studies utilize synthetic polyI:C as a long dsRNA
PAMP to determine the pathways that detect dsRNA. Researchers hypothesized that CoV
dsRNA formed by complementary strands of RNA thousands of basepairs in length will form a
PAMP and activate host sensors.
Development of dsRNA antibodies. To study dsRNA in cells, researchers generated
monoclonal antibodies directed against dsRNA epitopes (Schonborn et al., 1991). To develop the
dsRNA antibodies, mice were immunized with yeast L-dsRNA (Sweeney et al., 1976), and
murine plasmablasts were isolated and screened for antibody specificity. The anti-dsRNA
monoclonal antibodies (mAbs) were screened for their binding to ssRNA, ssDNA, dsDNA, and
dsRNA. The researchers selected antibodies that only bound to dsRNA with high affinity with no
additional binding to ssRNA, ssDNA, or dsDNA. The developed antibodies are now available
for purchase from Scicons Inc., and designated as mAb K1 and J2 (www.scicons.eu). The antidsRNA mAbs have mainly been used to detect viral dsRNA during infection of cells. One of the
techniques for viral dsRNA detection is immunofluorescence. For CoV infection, the dsRNA
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signal is detected by immunofluorescence and the dsRNA signal co-localizes with CoV
replication complexes (Weber et al., 2006). Using immuno-gold EM staining with a dsRNA
antibody, the dsRNA signal is localized within DMVs during SARS-CoV infection (Knoops et
al., 2008). This dsRNA result led to the hypothesis that CoV dsRNA is sequestered within
DMVs, which prevents the dsRNA from being detected by host PRRs.
Although these antibodies have been integral in detecting viral dsRNA, the exact epitopes
that the antibodies bind to on the viral RNA are not fully understood. A previous study found
that the J2 anti-dsRNA mAb antibody bound to a dsRNA signal that was at least 40 nucleotides
(nt) long (Bonin et al., 2000). The dsRNA antibody also preferentially bound to polyA:U or
mixed based pairs compared to polyI:C. It remains to be determined if the epitope that these
antibodies recognize are RNA sequence or RNA structure dependent.
Interferon Signaling
Once the viral PAMPs are produced, the cell must recognize and react to the viral
infection. One characterized innate immune pathway in response to viral infections is the
interferon signaling pathway. Interferons were discovered in the 1950’s as supernatant cytokines
that would inhibit influenza virus replication (Isaacs et al., 1957; Isaacs and Lindenmann, 1957).
Upon detection of viral PAMPS, PRRs will signal for cells to express interferon, which is then
secreted by the cells. The secreted interferon will interact with interferon receptors, which leads
to an upregulation of genes involved in forming an antiviral response (Müller et al., 1994). The
interferon response is crucial for cells to control viral replication and to limit damage to the host
during a viral infection.
Type I interferons. Interferon (IFN) is a family of cytokines that are recognized as key
component for defense against viral infections. There are three major types of IFN, type I (IFNα
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and IFNβ), type II (IFNγ), and type III (IFNλ). Each type of IFN has its own specific cellular
receptor that the IFN signals through. Type I signals through IFNα receptor (IFNAR), Type II
signals through the IFNγ receptor (IFNGR), and Type III signals through the IFNλ Receptor
(IFNLR)(Sadler and Williams, 2008). For this dissertation, I will address type I IFN expression
and signaling pathways.
Type I IFNs have many subsets of cytokines with 13 IFNα’s, IFNβ, IFNκ, IFNε, IFNο,
IFNτ, and IFNδ all signaling through the IFNAR. While the function of the overall class of type I
IFNs has been well characterized for inhibiting viral infections, what the differences are between
the subsets of type I IFN is not well known. Studies using IFNAR-/- mice have shown that mice
lacking type I IFN signaling have increased susceptibility to numerous virus and microbial
infections (Müller et al., 1994). These studies show that a type I IFN response is necessary to
control viral pathogenesis in vivo and limit the ability of viruses to replicate inside the host cell.
IFN expression stimulated by RIG-I-like receptors. Type I IFN can be produced by
almost any cell type (de Weerd and Nguyen, 2012). Transmembrane or cytosolic receptors, such
as RIG-I-like receptors (RLRs), will recognize a PAMP and activate the IFN signaling pathway.
These receptors will bind to PAMPs and activate a host signaling cascade to induce the cells to
express IFN. The RLR class of receptors consist of retinoic acid-inducible gene I (RIG-I),
melanoma differentiation associated protein 5 (MDA5), and Laboratory of Genetics and
Physiology protein 2 (LGP2). RLRs belong to the Asp-Glu-Ala-Asp (DEAD) box family and
contain an RNA helicase domain with ATPase activity and a C-terminal Domain (CTD), which
mediates the specificity of RNAs detected by the sensor. RIG-I and MDA5 also contain two
caspase activation and recruitment domains (CARDs), which allow for signaling by CARD
dimerization with the mitochondrial antiviral signaling protein (MAVS) (Yoneyama et al., 2004).
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Deletion studies have shown that RIG-I and MDA5 recognize different types of viral infections,
indicating that each sensor recognizes a specific RNA target (Kato et al., 2006). In contrast to
RIG-I and MDA5, LGP2 is not well understood. LGP2 can act as a negative regulator for RLR
signaling but can also activate IFN (Saito and Gale Jr, 2008). Recent studies have shown that
LGP2 acts as a positive regulator for MDA5 signaling (Bruns et al., 2014; Uchikawa et al.,
2016). An important aspect of RLRs is that they recognize and bind to dsRNA, although not all
types of dsRNAs will activate the sensors.
The host pattern recognition receptor that is central to the studies in this dissertation is
MDA5. Previous studies showed that MDA5 binds to and recognizes long dsRNA signals
(>1,000 bp)(Kato et al., 2008), but MDA5 has also been shown to be activated by higher-order
structured RNA (Pichlmair et al., 2009) and RNAs lacking 2-O-methylation (Züst et al., 2011).
Upon multiple MDA5 proteins binding to a long dsRNA strand, the CARD domains of MDA5
will bind and induce oligomerization of MDA5 proteins. The oligomerized MDA5 proteins then
act as a scaffold for binding and oligomerization of downstream signaling proteins like
mitochondrial antiviral-signaling protein (MAVS). The binding of MDA5 to MAVS leads to a
nucleation of MAVS proteins, which then form MAVS helical filaments on the mitochondrial
surface (Reikine et al., 2014) The MAVS filaments serve as a platform for further signaling
events. MAVS signals a kinase cascade to phosphorylate TBK1 and IKKi, which then activates
IRF3 to translocate to the nucleus of the cell. IRF3 interacts with IRF7 and binds to promoter
sites upstream of IFN to begin transcription of IFN mRNAs (Trinchieri, 2010). The IFN mRNA
is subsequently translated and the IFN protein is secreted from the cell for autocrine and
paracrine signaling. The secreted IFN will then bind to host receptors, with type I IFN interacting
with IFNAR on surface of the cell (Fig. 4).

25

Activating interferon stimulated genes. For IFN to induce an antiviral state in a cell,
the IFN cytokine must signal for the induction of IFN-stimulated genes (ISGs). Upon binding of
type I IFN to the IFNAR, the IFNAR activates a signaling cascade inside the cell. IFNAR is
present on all cell types, so this signaling pathway could occur in any cell of the body (de Weerd
and Nguyen, 2012). IFNAR signals through two Janus family kinases, Jak1 and Tyk2, which
results in the recruitment of STAT1 to STAT2 and the formation of a STAT1-STAT2
heterodimer. This STAT1-STAT2 heterodimer migrates to the nucleus of cells and interacts with
transcription factors, such as IFN regulatory factor (IRF) 9 and IFN-stimulated gene Factor 3
(ISGF3). The activated transcription factors then bind to upstream IFN-stimulated response
elements (ISRE), which promotes transcription of IFN-stimulated genes (ISGs) (Trinchieri,
2010). The IFN-induced transcription is regulated by the post-translational modification of
STATs, chromatin remodeling, the epigenetic landscape, and other transcription factors, coactivators, and co-repressors (Ivashkiv and Donlin, 2014). The binding of IFNs to the IFNAR
leads to upregulation of over 300 genes, most of which have been shown to have antiviral
functions (Der Zhou 1998). These interferon-stimulated genes (ISGs) will produce an antiviral
state not only in the virally infected, IFN-producing cells, but also in uninfected neighboring
cells, limiting the spread of the viral infection (Fig. 4).
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Figure 4. IFN Signaling Pathways. MDA5 senses dsRNA in the cytoplasm of the cell and
oligomerizes on the dsRNA. The MDA5 activates MAVS which leads to a phosphorylation of
TBK1 and IKKi. The activated TBK1 phosphorylates IRF3 and IRF7, which translocate to the
nucleus and signal for production of IFN mRNA. IFN protein is produced and secreted from the
cell. Type I IFN binds to and activates IFNAR at the cell surface. IFNAR activation
phosphorylates Jak1 and Tyk2, which then phosphorylate STAT1 and STAT2, causing
dimerization. Dimerized STAT1 and STAT2 bind with IRF9 and ISGF3, translocate to the
nucleus, and bind to an ISRE to signal for production of ISGs.
Interferon-Stimulated Genes (ISGs)
Upon IFN signaling, cells will induce multiple proteins that have a range of anti-viral
functions. These functions can be RNases, proteases, ubiquitinating proteins, proteins that alter
membrane rigidity or permeabilization, etc. Some of these proteins are ADAR1, ISG20, IFIT1,
IFIT2, ISG15, ISG54, Mx1, PKR, and OAS. Many of the host PRRs that regulate IFN signaling
are also upregulated by IFN, forming an amplification signaling loop. In addition to the
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production of ISG proteins, IFN-induced microRNAs that can also alter expression of cellular
proteins (Pedersen et al., 2007). Two of the ISG proteins, PKR and OAS, are discussed below.
Protein Kinase R. Protein Kinase R (PKR) is a host dsRNA receptor. PKR is an ISG that
can be induced by type I or type III IFN signaling. The upregulation of PKR during antiviral
states leads to the alteration of numerous cellular pathways (Gal-Ben-Ari et al., 2019; Kuhen and
Samuel, 1997). Upon PKR binding to dsRNA, PKR forms a homodimer and autophosphorylates
itself (Taylor et al., 2001). The phosphorylated PKR is then an active kinase which will
phosphorylate numerous host proteins. One protein PKR phosphorylates is eIF2α, which
prevents eIF2α from initiating translation by host ribosomes thus inhibiting translation of cellular
proteins (Hoang et al., 2018). PKR activation also leads to the activation of the FADD apoptotic
pathway, eventually leading to cell death (García et al., 2007). Regardless of whether eIF2α
phosphorylation will inhibit the protein translation, the apoptosis of the infected cells leads to
antiviral response and inhibition of viral replication. (Gal-Ben-Ari et al., 2019; Krahling et al.,
2009).
2’5’ Oligoadenylate Synthase. 2’5’ oligoadenylate synthetases 1 and 2 (OAS1/2) are
proteins from a family of interferon-induced PRRs that bind and recognize dsRNA. OAS binding
to dsRNA activates OAS enzymatic activity, which polymerizes ATP into 2’-5’-linked oligomers
(Rebouillat et al., 1998). The 2’5’ oligoadenylates then bind to RNAse L and activate the RNAse
activity of the enzyme (Dong and Silverman, 1995; Ogden et al., 2015). This process is regulated
by a 2’5’ phosphodiesterase, which degrades the 2’5’ oligoadenylate and prevents RNAse L
activation (Silverman and Weiss, 2014). RNAse L will cleave any host and viral RNA. The
RNAse L activity will eliminate the viral genome, prevent viral protein production, and damage
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host machinery that are necessary for viral replication. Eventual loss of the host RNA leads to
apoptosis of the cell, further preventing viral replication (Silverman, 2007).
Coronavirus Immune Antagonists
Overview
Viral infection can induce the expression of IFNs just hours after initial viral infection.
Since IFN signaling and ISGs induce an antiviral state, many viruses encode proteins that will
inhibit or antagonize the innate immune signaling pathways. CoVs are notorious for delaying
IFN responses (Channappanavar and Perlman, 2017; Menachery et al., 2014; Roth-Cross et al.,
2008; Totura and Baric, 2012). CoV-infected cells will eventually express IFN and stimulate the
production of ISGs, but the delayed IFN response leads to a dysregulation of the overall innate
immune response. The expression of IFN during CoV infection is stimulated through a MDA5mediated pathway, suggesting that viral dsRNA is detected during infection (Roth-Cross et al.,
2008).
The delayed IFN signaling during CoV infection leads to detrimental dysregulation of
innate immune signaling during in vivo infection. There are two pathogenic types of human
CoVs, low pathogenic and highly pathogenic CoVs. Low pathogenic CoVs cause a mild
respiratory illness, whereas high pathogenic CoVs, like SARS-CoV and MERS-CoV, will infect
lower airways and can cause fatal pneumonia. The CoV-induced pneumonia is associated with
massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine
profiles, which results in acute lung injury and acute respiratory distress syndrome. For both
SARS-CoV and MERS-CoV, viral infection leads to extensive infiltration of neutrophils and
macrophages in the lungs of infected patients. The lung histology showed lung consolidation and
edema, which led to loss of lung function. The increased inflammatory cell infiltration is driven
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by significant upregulation of pro-inflammatory chemokines, such as CCL3, CCL5, CCL2, and
CXCL10. Similarly, infected patients have enhanced expression of pro-inflammatory cytokines,
such as IFNγ, IL-1, IL-6, and IL-12 (Channappanavar and Perlman, 2020, 2017). Interestingly,
treating mice with IFNs early during SARS-CoV and MERS-CoV infection significantly reduced
the pro-inflammatory response and reduced immunopathogenic disease (Channappanavar et al.,
2019, 2016). These studies highlight that appropriate timing of IFN signaling is crucial for
controlling the pathogenesis of CoV infections.
One cell type that is important in the regulation of the innate immune response to CoVs is
the macrophage. For MHV, macrophages play a crucial role in recognizing and inducing the type
I IFN signal (Cervantes-Barragán et al., 2009; Roth-Cross et al., 2008). Priming macrophages
with IFN, leads to an enhancement of an antiviral state and decrease in the immunopathogenesis
caused by CoV infection (Zhou et al., 2010). Using virus infection of macrophages, we can
identify and evaluate the viral factors involved in antagonizing innate immune pathways. We and
others found that removing the activity of viral innate immune antagonists resulted in reduced
levels of virus replication in cell culture and attenuation of disease in vivo (Deng et al., 2017;
Kindler et al., 2017). Many groups hypothesize that mutating the CoV immune antagonists,
which allows for early detection of the virus replication and an early IFN response, will produce
a live-attenuated vaccine strain (Deng et al., 2017, 2019; Menachery et al., 2018). Many studies
have therefore sought to determine the mechanisms of which CoV proteins will inhibit IFN
signaling and innate immunity.
Hiding the Viral RNA/Mimicking Host mRNA
One strategy for CoVs to inhibit innate immune signaling has been to mimic host mRNA
and hide the viral PAMPs from detection by host sensors. The genomic positive-sense RNA has
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characteristics of host mRNA, so will appear as “native” RNA to host sensors. Viral proteins are
involved in capping viral RNAs. RIG-I is able to detect RNA containing 5’-triphosphates, which
normally are not present on host RNA. CoVs encode an RNA-triphophatase (nsp13), a N7methyltransferase (nsp14), and a 2’-O-methyltransferase (nsp16). These viral proteins mimic
host machinery to cap the viral RNA, thus preventing immune activation (Kindler and Thiel,
2014). CoV mRNA also contains a polyA tail, again mimicking host mRNA. The addition of the
polyA tail is possible performed by nsp8 (Tvarogova et al., 2019).
In addition to mimicking host mRNA, viral dsRNA signals are proposed to be
sequestered by viral replication complexes. Immuno-gold electron microscopy staining showed
that viral dsRNA signal was localized within DMVs (Knoops et al., 2008). The DMVs are not
open to the cytoplasm of cells, so cytoplasmic sensors cannot physically interact with RNA
inside of DMVs. While the dsRNA signal is localized to DMVs early in infection, the dsRNA
will disperse into more cytoplasmic staining late in infection (Becares et al., 2016). This
dispersal of the dsRNA signal may be the signal that induces late IFN signaling during CoV
infection. While dsRNA may be sequestered away from host sensors and other viral RNAs
mimic host mRNA, further studies are necessary to determine what the RNA signal is what
activates host innate immune pathways late during CoV infections.
Overexpression of CoV Innate Immune Antagonists
Many studies have sought to identify the viral protein(s) that antagonize host signaling
pathways. To determine which viral proteins are important, researchers overexpressed CoV
proteins in the context of IFN stimulation to determine if the viral proteins would inhibit the IFN
signal. For example, if SARS-CoV nsp1, PLpro, nsp7, nsp15, or ORF6 proteins are expressed
during the infection of an IFN-stimulating virus, then the IFN stimulation is reduced, showing
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potential roles of IFN antagonism for these proteins (Frieman et al., 2009). Overexpression
studies have provided evidence that indicates that viral proteins can inhibit innate immune
pathways. For CoV, many accessory proteins can inhibit innate immune signaling. SARS-CoV
ORF3b and ORF6 will prevent the translocation of IRF3 to the nucleus after MDA5 activation
(Freundt et al., 2009; Kopecky-Bromberg et al., 2007). Additionally ORF6 can block nuclear
import, thus inhibiting the signaling pathway of IFN (Hussain and Gallagher, 2010). The
overexpression of SARS-CoV ORF3a induces ER stress in cells and downregulates the IFNAR1
protein expression, which will dampen IFN responses (Minakshi et al., 2009). For MERS-CoV,
overexpression of ORF4a will inhibit MDA5 activation though interactions with dsRNA, as well
as prevent PKR activation in cells (Niemeyer et al., 2013; Rabouw et al., 2016).
Overexpression of replicase proteins can also inhibit innate immune signaling. SARSCoV PLPro, which contains protease, deubiquitinating activity, and deISGylating activity, can
inhibit IFN induction (Clementz et al., 2010), can block IRF3 and NF-κB signaling (Frieman et
al., 2009), and inhibit STING signaling (Sun et al., 2012). MHV PLP2 also functions as
protease, deubiquitinase, and deISGylatilase, which can prevent IFN induction in cells (Mielech
et al., 2014; Yang et al., 2014). Overall, ectopic expression of CoV proteins have led to the
identification of multiple potential IFN and innate immune antagonists.
Generating Coronaviruses with Inactive Immune Antagonists
To determine if CoV proteins functioned as immune antagonists, CoVs containing
mutations in IFN antagonists were generated using reverse genetics. A list of all innate immune
antagonists that have been determined during CoV infection is listed in Table 2.
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Table 2. Innate Immune antagonists during CoV Infection. Listed are the studies that
generated viruses that contained mutations in innate immune antagonists.
Virus

Viral Protein

Target; Enzymatic Activity

References

SARS

ORF6

Inhibits Nuclear Import

(Frieman et al., 2007)

Nsp1

Block Phosphorylation of
STAT1

(Wathelet et al.,
2007)

Ns4a

Inhibits PKR Phosphorylation

(Comar et al., 2019)

Ns4b

Inhibits activation of RNAse L

(Comar et al., 2019)

Nsp16

Necessary for IFN resistance and
pathogenesis; 2’-OMethyltransferase

(Menachery et al.,
2017, 2018)

Ns2

Inhibits RNAseL activation;
2’-phosphodiesterase

(Zhao et al., 2012)

Nsp15

Inhibits production of dsRNA
PAMP; Endoribonuclease

(Athmer et al., 2018;
Deng et al., 2017;
Kindler et al., 2017)

ORF5a

Inhibits IFN expression

(Koetzner et al.,
2010)

Nsp3/PLP2

Inhibits IFN expression;
Deubiquitinase, Protease,
DeISGylase

(Mielech et al., 2015)

MERS

MHV

Nsp3/Macrodomain Inhibit IFN expression;

(Deng et al., 2019)

Nsp14

Necessary for IFN resistance;
Exonuclease

(Case et al., 2017)

HCoV-229E

Nsp15

Inhibits activation of dsRNA
sensors; Endoribonuclease

(Kindler et al., 2017)

FIPV

ORF7

Necessary for IFN resistance

(Dedeurwaerder et al.,
2014)

TGEV

ORF7

Prevents activation of dsRNA
sensors/IFN expression

(Cruz et al., 2013,
2011)

Nsp14

Inhibits dsRNA pathways;
Exonuclease

(Becares et al., 2016)

Nsp15

Inhibits IFN expression;
Endoribonuclease

(Deng et al., 2019)

Nsp16

Necessary for IFN resistance; 2’O-Methyltransferase

(Hou et al., 2019)

PEDV
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The generation of IFN-stimulating or IFN-sensitive CoVs has been driven by deleting or
mutating the sequences that encode putative interferon antagonists. Since overexpression studies
implicated accessory proteins as IFN antagonists, researchers hypothesized that deletion or
mutation of accessory proteins would result in attenuated viruses. For example, catalytic
mutations in MERS-CoV ns4a and ns4b have shown that ns4a prevents the phosphorylation of
PKR and induction of IFN, whereas ns4b inhibits activation of RNAse L (Comar et al., 2019).
Interestingly, studies using mutant CoVs have also implicated numerous replicase
proteins as IFN antagonists. SARS-CoV Nsp1 had been determined to decrease phosphorylation
of STAT1, thus inhibiting the signaling for multiple ISG production (Wathelet et al., 2007).
Mutating nsp16 decreases the IFN resistance and pathogenesis of MERS-CoV (Menachery et al.,
2017, 2018). For MHV, there have been multiple viruses generated with mutated IFN
antagonists. MHV lacking ns2 phosphodiesterase activity exhibit activation of RNAse L (Zhao et
al., 2012). Multiple mutations in nsp15 lead to increased activation of dsRNA sensing pathways,
which eventually leads to attenuation of the viral replication (Athmer et al., 2018; Deng et al.,
2017; Kindler et al., 2017). Also mutations in nsp3 have led to attenuation of viral replication
and activation of IFN signaling (Deng et al., 2019; Knoops et al., 2008; Mielech et al., 2015).
Overall, CoVs contain multiple proteins that will interact and inhibit many host innate immune
pathways. For this dissertation, I will discuss the mechanism for CoV nsp15/EndoU in inhibiting
the detection of dsRNA by host sensors.
Nonstructural protein 15/EndoU
Overview
For this dissertation, I will focus on one CoV protein that we have found to be an IFN
antagonist. This protein contains an endoribonuclease domain that cleaves at uridine residues,
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hence the name EndoU or NendoU (Snijder et al., 2003). EndoU is encoded by nsp15 and is
translated as part of pp1ab before cleavage into a separate EndoU protein by the 3CLpro. Here I
will discuss the background information on EndoU, which led us to study this protein in the
context of innate immune antagonism.
Discovery and Conservation of EndoU
EndoU/nsp15 is a protein that is generated during proteolytic processing of the pp1ab
polyprotein. The nsp15 protein generated during MHV infection is 35 kDa (Heusipp et al., 1997)
and is localized to replication complexes in perinuclear regions of infected cells (Shi et al.,
1999). EndoU was first characterized by using bioinformatics to compare the viral sequence with
known sequences of other viral and host proteins. A previous study sought to describe the
unknown functions of many of the cleavage products of the CoV polyproteins and found that
SARS-CoV EndoU had a domain that was conserved with a known endoribonuclease called
XendoU (Snijder et al., 2003). XendoU is a host endoribonuclease found in Xenopus laevis that
cleaves polyU-specific RNA, produces 2’-3’-cyclic phosphate termini, and processes small
nucleolar RNA (snoRNA)(Laneve et al., 2003).
EndoU has been found to be conserved across the nidovirus family. All known
coronaviruses encode EndoU within nsp15. Arteriviruses contain an EndoU domain in nsp11. In
CoVs, EndoU contains less than 50% amino acid conservation, but the catalytic histidines and
endoribonuclease domain folds are fully conserved (Deng and Baker, 2018). Due to this
conservation, EndoU was first named NendoU for being a nidovirus-specific EndoU (Snijder et
al., 2003). Interestingly, Mesoniviridae and roniviruses, which infect invertebrates, were found to
belong to the nidovirus family, but lack the EndoU domain (Lauber et al., 2012; Nga et al.,
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2011). These findings suggest that EndoU is only conserved among vertebrate-infecting
nidoviruses, thus might play a role only during vertebrate infections.
EndoU Biochemical Cleavage Assays
With EndoU being conserved among CoVs, many studies were conducted to determine
the structure and function of EndoU during CoV replication. One study expressed and purified
EndoU from SARS-CoV, MHV-CoV, and IBV-CoV. They found that purified EndoU cleaves
ssRNA and dsRNA, but not ssDNA or dsDNA (Bhardwaj et al., 2004). An additional study
found that EndoU from SARS-CoV and hCoV-229E both cleaved ssRNA and dsRNA, but more
effectively cleaved dsRNA. This study also showed that EndoU produced 2’-3’ cyclic phosphate
ends similar to XendoU (K. A. Ivanov et al., 2004). Both studies determined that Mn2+ was
necessary for EndoU activity in the biochemical assays and that EndoU cleaves at uridine
residues. A follow-up study found that EndoU only cleaves uridines at the 3’ of uridine residues
(Bhardwaj et al., 2006). Interestingly, the RNA sequence recognized and cleaved by EndoU
during the biochemical assays was not specific. One study tried to determine if only specific
uridines of a viral RNA stem loop were cleaved to determine if structure of the RNA played a
role in specificity (Bhardwaj et al., 2006). They found that not all uridines of the RNA stem loop
were cleaved, but multiple uridines were cleaved with no specific epitope emerging. This result
suggests that EndoU cleavage can be influenced by RNA structure, but an exact cleavage site
during viral replication was still unknown.
For MHV-A59, biochemical studies show that EndoU will cleave ssRNA and dsRNA.
Importantly, mutation of the two catalytic histidines, H262 and H277, to alanines resulted in loss
of RNA cleavage activity (Kang et al., 2007). Further studies have confirmed EndoU activity is
conserved in CoVs such as MERS-CoV (Zhang et al., 2018) and even arteriviruses (Cao et al.,
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2008; Nedialkova et al., 2009) showing conservation of EndoU cleavage activity and specificity
across the nidovirus family.
EndoU Overexpression Studies
To study EndoU in the cellular environment, many studies overexpressed EndoU and
measured the effect on host gene expression pathways to determine which pathways were
perturbed by EndoU activity. Many pathways were inhibited by the overexpression of EndoU.
EndoU inhibits MAVS-mediated apoptosis (Lei et al., 2009), can bind to retinoblastoma tumor
suppressor protein and block tumorigenesis (Bhardwaj et al., 2012), and can block IFN
production (Frieman et al., 2009). Reserachers reported that overexpression of EndoU prevents
phosphorylation and nuclear translocation of the NF-κB p65 subunit. (Liu et al., 2019).
Additionally, overexpression of PRRSV EndoU/nsp11 blocked MAVS and RIG-I signaling,
indicating a role of EndoU of modulating IFN signaling during arterivirus infection (Sun et al.,
2016). Overall, overexpression of EndoU in cell culture can inhibit multiple pathways. The main
pathways that were reported were MAVS-related IFN signaling pathways. The expression of
EndoU can inhibit these pathways in the absence of viral replication and infection, indicating a
possible role for EndoU as an IFN antagonist.
One characteristic of overexpression is that EndoU is no longer co-localized to the
replication complex, but has cytoplasmic localization (Liu et al., 2019; Sun et al., 2016). This
cytoplasmic localization may alter the protein and RNA interactions of EndoU. During viral
replication, EndoU is confined to the viral replication complex and may only interact with
proteins and RNAs near the replication complex. Also, we note that in our hands, EndoU activity
during overexpression prevents the translation of multiple biosensors, such as luciferase and RFP
(data not shown). While overexpression studies may highlight new pathways for EndoU to
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interact with, we propose that studying EndoU in the context of viral infection will provide a
more accurate method to determine the function EndoU.
EndoU Structure
Researchers have shown that EndoU can be expressed and purified for biochemical
assays, and the structure of EndoU has been determined for several CoVs. The first study did not
resolve the crystal structure of EndoU, but using cryo-EM, determined that SARS-CoV EndoU
can form either monomeric or hexameric oligomers. Interestingly, mutations that disrupt
hexameric formation also disrupt the RNA cleavage activity of EndoU. This suggests that the
hexamer formation by EndoU is necessary for activity during viral replication (Guarino et al.,
2005). The hexameric, X-Ray crystal structures of EndoU for SARS-CoV (Ricagno et al., 2006),
MHV-A59 (Xu et al., 2006), and MERS-CoV (Zhang et al., 2018) have been solved (Fig. 5). XRay crystal structure for the arterivirus PRRSV EndoU/nsp11 and PDCoV EndoU show that
functional EndoU forms a dimer, showing divergence from the other CoVs in oligomerization.
Further studies sought to determine how RNA was bound and recognized by EndoU. One
study crystalized polyU RNA with EndoU and found that the RNA bound in a channel formed
during the oligomerization of EndoU (Bhardwaj et al., 2006). Two strands of RNA ran along the
EndoU complex into the enzymatic active site. Another study removed the domain that drove
hexamer formation from EndoU and found that the active pocket changed between trimmed
monomeric EndoU and full-length hexameric EndoU (Joseph et al., 2007). Researchers tried to
determine how RNA bound into the catalytic mutant of SARS-CoV EndoU (Bhardwaj et al.,
2008). This study determined that the RNA binding pocket had unreported flexibility and that
EndoU binding pocket structure is altered by the hexamer formation of the EndoU subunits.
Overall, purified EndoU oligomerizes to form an active RNAse complex.
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Figure 5. X-Ray Crystal Structure of MHV-A59 EndoU. The catalytic histidines are
highlighted in red. This structure was solved by Xu et al. (Xu et al., 2006) and is available at the
RCSB Protein Data Bank (PDB# 2GTH).
Reverse Genetics EndoU-Mutant Viruses
In order to study EndoU in the context of viral replication, CoVs with mutations in
EndoU were generated. The first attempt was using hCoV-229E, but a replicative virus could not
be recovered, suggesting that EndoU was necessary for viral replication (K. A. Ivanov et al.,
2004). Similarly, catalytic mutations in EndoU for the arterivirus EAV could not be recovered.
Mutations in other conserved, non-catalytic sites showed reduced plaque size and a decrease in
the yield of infectious virus produced compared to wild-type infection (Posthuma et al., 2006).
In MHV-A59, viruses containing EndoU catalytic mutations, H262A and H277A, could
be recovered. These viruses generated similar plaque sizes in DBT cells, but had about a 10-fold
reduction in viral titers upon infection, suggesting that EndoU activity was necessary for efficient
viral replication. When studying viral RNA production, the study found that EndoU-mutant
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viruses produced less positive and negative-sense sgRNAs, which led to a decrease in the
production of the spike protein compared to wild-type virus. Researchers found that if EndoU
was transiently transfected into infected cells, then viral RNA synthesis was partially restored
(Kang et al., 2007).
More recently studies have utilized different cell types to determine the role of EndoU
during viral infection. One study in situ tagged EndoU to study interaction of EndoU with
different replication complex proteins. The researchers found that EndoU localized with
replication complexes during infection and that during immunoprecipitation, EndoU was
precipitated with nsp12 and nsp8. These results indicate that EndoU complexes with the RNA
polymerase during replication (Athmer et al., 2017). Interestingly, since the in situ tag was added
to the packaging signal of MHV, this tagged virus had increased packaging of negative-sense
RNA in the virions and induced increased IFN production upon infection (Athmer et al., 2018).
One of our studies was published at the same time of another study that focused on
EndoU (Kindler et al., 2017). The findings in this study support our study with a virus with an
EndoU catalytic mutation (H277A) that can replicate as efficiently as wild-type virus in the
absence of innate immune signaling. Kindler and colleagues found that an EndoU-mutant virus
induced IFN in an MDA5-dependent manner and activated multiple host sensors such as PKR
and OAS. The activation of the innate immune sensors led to an attenuation of the viral
replication in macrophages and during in vivo infections. Our studies utilizing an EndoUcatalytic mutant (H262A) virus are discussed in this dissertation.
Currently, work in the Baker Lab has produced another CoV that contains an EndoU
catalytic mutation. Deng et al. have produced a EndoU-mutant porcine epidemic diarrhea virus
(PEDV), that can efficiently replicate in Vero cells. In IFN-responsive PK1 cells, the EndoU-
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mutant virus has increased type I and type III IFN signaling. The EndoU-mutant virus also
contained a mild attenuation during infection of piglets compared to the wild-type infectious
clone (Deng et al., 2019). Overall, EndoU-mutant viruses can be generated with efficient
replication if they are propagated in the absence of host innate immune sensing. Prior to our
work, it was uncertain if EndoU played a role in inhibiting innate immunity during viral
replication.
Objective of Dissertation Research
The goal of my project is to determine the role of EndoU during viral infection. While
EndoU has been shown to cleave ssRNA or dsRNA in biochemical assays, the target and
function of EndoU during viral replication was still unknown. Previous studies had mixed results
on whether EndoU was necessary for viral RNA synthesis. Since overexpression of EndoU in
cell inhibits IFN signaling, we also sought to determine if EndoU inhibited innate immune
signaling during viral infection. To test if EndoU was an IFN antagonist or played a role in viral
replication, we generated an EndoU-mutant (EndoUmut) MHV-A59. We predicted that in the
absence of IFN signaling, the EndoUmut virus would grow similar to wild-type MHV. With IFN
signaling intact, we hypothesized the EndoUmut virus would be attenuated and stimulate a
heightened IFN response compared to wild-type MHV. Since EndoU was proposed to cleave
dsRNA during infection, we hypothesized that EndoUmut viruses would have an increased
activation of dsRNA sensors due to an increased abundance of a dsRNA epitope. We predicted
that one role of EndoU would be to reduce the dsRNA in infected cells, reducing the signal to
activate host sensors. Here I describe my efforts to i) characterize the IFN antagonism of EndoU
during mutant infection; ii) determine the mechanism for EndoU to inhibit the activation of
dsRNA sensors; iii) and finally evaluate EndoU-mutant viruses as potential vaccine candidates.
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Overall, the contribution of this dissertation is to provide mechanistic details for the role of
EndoU activity during viral infection and provide a target for the development of antivirals and
for the generation of live-attenuated vaccine strains for CoVs.

CHAPTER 2
MATERIALS AND METHODS
Viruses and Cells
Viruses
An infectious clone of Mouse hepatitis virus strain A59 (MHV-A59) (genbank accession
no. AY910861) was previously generated by Dr. Anna Mielech in Dr. Susan Baker’s Lab at
Loyola University Chicago. EndoU mutant viruses containing a catalytic site mutation (H262A)
or a protein destabilization mutation (T98M) were previously generated by Dr. Anna Mielech
and Dr. Xufang Deng in the Baker Lab (Deng et al., 2017). Viruses were propagated in DBT
cells and stored at -80°C. Briefly, T-75 flasks of DBT cells were infected with virus at a
multiplicity of infection of 1 for 1 hr in 2 mL of serum-free media at 37°C with 5% CO2. After
24 hrs, supernatants were collected and cleared of cell debris by centrifugation at 1,000xg for 10
min at 4°C. Virus-containing cell-free supernatants were aliquoted and stored at -80°C. Titers of
viral stocks were determined by plaque assay on DBT cells. Infectious clones of wild-type
PEDV or EndoUmut PEDV (H226A) were previously generated by reverse genetics and fullgenome-sequenced by Dr. Xufang Deng in the Baker Lab (Deng et al., 2019).
HEK 293T Cells
Human embryonic kidney 293T cells (CRL-11268, ATCC) were cultured at 37°C with
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) (10-017-CV, Corning) containing
10% fetal bovine serum (FBS), 1% nonessential amino acids, 1% HEPES, 1% L-glutamine, 1%
sodium pyruvate, and 1% nonessential amino acids, 1% HEPES, 1% L-glutamine, 1% sodium
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pyruvate, and 1%nonessential amino acids, 1% HEPES, 1% L-glutamine, 1% sodium pyruvate,
and 1% penicillin/streptomycin. When confluent in a T-75 flask, the monolayer was washed with
phosphate-buffered saline (PBS), then cells were removed by addition of 1 mL of 0.25% trypsinversene solution for 2 min at 37C. For routine passaging, cells were split 1:10 every 3-4 days.
DBT Cells
Delayed brain tumor (DBT) cells were cultured at 37°C with 5% CO2 in MEM (M0268,
Sigma) containing 5% FBS, 10% tryptone phosphate broth (TPB), 1% L-glutamine, and 1%
penicillin/streptomycin. When confluent in a T-75 flask, the monolayer was washed with PBS,
then cells were removed by addition of 1 mL of 0.25% trypsin-versene solution for 2 min at
37°C. For routine passaging, cells were split 1:10 every 3-4 days.
AML12 Cells
AML12 hepatocytes (CRL-2254, ATCC) were cultured at 37°C with 5% CO2 in
DMEM/F-12 (12400-024, Invitrogen) supplemented with 1% penicillin/streptomycin, 10% FBS,
Insulin, Transferrin, and Selenium (41400045, Life Technologies) and Dexamethasone
(40ng/mL)(D4902, Sigma). When confluent in a T-75 flask, the monolayer was washed with
PBS, then cells were removed by addition of 1 mL of 0.25% trypsin-versene solution for 20 min
at 37°C. For routine passaging, cells were split 1:5 every 3-4 days.
L929 Cells
L929 cell line was gifted from Dr. Francis Alonzo (Loyola University Chicago). These
cells secrete macrophage colony stimulating factor (M-CSF), which is used to promote
macrophage differentiation from bone marrow (Weischenfeldt and Porse, 2008). The cells are
maintained at 37°C with 5% CO2 in DMEM (10-017-CV, Corning) supplemented with 10%
FBS, 1% L-glutamine, 1% sodium pyruvate, 1% nonessential amino acids, and 1%

44

penicillin/streptomycin. When confluent in a T-75 flask, the monolayer was washed with PBS,
then cells were removed by addition of 1 mL of 0.25% trypsin-versene solution for 5 min at
37°C. For routine passaging, cells were split 1:10 every 3-4 days. For supernatant collection,
cells were passaged 3.75 x 105 cells into 75 mL media into a T-125 flask. Cells were incubated at
37°C with 5% CO2 for 6 days, then supernatant was filtered with a 0.2µm filter (73520-994,
VWR) and stored at -20°C.
Generation of Bone Marrow-Derived Macrophages (BMDMs)
Bone marrow was collected from femurs of C57BL/6 (#000664, The Jackson Laboratory)
or IFNα1 receptor knockout (IFNAR-/-) mice (breeder pair provided by Deborah Lenschow,
Washington University in St. Louis, St. Louis, MO). Differentiated BMDMs were maintained in
BMDM media containing DMEM (10-017-CV, Corning) supplemented with 30% L929 cell
supernatant, 20% FBS, 1% L-glutamine, 1% sodium pyruvate, and 1% penicillin/streptomycin.
For generation, 5 × 106 bone marrow cells were plated in 100 × 26-mm petri dishes (25387-030,
VWR) with 15 mL BMDM media with 50 μM β-mercaptoethanol (2-ME). After 3 days of
incubation at 37°C with 5% CO2, 10 mL of BMDM media with β-mercaptoethanol was added.
Following another 3 days of differentiation, BMDMs were either plated for experiments or
harvested and stored in liquid nitrogen until use (1 x 107 cells/tube). To remove BMDMs from
plate, cells were washed with 10 mL of cold PBS, incubated for 30 min at 4°C in 10 mL PBS,
and then gently rinsed from the plates by manual pipetting. For liquid nitrogen storage, 1 × 107
cells/mL were suspended in BMM media with 10% DMSO and stored in liquid nitrogen until
use. For viral infections, BMDMs were thawed and plated in 100 × 26-mm Petri dishes in BMM
media without β-mercaptoethanol. After 3 days of incubation at 37°C with 5% CO2, cells were
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plated onto tissue culture dishes (6 x 105 cells/mL plated dilution). The plated BMDMs were
allowed to adhere and rest for at least 24 hrs before subsequent infection experiments began.
Experimental Methods
Immunofluorescence Studies
BMDMs (1.5 x 105 cells per well) AML12 hepatocytes (1.5 × 105 cells per well) were
plated on a glass coverslip in a 24-well plate. Glass coverslips were autoclaved and baked dry
before use. After incubating at 37°C with 5% CO2 for 24 hrs, the cells were infected with wildtype or mutant MHV at an MOI of 0.1 in serum-free media. Briefly, cell supernatant was
removed by vacuum and cells were washed with 2 mL of PBS. 300 ul of infectious media was
added to the cells and the cells were incubated at 37°C with 5% CO2 for 1 hour with tilting the
plate every 15 min. After incubation, infectious media was removed, 2 mL of complete media
with FBS was added, and cells were incubated for indicated times at 37°C with 5% CO2.
At the indicated timepoints, cells were washed with 500 µL of PBS, then fixed with 500
µL of 3.7% formaldehyde in PBS by incubating for at least 20 min at room temperature. Cells
were then washed 2 times with 500 µL PBS and permeabilized with 500 µL of 0.1% Triton X100 (T8787, Sigma) in PBS by incubating at room temperature for at least 30 min. Cells were
again washed 2 times with 500 µL PBS, then 500 µL of 5% normal goat serum (NGS) was
added to block non-specific interactions. Depending on the antibodies used for staining, 10%
FBS in PBS was also used for blocking. Fixed cells treated with blocking buffer were incubated
overnight at 4°C. Blocking buffer was removed, and the coverslips were stained with antibodies
in 0.5% NGS in PBS. Primary antibodies were used as follows: anti-nsp2/3 (1:1,500, Schiller et
al (Schiller et al., 1998)), anti-dsRNA (1:500, Scicons, K1), and anti-nsp15 (1:500, Schiller et
al). Secondary antibodies used are: donkey anti-rabbit IgG alexafluor 488 (1:1,000; A-21441,
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Invitrogen) and goat anti-mouse IgG Alexa Fluor 568 (1:1,000; A11004, Thermofisher). Nuclei
were visualized with Hoescht 33342 (1:2,500; H1339, Life Technologies). Briefly, 300 µL of
primary antibody solution was added to the fixed cells and were incubated at room temperature
for 2 hours. The primary antibody solution was removed, and the cells were washed 2 times with
500 µL of PBS. After addition of 300 µL of secondary antibody solution with Hoescht 33342
stain, the cells were incubated at room temperature for 1 hour while covered with aluminum foil.
After incubation, the cells were washed 2 times with 500 µL of PBS. To prepare the samples for
viewing, I added 10 µL drop of Fluorogel Mounting Medium (50-247-04, Fisher Scientific) on
microscope slides, carefully added the coverslip, and sealed the edges of the coverslip to the
slide with clear coat nail polish. Cells were imaged by collecting z-stack images with a
Deltavision wide-field fluorescent microscope (Applied Precision, GE) equipped with a digital
camera (CoolSNAP HQ, Photometrics). Images were taken with either a 20x, a 60x, or a 100x
lens. Samples were excited with light generated by an Insight SSI solid-state illumination module
(Applied Precision, GE) and deconvolved with SoftWoRx deconvolution software (Applied
Precision, GE). All images were collected under identical acquisition conditions and processed
using Imaris 7.6.4 (Bitplane).
dsRNA Immunopreciptiation, RNA-Sequencing, and RT-qPCRs
IFNAR-/- BMDMs, C57Bl/6 BMDMs, or AML12 cells were plated with 2 mL of cell
dilution into 6 well plates. The cell concentration for BMDMs is 6 x 105 cells per mL. AML12
cell concentration is 3.5 x 105 cells per mL. Cells were infected with wild-type or EndoUmut
MHV at a MOI of 1. Briefly, cell supernatant was removed by vacuum and cells were washed
with 2 mL of PBS. 400 µL of infectious media was added to the cells and the cells were
incubated at 37°C with 5% CO2 for 1 hour with tilting the plate every 15 min. After incubation,
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infectious media was removed, 2 mL of complete media with FBS was added, and cells were
incubated for indicated times at 37°C with 5% CO2.
At indicated times post infection, cell supernatants were removed and cells were washed
1 time with 2 mL of PBS. To obtain total RNA, I added 350 µL of RLT buffer to lyse the cells
and collected the samples into 1.5 mL tubes. Cellular RNA was isolated with RNeasy kit (74104,
Qiagen) according to the manufacturer’s instructions. After RNA isolation, RNA concentrations
were measured by nanodrop.
To immunoprecipitate the dsRNA, I mixed 1 µg of cellular RNA in a 1.5 mL tube with 2
µL anti-dsRNA antibody (K1, Scicons) or mouse anti-β-actin (A00702-40, Genscript) and 500
µL of RNA binding buffer (50mM Tris pH 8.0, 150mM NaCl, 1% NP-40, and 20 U/mL
Ribolock (EO0381, Thermofisher). The RNA immunoprecipitation mixture was incubated
overnight at 4°C, with mixing on tube rotator. After overnight incubation, 50 µL of protein G
beads (LSKMAGG02, Millipore) were added and the mixture incubated rotating for 4 hours at
4°C. Protein G beads were precipitated with magnets then washed 5 times with 500 µL cold
binding buffer. Washing was performed by addition of binding buffer then slowly spinning the
tubes for 10 min at 4°C. The last wash was removed and 350 µL of RLT buffer was added to the
precipitated beads. After incubating the beads in RLT buffer for 10 min spinning at room
temperature, the RLT buffer mixture was added to the RNeasy Column and RNA was purified
with RNeasy Kit. Purified RNA was either reverse transcribed into cDNA with RT2 First Strand
kit (330411, Qiagen) or sent for RNA sequencing to the Genomics Facility at the University of
Chicago. For cDNA synthesis, 8 µL of purified RNA per sample was reverse transcribed into
cDNA, since RNA concentration was not measurable by nanodrop. qPCR of cDNA was
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performed as described below. For qPCR, viral N gene was measured using primers listed in
Table 4.
For RNA-sequencing, RNA was processed by University of Chicago Genomics Facility.
cDNA sequencing libraries were generated with TruSeq Stranded Total RNA with Ribo-zero
subtraction (Illumina), then sequenced on Illumina HiSeq4000. RNA-sequencing reads were
analyzed with Galaxy’s online platform (www.usegalaxy.org). Reads were groomed, clipped,
and mapped with Hisat2 to the wild-type MHV strain A59 (genbank accession no. AY910861)
or host genome (GRCm38 Ensembl build of the C57BL/6J). The number of reads at individual
viral nucleotides was calculated by plotCoverage. RNA seq data has been deposited and is
available in the NCBI GEO database (Accession number: GSE144886).
Quantitative Polymerase Chain Reaction (qPCR)
At indicated timepoints, 350 µL of RLT buffer was added to lyse the cells and cellular
lysate was collected into 1.5 mL tubes. Cellular RNA was isolated with RNeasy kit (74104,
Qiagen) according to the manufacturer’s instructions. Briefly, 350 µL of 70% EtOH was added
to the cell lysate, mixed, and added to the RNeasy column. The columns were centrifuged at
14,000 rpm for 1 min, then the flowthrough is discarded. The columns were washed with 700
µL of RWI buffer, then 2 times with 500 µL of RPE buffer. After last wash, the column was
placed into a new collection tube and centrifuged at max speed for 2 min to dry out column.
Then, the column was transferred to a 1.5 mL tube, 35 µL of nuclease-free (NF) H20 was added
to column, and incubated at room temperature for 1 min. The RNA was eluted from the column
by centrifuging the column and tube at max speed for 1.5 min. Purified RNA was measured by
nanodrop.
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To generate cDNA, I reverse transcribed 500 ng of purified RNA into cDNA with RT2
First Strand kit (330411, Qiagen). For cDNA synthesis, 8 µL of purified RNA/H20 was mixed
with 6 µL of GE2 buffer in a 0.2 mL PCR tube and incubated for 5 min at 37°C. The mix was
cooled on ice and 6 µL of BC4 buffer was added. The reverse transcription reaction was
incubated at 42°C for 15 min, then 95°C for 5 min to inactivate the reverse transcriptase, and
finally a 4°C hold. cDNA was then diluted with 91 µL of nuclease-free NF H20.
qPCR reactions were performed using RT2 Kit (330502, Qiagen). The measurements of
qPCR mixture per well is shown in Table 3. Each sample was quantified from triplicate wells.
qPCR cycles were 1) 95°C for 10 min, 2) 95°C for 15 sec, 3) 60°C for 1 min, and repeated steps
2-3 for 40 cycles. A melt curve was performed after the qPCR reaction to determine melting
temperatures of PCR products. Primer mixtures used are IFNβ1 (PPM03594C, Qiagen), β-actin
(PPM02945B, Qiagen), and 18s rRNA (PPM57735E, Qiagen). Other primer sets are listed in
Table 4.
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Table 3. PCR Reaction Mixtures.
2 Primers

2 Primers and Probe

1 Primer Mix

Component /Rxn (µL)

Component

/Rxn (µL)

Component

/Rxn (µL)

NF H20

4.75

NF H20

4.25

NF H20

4.25

RT2 SYBR

6.25

RT2 SYBR

6.25

RT2 SYBR

6.25

Mix

Mix

Mix

cDNA

0.5

cDNA

0.5

cDNA

0.5

Primer Fwd

0.5

Primer Fwd

0.5

Primer Mix

0.5

(10 µM)
Primer Rev

(10 µM)
0.5

Primer Rev

(10 µM)

0.5

(10 µM)
Probe

0.5

Table 4. List of MHV Primers Used in these Studies.
Primer set
IFNλ2/3
IFNλ2/3
N Gene
N Gene
Negative-Sense cDNA
PolyU qPCR Set 1
PolyU qPCR Set 2
PolyU Length Set 1
PolyU Length Set 2
Probe

F
R
F
R
R
F
R
F
R
F
R
F

Sequence
5’-AGTGGAAGCAAAGGATTG-3’
5’-GAGATGAGGTGGGAACTG-3’
5’-AGCAGACTGCAACTACTCAACCCAACTC-3’
5’-GCAATAGGCACTCCTTGTCCTTCTGCA-3’
5’-GAATTCTGGTGGTGCTGATGAAC-3’
5’-TGTGTGAGAGAAGTTAGCAAGG-3’
5’-GCAGGAATAGTACCCTGATGTG-3’
5’-TGTGTGAGAGAAGTTAGCAAGG-3’
5’-GGGGATCCGCGGTTTTTTTTTT-3’
5’-CAGATGTGGTGAGCCCAAAG-3’
5’-GGGGATCCGCGGTTTTTTTTTT-3’
5’-CACATCAGGGTACTATTCCTGC-3’
5’-GATAGGGGATCCGCGGT-3’
5’-6-FAM-TAACCATAA/ZEN/GAACGGCGATAGGCGC/Iowa Black FQ-3’
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Table 5. List of PEDV Primers Used in these Studies.
Primer Set
Negative-sense
cDNA
PolyU qPCR Set 1
PolyU qPCR Set 2
PolyU Length Set 1
PolyU Length Set 2
Probe

Sequence
5'-GCAGCATTGCTCTTTGGTG-3'
R
F
R
F
R
F
R
F

5'-CACTGTCATGAGGGGAACG-3'
5'-GTCCTTGAGTCAAATACCTGG-3'
5'-CACTGTCATGAGGGGAACG-3'
5’-GGGGATCCGCGGTTTTTTTTTT-3’
5'-CAAGCGTGAAACCACGC-3'
5’-GGGGATCCGCGGTTTTTTTTTT-3’
5'-CCAGGTATTTGACTCAAGGAC-3'
5’-GATAGGGGATCCGCGGT-3’
5’-6-FAM-CCTTTGCACGAGTAATCAAAGATCCGCIowa Black FQ-3’

PolyU Extension PCRs
IFNAR-/- BMDMs (6 x 105 cells/mL) or AML12 cells (3.5 x 105 cells/mL) were plated
into 6 well plates. Cells were infected with wild-type or EndoUmut MHV at a MOI of 1. For
PEDV, Dr. Xufang Deng infected PK1 or Vero cells with wild-type or EndoUmut PEDV at an
MOI of 0.1. Briefly, cell supernatant was removed by vacuum and cells were washed with 2 mL
of PBS. 400 µL of infectious media was added to the cells and the cells were incubated at 37°C
with 5% CO2 for 1 hour with tilting the plate every 15 min. After incubation, infectious media
was removed, 2 mL of complete media with FBS was added, and cells were incubated for
indicated times at 37°C with 5% CO2. At indicated times post-infection, RNA was isolated by
RNeasy Kit. For strand-specific cDNA, 500 ng of RNA was reverse transcribed with Omniscript
(205113, Qiagen). Briefly, 15 µL of RNA (500 ng) in NF H20 was mixed with the primer and
incubated at 95°C for 5 min to denature the RNA. The RNA/ primer mix was immediately
chilled on ice. Next, 2 µL 10x Buffer, 2 µL dNTPs (5 µM), and 1 µL Omniscript was added to
the sample mixture and cDNA was synthesized at 50°C, the temperature shown to reduce selfprimed cDNA synthesis (Haddad et al., 2007). For negative-sense RNA, the cDNA primer was
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5’-GAATTCTGGTGGTGCTGATGAAC-3’ for MHV and 5'-GCAGCATTGCTCTTTGGTG-3'
for PEDV. For total RNA, the cDNA primers were random hexamers and positive-sense RNA
primer was oligo-dT. The cDNA was diluted by addition of 91 µL of NF H20. qPCR was
performed with SsoAdvanced Universal Probes Supermix (1725281, Bio-rad). qPCR reaction
was performed with an annealing temperature of 60°C with either primer set PolyU qPCR Set 1
or PolyU qPCR set 2. Primers are listed in Tables 4 and 5.
PolyU length nested PCRs were performed with PFU Ultra Polymerase (600380, Agilent)
with an annealing temperature of 60°C. cDNA was generated as described above. For negativesense RNA, the cDNA primer was 5’-GAATTCTGGTGGTGCTGATGAAC-3’ for MHV and
5'-GCAGCATTGCTCTTTGGTG-3' for PEDV. For positive-sense RNA, the cDNA primer was
5’-GGGGATCCGCGGTTTTTTTTTT-3’. A PCR was performed with Set 1 primers for PolyU
Length. Then the product was diluted 1:1000 and utilized in a PCR with Set 2 primers for PolyU
length. PCR products were separated on a 10% polyacrylamide gel with TBE running buffer by
loading PCR products in 6x Loading Dye (NEB) and running the gel at 180V for 45 min. The gel
was then transferred to a dish and stained with SYBR Green II dye (S7564, Thermofisher) in 50
mL of TBE. Primers for cDNA synthesis and PCRs are listed in Tables 4 and 5. For polyU
length sequencing, sequencing libraries were generated with custom amplicon primers with
nextera XT indexes and the amplicons were sequenced on an Illumina Miseq V2 500 with
paired-end 250bp reads. Reads were groomed, clipped, and mapped with Hisat2 to the wild-type
MHV strain A59 (genbank accession no. AY910861).
RNA Transfections
Gene blocks (gBlocks) containing a T7 promoter, a segment of the viral genome
segment, and a HindIII cleavage site were synthesized by Integrated DNA technologies (IDT).
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The viral sequences are listed in Table 6. To clone these geneblocks into plasmid DNAs, the
pCAGGs vector was digested with EcoRI-HF (R3101S, NEB)and HindIII (R3104S, NEB)
restriction enzymes, treated with Antarctic Phosphatase (M0289S, NEB), and gel purified from
an 1% agarose gel with Wizard SV Gel and PCR Purification Kit (A9281, Promega). Viral
genome segments were cloned into the digested pCAGGs vector by Gibson Assembly. Briefly,
50ng of digested vector was mixed with ~25 ng of a gBlock and 2x NEBuilder Hifi DNA
Assembly Mix (E2621S, NEB). The mixture was incubated at 50°C for 1 hour, then transformed
into competent E. coli cells. Colonies containing pCAGGs-viral gene plasmids were selected
using ampicillin (100 ng/mL). The DNA plasmids were maxiprepped with PureYield Plasmid
Maxiprep System and sequenced to ensure the correct viral sequence was present.
RNAs of the viral sequences were generated through T7 transcription. Briefly, plasmids
were digested with HindIII-HF, then purified with Wizard Gel and PCR Purification Kit. RNA
was in vitro transcribed using 1 µg of digested plasmid. The plasmid was mixed with 4 µL of 5x
Transcription Buffer, 2 µL of rNTPs (N0466S, NEB), 1 µL Ribolock, and 2 µL of T7 RNA
polymerase (EP0111, Thermofisher) in a 20 µL total volume reaction. The mixture was
incubated at 37°C for 5 hours. The RNA was then purified by adding 1:3 volume of 7.5M LiCl
precipitation solution and 1:3 volume of NF H20. The RNA/LiCl solution was incubated
overnight at -20°C, then centrifuged at maximum speed at 4°C for 30 min. After removal of the
LiCl, the pellet was washed with 300 µL of ice-cold 75% EtOH. After removal of the EtOH
wash, the RNA pellet was dried then resuspended in 35 µL of NF H20. RNA concentrations were
determined by nanodrop and RNA was stored at -80°C until use.
For RNA transfections, AML12 cells (3.5 x 105 cells/mL) were plated into 24 well plates
and incubated for 24 hours at 37°C with 5% CO2. Poly I:C (P1530, Sigma) or 5 pmol of in vitro-
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transcribed RNA was transfected into AML12 cells using Lipofectamine 2000 (11668027,
Thermofisher). Briefly, RNA was diluted into 50 µl of OptiMEM (11058021, Thermofisher) and
3 µl of Lipofectamine 2000 was added. The RNA mixture was incubated at room temperature for
20 min, then added dropwise into AML12 wells. The plates were gently mixed by tilting then
incubated for 8 hours at 37°C with 5% CO2. After incubation, RNA was isolated using RNeasy
kit as described above and qPCR for IFNβ1 (PPM03594C, Qiagen) and 18s rRNA (PPM57735E,
Qiagen) was performed as described above.
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Table 6. List of RNA Constructs for In Vitro Transcription.
RNA
construct

Gene Block Sequence
UUUUUUUUUUUUGUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUG
CAGGAAUAGUACCCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCGUUCUUAUGGUUAGAC
GUAGGACCUUGCUAACUUCUCUCACACAUUCUCUAUUUUGCAAUCUCUUUCAACUAAUUGAUAC
AGGGUCUGCCACAACCUUCUCUAUCUGUUAUGACAGCAAGACAUCCAUUCUGAUAGAGAGUGU
CCUAUCCCGACUUUCUCGCGAGGGGUUACCACCGAGCGCCGACAUAGGAUUCAUUCUCUUUACA
CAUUAGAGUCAUCUUCUAACCCAUCUGGCACUAC
GUAGUGCCAGAUGGGUUAGAAGAUGACUCUAAUGUGUAAAGAGAAUGAAUCCUAUGUCGGCGC
UCGGUGGUAACCCCUCGCGAGAAAGUCGGGAUAGGACACUCUCUAUCAGAAUGGAUGUCUUGC
UGUCAUAACAGAUAGAGAAGGUUGUGGCAGACCCUGUAUCAAUUAGUUGAAAGAGAUUGCAAA
AUAGAGAAUGUGUGAGAGAAGUUAGCAAGGUCCUACGUCUAACCAUAAGAACGGCGAUAGGCG
CCCCCUGGGAAGAGCUCACAUCAGGGUACUAUUCCUGCAAUGCCCUAGUAAAUGAAUGAAGUU
GAUCAUGGCCAAUUGGAAGAAUCACAAAAAAAAAAAA

N5

P3

N3

UAACUGGCUCCAGCAUGGGGCCCUGUGCCAAGAUAGUAAAAAUACCAUCUGGGCAGUAAUUGC
UUCUGCUGCCCAUCAGGUGUUUUAAAAGAACGGCGGUUGUGUCUAUACCAAUAUCCCUUUUGC
UCUGAAGCGGGGAUUCCAUUGGCAAUAGGCACUCCUUGUCCUUCUGCAAACUGAAACUCCUUUC
CCUUUUGGAACUGGGUAAUGCCAGAAAACCAGGAGUAAUGGGGAACCACACUCCCGGAGUUGG
GUUGAGUAGUUGCAGUCUGCUUUGGCUGAUUCCUUCUGCCUCUAUUUUGAUUAUUUGGUCCAC
GCUCGGUUUGGUCAGCCCAAGUGGUCUUCUUGAGGAUUCCAUUACCAGCGCGGUUUACAGAGG
AGCUUCUGCCACCGGCAUUUUCUUGCCCAGGAACAAAAGACAUCCUUAAAGUUUAGAUUAGAU
UUAAACUACAAGAGUUUUAGAGUUGAGAGGGUACGUACGGACGCCAAUCACUCUUAUC

P5

GAUAAGAGUGAUUGGCGUCCGUACGUACCCUCUCAACUCUAAAACUCUUGUAGUUUAAAUCUA
AUCUAAACUUUAAGGAUGUCUUUUGUUCCUGGGCAAGAAAAUGCCGGUGGCAGAAGCUCCUCU
GUAAACCGCGCUGGUAAUGGAAUCCUCAAGAAGACCACUUGGGCUGACCAAACCGAGCGUGGAC
CAAAUAAUCAAAAUAGAGGCAGAAGGAAUCAGCCAAAGCAGACUGCAACUACUCAACCCAACUC
CGGGAGUGUGGUUCCCCAUUACUCCUGGUUUUCUGGCAUUACCCAGUUCCAAAAGGGAAAGGA
GUUUCAGUUUGCAGAAGGACAAGGAGUGCCUAUUGCCAAUGGAAUCCCCGCUUCAGAGCAAAA
GGGAUAUUGGUAUAGACACAACCGCCGUUCUUUUAAAACACCUGAUGGGCAGCAGAAGCAAUU
ACUGCCCAGAUGGUAUUUUUACUAUCUUGGCACAGGGCCCCAUGCUGGAGCCAGUUA

N5.NoU

GUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUGCAGGAAUAGUAC
CCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCGUUCUUAUGGUUAGACGUAGGACCUUGC
UAACUUCUCUCACACAUUCUCUAUUUUGCAAUCUCUUUCAACUAAUUGAUACAGGGUCUGCCAC
AACCUUCUCUAUCUGUUAUGACAGCAAGACAUCCAUUCUGAUAGAGAGUGUCCUAUCCCGACUU
UCUCGCGAGGGGUUACCACCGAGCGCCGACAUAGGAUUCAUUCUCUUUACACAUUAGAGUCAUC
UUCUAACCCAUCUGGCACUAC

N5.180
N5.100

N5.8U

N5.4U

UUUUUUUUUUUUGUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUG
CAGGAAUAGUACCCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCGUUCUUAUGGUUAGAC
GUAGGACCUUGCUAACUUCUCUCACACAUUCUCUAUUUUGCAAUCUCUUUCAACUAAUUGAUAC
A
UUUUUUUUUUUUGUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUG
CAGGAAUAGUACCCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCG
UUUUUUUUGUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUGCAGG
AAUAGUACCCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCGUUCUUAUGGUUAGACGUA
GGACCUUGCUAACUUCUCUCACACAUUCUCUAUUUUGCAAUCUCUUUCAACUAAUUGAUACAGG
GUCUGCCACAACCUUCUCUAUCUGUUAUGACAGCAAGACAUCCAUUCUGAUAGAGAGUGUCCUA
UCCCGACUUUCUCGCGAGGGGUUACCACCGAGCGCCGACAUAGGAUUCAUUCUCUUUACACAUU
AGAGUCAUCUUCUAACCCAUCUGGCACUAC
UUUUGUGAUUCUUCCAAUUGGCCAUGAUCAACUUCAUUCAUUUACUAGGGCAUUGCAGGAAUA
GUACCCUGAUGUGAGCUCUUCCCAGGGGGCGCCUAUCGCCGUUCUUAUGGUUAGACGUAGGACC
UUGCUAACUUCUCUCACACAUUCUCUAUUUUGCAAUCUCUUUCAACUAAUUGAUACAGGGUCU
GCCACAACCUUCUCUAUCUGUUAUGACAGCAAGACAUCCAUUCUGAUAGAGAGUGUCCUAUCCC
GACUUUCUCGCGAGGGGUUACCACCGAGCGCCGACAUAGGAUUCAUUCUCUUUACACAUUAGAG
UCAUCUUCUAACCCAUCUGGCACUAC

Generation of MDA5-Knockdown Cells
A modified CRISPR/Cas9 protocol, based on the GeCKO system (Shalem et al., 2014)
was used to knock-down the expression of MDA5 or RIG-I in AML12 cells. Single-guide RNAs

56

were identified with Benchling (Benchling, Inc) to target the Ifih1 (MDA5) or Ddx58 (RIG-I)
genes. The sequence used for the clonal MDA5-knockdown (MDA5-KD) AML12 cells
discussed in Figure 23 targeting Ifih1 was 5’-ATGGACGCAGATGTTCGTGG-3.’ The
remaining guide RNA sequences are listed in Table 7. Complementary DNA versions of guide
RNA were annealed and inserted into a pLentiCRISPRv2-puro (Addgene #52961) cassette
between flanking BsmBI sites. Briefly, the complementary DNA oligos were annealed by mixing
the oligos with 1x T4 DNA ligase buffer containing ATP, and T4 PNK ligase (M0201S, NEB).
Then the reaction was incubated at 37°C for 30 min, 95°C for 5 min, and ramping from 95-25°C
for at 5°C intervals for 5 min holding at each interval. The annealed oligos were then mixed with
BsmBI-linearized pLentiCRISPRv2-puro plasmid and ligated with T4 DNA ligase (M0202S,
NEB) at 16°C overnight. The ligated plasmid was then transformed into competent E. coli and
miniprepped with PureYield Miniprep Kit (A1222, Promega).
Transducing particles (TPs) were generated by transfecting HEK-293T/17 cells with
pLentiCRISPRv2-puro, pPax2 (lentiviral packaging plasmid), and pHEF-VSV-G (vesicular
stomatitis virus glycoprotein) and collecting supernatant. Briefly, 5 x 106 HEK-293T/17 cells
were plated into a 10 cm dish and incubated at 37°C 5% CO2. After overnight incubation, the
plasmids were mixed with OptiMEM and Trans-LTI (Mirus), incubated for 20 min at room
temperature, then added dropwise to the 293T cells. Supernatants were collected at 24- and 48hours post transfection. TPs were isolated by centrifuged the cell supernatant at 1000xg for 10
min at 4°C then filtering the supernatant through a 0.45uM filter (Millipore Sigma). TPs were
stored at -80°C until use.
AML12 cells (2x 105 cells/mL) were plated into 6-well plates and incubated overnight at
37°C 5% CO2. The AML12 cells were then transduced with the TPs by removing the AML12
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supernatant, washing the cells with 2 mL of PBS, then adding 300 µL of Purified TP supernatant.
The cells were then incubated for 1 hrs at 37°C 5% CO2 with tilting to mix the plate every 15
min. After the 1 hour incubation, 2 mL of complete media was added and the cells were
incubated for 24 hours at 37°C 5% CO2. Transduced AML12 cells were then selected by
replacing the media with complete media containing 1µg/µl puromycin (InvivoGen) for 96 hrs.
The polyclonal populations of selected cells were then grown to confluency in puromycinselection. To obtain monoclonal knock-down cell populations, the KD AML12 cells were diluted
to a 1 cell/100 µl dilution and 100 µl of solution was plated into a 96-well flat-bottom plate.
Wells containing 1 colony were then selected and grown to confluency. To reach confluency, the
cells were grown about 3 weeks with fresh complete media added to the cells every 3 days.
Knockdown of MDA5 was determined by western blot using rabbit anti-MDA5 (SAB3500356,
Sigma) and mouse anti-actin (A00702-40, Genscript).
Table 7. List of Guide RNA Sequences for CRISPR/Cas9 Knockdowns.
Single Guide RNAs

Sequence

Ifih1-1

CAAGTGGAGACACTCGTCAT

Ifih1-2

ATGGACGCAGATGTTCGTGG

Ifih1-3

TTGGACCACTTGCTTCGAGAA

Ddx58-1

GTCGGATCTGATAAGACATT

Ddx58-2

TTGAAAGTCCCAACTTTCGA

Ddx58-3

GATATCATTTGGATCAACTG

RNA Cleavage Assay
Cleavage of RNA substrates were performed according to Kang et al (Kang et al., 2007).
Purified, wild-type EndoU was kindly gifted by Dr. C. Kao (Formerly of Indiana University,
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currently at Aligos Theraputics). Briefly, 1 µM RNA was mixed with EndoU in Cleavage Buffer
(50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT) with or without 5 mM MnCl2. Reactions were
incubated at 30°C for the indicated time and reactions were stopped by addition of RNA Gel
Loading Buffer (B0363S, NEB), followed by incubation at 95°C for 5 min. Reaction products
were immediately loaded into a 10% poly-acrylamide gel with TBE buffer or a 1% agarose gel
with TAE buffer and bands were separated by electrophoresis. Gels were moved into a staining
box then stained with SYBR Green II dye in 50 mL TBE buffer. The gels were visualized with a
ChemiDoc XRS+ imager (Bio-rad)and processed with Image Lab software (Bio-rad).
For RNA transfection, 500 ng of in vitro transcribed RNA was mixed with EndoU in
Cleavage Buffer (50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT) with or without 5 mM MnCl2.
The mixture was incubated at 30C for 45 min, then the mix was heated to 95C for 5 min, then
mixed with 40 µL OptiMEM and 3 µL Lipofectamine 2000. The RNA mixture was incubated at
room temperature for 20 min, then added dropwise into AML12 wells. The transfection mixture
and cells were gently mixed by tilting the plates, then incubated for 8 hours at 37°C with 5%
CO2. After incubation, RNA was isolated using RNeasy kit as described above and RT-qPCR for
IFNβ1 (PPM03594C, Qiagen) and 18s rRNA (PPM57735E, Qiagen) was performed as described
above.
Viral Titration by Plaque Assay
IFNAR-/- BMDMs (6 x 105 cells/mL), C57Bl/6 BMDMs (6 x 105 cells/mL), or AML12
cells (3.5 x 105 cells/mL) were plated into 6 well plates. Cells were infected with wild-type or
EndoUmut virus at a MOI of 0.1. Briefly, cell supernatant was removed by vacuum and cells
were washed with 500 µL of PBS. 250 µL of infectious media was added to the cells and the
cells were incubated at 37°C with 5% CO2 for 1 hour with tilting the plate every 15 min. After
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the 1 hour incubation, inoculum was replaced with 500 µL of fresh, complete medium. Cells
were then incubated at 37°C with 5% CO2. At indicated time points, cell culture supernatants
were collected and stored at -80°C.
Serial dilutions of supernatants were made in serum-free media and analyzed by plaque
assay in DBT cells. Briefly, DBT cells (2.5 x 105 cells/mL) were plated into 6 well plate and
incubated for 20 hours at 37°C with 5% CO2. After incubation, the DBT cells were subsequently
infected with diluted supernatants. Cell supernatants were removed by vacuum and cells were
washed with 500 µL of PBS. 3000 µL of infectious media was added to the cells and the cells
were incubated at 37°C with 5% CO2 for 1 hour with tilting the plate every 15 min. After
incubation, infectious media was removed and cells were overlaid with MEM containing 2%
FBS and 0.4% Noble Agar. Cells were incubated for 48 hours at 37°C with 5% CO2. After 48
hours, the cells were fixed with 3.7% formaldehyde in PBS for 30 min. After fixation, the
formaldehyde and agar mixtures were removed and the fixed cells were stained with 0.1%
crystal violet solution for 1 hour at room temperature. The crystal violet stain was removed and
the cells were washed with distilled H20 and dried. The number of plaques was quantified by
manual counting. Titers were obtained from three independent assays for each sample.
EM Imaging
IFNAR-/- BMDMs or C57Bl/6 BMDMs were plated at 3 x 105 cells/mL in a 12-well plate
and grown overnight at 37°C with 5% CO2. The BMDMs were infected with wild-type or
EndoUmut MHV at an MOI of 2. Cell supernatant was removed by vacuum and cells were
washed with 1 mL of PBS. 300 µL of infectious media was added to the cells and the cells were
incubated at 37°C with 5% CO2 for 1 hour with tilting the plate every 15 min. After the 1 hour
incubation, inoculum was replaced with 1 mL of fresh, complete medium. Cells were then
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incubated at 37°C with 5% CO2. At indicated time points, the cell supernatant was removed and
the cells were washed 2 times with PBS. The cells were fixed for 1 hr with 5% acrolein (A24001,
Sigma Aldrich) in phosphate buffer (pH 7.2). Cells were washed twice with PBS, stained, and
then embedded in epoxy resin. Staining and embedding was performed by Dr. David
Rademacher of the Loyola University Chicago Imaging Core. Images were taken with a Philips
CM120 120kV transmission electron microscope (TEM) at Loyola University Chicago Imaging
Core.
Flow Cytometry
Triplicate wells of 6 x 105 BMDMs were plated in a 12-well plate for 6 hpi experiments
or six well plates for the 12 hpi experiments to lessen syncytia formation. After 24 hour
incubation at 37°C with 5% CO2, the BMDMs were infected with wild-type or EndoUmut MHV
at an MOI of 0.1. After 6 hours or 12 hours, cells were removed from the wells by addition of
cold PBS and incubation at 4°C for 30 min. Cells were manually pipetted off the wells and
transferred into a 96-well, V-bottom plate. Cells were centrifuged at 2,000xg in the plate to pellet
cells at the bottom, then resuspended in PBS containing fixable viability dye (65-0865-14,
eBioscience) and stained for 30 min at room temperature. After washing the cells 2 times with
PBS, the cells were fixed with 3.7% formaldehyde in PBS. After 2 washes with PBS, the cells
were permeabilized with 0.1% Triton X-100 in PBS. The cells were then washed 2 times with
PBS and blocked with PBS containing 5% normal goat serum (NGS). Cells were labeled with
anti-dsRNA (5ug/mL, K1, Scicons), and goat anti-mouse Alexafluor 568 (1;1000). Cells were
analyzed using an LSR Fortessa cell analyzer (BD Bioscience). Flow Cytometry data were
analyzed using FlowJo software (Treestar).
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Evaluating Pathogenesis of MHV in Mice
All experiments were completed using protocols reviewed and approved by the Loyola
University Chicago IACUC. C57BL/6 mice were purchased from Jackson Laboratory and Ifnar-/C57Bl/6 mice were gifted from Dr. Deborah Lenschow of Washington University in St. Louis
and bred in the Loyola University Chicago Animal Facility. For intraperitoneal infections, 6-wkold female mice were injected with 60,000 pfu of wild-type or EndoUmut viruses in 100 ul PBS.
Mice were then monitored by percentage of initial body weight until they were euthanized. Mice
were euthanized at indicated time points by inhalation of CO2, and organs were harvested for
analysis. For viral titers, tissues were removed, weighed, and dissociated with 1 mm
zirconia/silica beads (11079110z, BioSpec Products) for 40 seconds in a bead beater (MP
Biomedical). Tissue extract was separated from the beads and stored at -80°C until use. Viral
titers were measured by plaque assay in DBT cells as described above. H&E staining of liver
slices was performed by the Tissue Processing Core Facility at Loyola University of Chicago.
For intracranial infections, 6-wk-old female mice were inoculated with 600 pfu in 20 ul PBS.
Infections were performed by Dr. Xufang Deng in the Baker lab. Infected mice were monitored
for body weight daily and euthanized when weight loss was over 25% of original body weight.
Western Blotting
For western blotting experiments, 1 mL of IFNAR-/- BMDMs (6 x 105 cells/mL) or
AML12 cells (3.5 x 105 cells/mL) was plated into 12 well plates. After 24 hour incubation at
37°C with 5% CO2, the cells were infected with wild-type or EndoUmut MHV at an MOI of 0.1.
After incubation for indicated times at 37°C with 5% CO2, cell lysates were collected by lysing
cells with 150 µL IκB lysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 12.5 mM Na pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na
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orthovanadate, 1 mg/mL Leupeptin, 1 mM PMSF) and moving cell lysate into 1.5 mL tubes. The
lysates were then centrifuged at 14,000xg at 4°C to pellet nuclei. Supernatants were then
transferred to a new 1.5 mL tube and 2x Sample Buffer (10% Glycerol, 5% β-mercaptoethanol,
3% SDS, Bromophenol Blue, 1.0 M Tris-HCl buffer pH 6.8) was added to denature proteins.
Proteins were heated at 95°C, then cooled to room temperature before evaluation by SDS-PAGE.
Cell lysates were separated using 10% SDS-PAGE, then transferred to a PVDF
membrane using a semi-dry transfer apparatus (Bio-rad). The conditions for the transfer were:
25V and 1.0A for 30 min. After transfer, membranes were blocked with 5% milk in TBS-T
overnight at 4°C. Primary antibodies were diluted in 5% milk in TBS-T then either incubated at
room temperature for 1 hour or overnight at 4°C. Membranes were then washed 3 times with
TBS-T for 10 min, then incubated at 1 hour at room temperature with 1:2500 dilution of HRPconjugated secondary antibodies. Membranes were again washed 3 times with TBS-T for 10 min
before addition of Western Lightning Plus-ECL (PerkinElmer, Inc.) chemiluminescent substrate
and visualization of the blots on a FluorChem E (Protein Simple). Band sizes were determined
relative to PageRuler Plus Prestained Protein ladder (26619, Thermofisher). The antibodies
used for western blotting are anti-nsp1 (anti-p28(Schiller et al., 1998), , anti-nsp2/3 (D3, (Shi et
al., 1999)), anti-N protein (J3.3, gift from Dr. John Fleming, University of Wisconsin), and antiβ-actin (A00702-40, Genscript). The secondary antibodies used were donkey anti-rabbit-Ig-HRP
(6440-05, Southern Biotech) and goat anti-mouse-Ig-HRP (1010-05, Southern Biotech).
Generation of Figures, Graphics, Tables, and Reference Management
The graphic figures and illustrations were generated using Adobe Illustrator. All figures
that incorporate experimental data and statistical analysis were generated using GraphPad Prism
6 software (Graphpad.com). Tables were created using Microsoft Word (Microsoft). All
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reference materials were organized and incorporated using Mendeley software version 1.19.3
(Mendeley Ltd.)
Data Availability Statement
RNA-sequencing data has been deposited and is available in the NCBI GEO database
(Accession number: GSE144886).

CHAPTER 3
EXPERIMENTAL RESULTS
In this chapter, I describe our work investigating the roles of EndoU during CoV
infection. First, I describe the effects of active versus inactive forms of EndoU on viral
replication and immune cell activation. Second, I describe experiments investigating the
mechanism used by EndoU to antagonize host immune signaling. Lastly, I describe in vivo
infection experiments that document a role of EndoU in MHV virulence. Overall, these results
parse out how EndoU inhibits the sensing of viral RNA by host innate immune pathways and
how inactivating EndoU may be a new approach for generating live-attenuated vaccines for
CoVs.
Characterizing EndoU-mutant Viruses in Cell Culture
In this section, the experiments address the question of whether EndoU plays a role in
viral replication and whether EndoU antagonizes innate immune signaling pathways during viral
infection of macrophages. I hypothesize that since viruses that encode catalytic mutations in
EndoU can be generated through reverse genetics and can grow to high titers in cell culture, that
EndoU is not necessary for efficient viral replication. Instead, I predict EndoU inhibits the
signaling of host innate immune pathways. Since the viral dsRNA signal can activate MDA5,
PKR, and OAS (Deng et al., 2017), I predict EndoU can block the dsRNA signal from being
detected by these host sensors. The following experiments are designed to determine if MHV
with EndoU mutations activate multiple PRRs leading to attenuation of the mutant-MHV
replication in macrophages.
64
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Coronaviruses Encoding EndoU Mutations Exhibit Impaired Replication in Macrophages
To determine if EndoU played a role in viral replication or inhibiting innate immunity,
we infected bone marrow-derived macrophages (BMDMs) with WT-MHV or two viruses
containing EndoU mutations (EndoUmut)(Fig. 6). The first virus named N15m3 contained a
catalytic histidine to alanine mutation (H262A) in the EndoU protein. The second virus
contained an EndoU destabilizing mutation (T98M), but also contained a mutation in nsp3
(R971A). To control for the nsp3 mutation, a third mutant virus was generated (N3m), which
contained the nsp3 mutation, but lacked the nsp15 mutation. Upon infection of wild-type
C57Bl/6 BMDMs, we found that EndoUmut viruses had significantly decreased viral replication
compared to wild-type virus (Fig. 7A). This defect in viral replication is noticeable as early as 12
hpi, and the difference becomes more predominant as time progresses. The N3m virus replicated
similarly to wild-type MHV. Interestingly EndoUmut viruses do not contain a defect in viral
replication during infection of IFNAR-/- BMDMs, which lack type I interferon signaling (Fig.
7B). These experiments suggest that EndoUmut viruses are attenuated through IFN signaling in
BMDMs. EndoU is not necessary for general viral replication, since there is no replication defect
in IFNAR-/- BMDMs. Instead, EndoU is necessary for efficient viral replication in IFNresponsive cells.
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Figure 6. Diagrams of mutant MHV-A59 strains. Depicted are the viral genome of wild-type
and each EndoUmut virus described in this study. N15m3 contains a H262A catalytic mutation
in nsp15/EndoU. N15m1 contains a T98M destabilizing mutation in nsp15/EndoU and an
R971A mutation in nsp3. N3m contains the R971A mutation in nsp3.

Figure 7. Evaluating the Growth Kinetics of EndoUmut Viruses in BMDMs. Cells were
infected with WT- or EndoUmut-MHV (N15m1 and N15m3) at an MOI of 0.1. N3m is a control
virus that contains an identical nsp3 mutation as N15m1, but lacks the EndoU mutation. At
indicated timepoints, cell supernatants were collected and viral titers were measured by plaque
assay in DBT cells. (A) C57Bl/6 BMDMs infected with viruses and viral titers measured from 4
to 24 hours post infection. (B) IFNAR-/- BMDMs infected with viruses and viral titers measured
from 4 to 24 hours post infection. Values were analyzed using a nonlinear regression test. ***P <
0.001; n.s., not significant. Data are representative of two to three independent experiments and
presented as the mean ± SD.
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Another phenotype that was associated with EndoUmut virus attenuation was increased
cell death during infection of wild-type BMDMs (Fig. 8). At 12 hpi during an multiplicity of
infection (MOI) of 1 infection or 24 hpi during an MOI of 0.1 infection, EndoUmut virus
induced increased cell death compared to wild-type virus. This was observed by a decrease in
cell density left on the plate and an increase in cell floating or lifted up off the plate. In
IFNAR-/- BMDMs, EndoUmut and wild-type viruses induce similar cell morphology. All viruses
formed syncytia, which are multinucleated cells fused together by viral spike protein. The
syncytia form at an identical rate beginning around 9 hpi and form to a similar extent in both
EndoUmut and wild-type virus infections. The IFNAR-/- BMDMs begin to form syncytia early
during replication, but do not detach from the plate like wild-type BMDMs. We hypothesize that
the increased cell death is one factor that attenuates EndoUmut viruses during macrophage
infection.
EndoUmut CoVs Stimulate Early and Robust IFN Responses
To determine EndoU is an IFN-antagonist, we quantitated the expression of a type I IFN
gene by qPCR during EndoUmut virus infection. We found that in wild-type BMDMs,
EndoUmut viruses induced significantly more IFNα11 expression at 8 hpi, 12 hpi, and 16 hpi
compared to WT or the N3m control virus (Fig. 9A). With the increase in IFN expression, the
amount of viral RNA replication was decreased as measured by expression of the N gene region
of the viral genome (Fig. 9B). At 12 hpi and 16 hpi, EndoUmut viruses had attenuated viral RNA
production, which ultimately leads to the decrease in viral titers found in Figure 7. These data
show that EndoU is an IFN antagonist during viral replication, and viruses lacking this
antagonist activity have attenuated viral RNA production during infection of macrophages.
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Figure 8. Evaluation of Cell Morphology During EndoUmut Virus Infection. BMDMs were
infected with WT- or EndoUmut-MHV at an MOI of 1 or 0.1. Cells were monitored over time
and at 12 or 24 hpi, images were taken of the cells. We observed differences cell number and
morphology during infection of IFN-competent BMDMs.

Figure 9. Evaluating IFN Stimulation by EndoUmut Viruses in C57Bl/6 BMDMs. Cells
were infected with WT- or EndoUmut-MHV (N15m1 and N15m3). At indicated timepoints,
cells were lysed and RNA was collected. After cDNA synthesis, qPCR was used to quantify the
levels of (A) Ifnα11 mRNA and (B) viral N gene RNA. Values were analyzed using a two-way
ANOVA test by time in A–C or an unpaired t test in D. *P < 0.05; n.s., not significant. **P <
0.01; ***P < 0.001; ****P < 0.0001. Data are representative of two to three independent
experiments and presented as the mean ± SD. These experiments were performed by Dr. Robert
Mettelman and Dr. Xufang Deng in Deng, Hackbart, et al. 2017.
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To determine if the increased expression of IFN mRNA led to increased production of
interferon-stimulated genes (ISGs), we tested if an EndoUmut virus increases the amount of ISG54
protein expressed in the cytoplasm of BMDMs. We found that EndoUmut virus induced increased
expression of ISG54 protein, not only in infected cells, but also neighboring cells (Fig. 10). While
WT had some low levels of ISG54 seen in infected cells, the EndoUmut cells were substantially
brighter. These results indicate that ISG protein production is enhanced during EndoUmut virus.
One important note is that the IFN is working in both an autocrine and paracrine fashion, so an
anti-viral response is being mounted in uninfected cells as well as infected cells.

Figure 10. Evaluating Expression of ISG54. C57Bl/6 BMDMs were infected with WT- or
EndoUmut-MHV at an MOI of 1. At 12 hpi, the cells were fixed, stained with anti-ISG54, anti-N
protein, and Hoescht 33342 stain for nuclei. Cells were then imaged and evaluated for expression
of ISG54 during infection.
To determine if the EndoU antagonist activity is detected in a stable cell line, we also
infected AML12 hepatocytes and measured viral replication and IFN stimulation. We found that
EndoUmut and wild-type MHV replicated to similar titers in AML12 cells (Fig. 11A) and had a
similar production of intracellular viral RNA (Fig. 11B). Mirroring the BMDMs, EndoUmut
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virus induced a type I IFN response in AML12 cells compared to wild-type virus (Fig. 11C).
EndoUmut virus also induced a type III IFN response in the hepatocytes as measured by IFNλ
expression (Fig. 11D). Interestingly, while EndoUmut infection produces a heightened IFN
response in AML12 cells, the viral replication of EndoUmut virus did not differ compared to
wild-type virus. One hypothesis for why replication is similar is that the IFN response is too slow
to effectively induce ISGs and halt the viral replication. It appears that peak viral titers have been
reached by 16 hpi, similar to peak expression of IFN mRNA production. The expression of IFN
may be too little and too late then to signal for production of ISGs to prevent the production of
infectious viral particles. Since this experiment was performed at a high MOI (MOI of 1), it
would be interesting to determine if the kinetics of viral replication is affected when cells are
infected lower MOIs. A low MOI may allow the IFN to signal before high titers of infectious
virus would enter the culture supernatant, thus allowing for an antiviral response to be mounted
against the EndoUmut virus.
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Figure 11. Growth Kinetics of Wild-type and EndoUmut MHV-A59 in AML12
Hepatocytes. AML12 cells were infected with wild-type (WT) or EndoUmut MHV-A59 at an
MOI of 1. At indicated timepoints, supernatant and intracellular RNA was collected. (A) Growth
kinetics of WT- and EndoUmut-viruses as measured by plaque assay in DBT cells. (B) Viral
gene expression measured by qPCR of N gene transcripts. Gene expression is normalized to 18s
rRNA and set relative to WT at 4hpi. (C) IFNβ1 gene expression as measured qPCR. (D)
IFNλ2/3 gene expression as measured by qPCR. Gene expression is normalized to 18s rRNA and
set relative to mock. Values were analyzed by student T-tests. Data are representative of three
independent experiments and presented as mean ± standard deviation.
EndoUmut CoVs Activate Multiple dsRNA Sensors, Leading to Apoptosis in Macrophages
Upon seeing enhanced cell death and increased IFN production during EndoUmut
infection of BMDMs, we sought to determine if other host dsRNA sensors were also activated
during EndoUmut virus replication. We evaluated PKR activation by analyzing phosphorylation
of eIF2α. Upon PKR binding to dsRNA, PKR will oligomerize and phosphorylate eIF2α, which
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blocks the translation of cellular proteins. PKR will also activate FADD which leads to apoptosis
in cells (Gal-Ben-Ari et al., 2019). We hypothesize that EndoUmut viruses will have increased
activation of dsRNA sensors, including PKR activity. We observed that EndoUmut viruses have
increased p-eIF2α, without an elevation in eIF2α (Fig. 12A). We also determined activation of
OAS1/2, which produces 2’5’ oligoadenylate (2’-5’A). The 2’-5’A binds to and activates RNAse
L, which then indiscriminately degrades cellular RNAs (Zhao et al., 2012). For OAS activation,
we measured cellular RNA degradation by a bioanalyzer assay (Fig. 12B). We observed that
EndoUmut viruses have increased RNA degradation in BMDMs, which decreases the RNA
integrity number (RIN), compared to wild-type MHV infections. The activation of PKR and
OAS, which leads to host translational shutoff and RNA degradation, ultimately causes apoptosis
in the BMDMs. We determined that the BMDMs underwent caspase-dependent apoptosis over
necroptosis and pyroptosis. While necrostatin-1 (Nec-1), a necroptosis inhibitor, or caspase-1
inhibitors (VX-765), a pyroptosis inhibitor, did not prevent the virus-induced cell death, a pancaspase inhibitor (zVAD) prevented the EndoUmut induced cell death (Fig. 12C). These data
suggest that EndoUmut viruses activated multiple host dsRNA sensors and the BMDMs
underwent apoptosis. In conjunction with the viral replication data, we hypothesize that the
macrophage apoptosis blocks and prevents infectious virus production.
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Figure 12. Evaluation of PKR and OAS Activation by EndoUmut Viruses. C57Bl/6
BMDMs were infected with wild-type or EndoUmut viruses at and MOI of 0.1. (A) At 8 hpi, cell
lysates were collected and evaluated for p-eIF2α, eIF2α, N protein, and β-actin by Western
Blotting. (B) RNA was extracted from cells at indicated timepoints. 200 ng of total RNA was
analyzed by bioanalyzer for RNA degradation patterns. RNA integrity numbers (RIN) and the
positions of 28S and 18S ribosomal RNA are shown. (C) Infected cells were subsequently
treated with either DMSO, zVAD (20 µM), Nec-1 (25 µM), or Vx-765(20 µM). Cell viability
was measured by CellTiter Glo Assay (Promega). Results were analyzed by two-way ANOVA.
These experiments were performed by Dr. Xufang Deng in Deng, Hackbart, et al. 2017.
The Mechanism of EndoU for Antagonizing IFN Signaling
In this section, I describe experiments aimed at investigating the mechanisms EndoU uses
to ensure that viral RNA is not recognized by host PRRs.
EndoU Activity Prevents the Dispersal of dsRNA from Replication Complexes
Since we observed a difference in host dsRNA sensor activation in EndoUmut virusinfected cells as compared to wild-type virus-infected cells, we sought to identify differences in
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the dsRNA signal during virus infections. We began the investigation of viral dsRNA by
performing immunofluorescence with the K1 anti-dsRNA antibody. We hypothesized that the
dsRNA is escaping from replication complexes during EndoUmut virus infection. The goal of
these experiments was to if EndoUmut virus had increased abundance and dispersal of dsRNA
signal away from viral replication complexes compared to wild-type MHV infection. We found
that indeed EndoUmut viruses had an increase in dispersed dsRNA away from replication
complexes. During infection of IFNAR-/- BMDMs, wild-type- and EndoUmut-MHV had similar
production of replication complexes as measured by nsp2/3 foci (Fig. 13A and B). In line with
our hypothesis, EndoUmut virus had increased dsRNA foci detected in the BMDMs, and the
number of “free” dsRNA away from replication complexes was also increased compared to wildtype virus. While observing if the dsRNA signal now lacks colocalization with nsp15, we
performed immunofluorescence with an anti-nsp15 antibody and the K1 antibody. We again
found that the viral dsRNA signal is dispersed from nsp15 during EndoUmut virus infection,
which leads to a decrease in co-localized foci of nsp15 and dsRNA (Fig. 13C and D).
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Figure 13. Mutation of Nsp15 Affects dsRNA Distribution in Virus-Infected BMDMs.
IFNAR-/- BMDMs were infected with WT or N15m3 at an MOI of 0.1. Cells were fixed at 6 hpi
and stained with (A) anti-nsp2/3, anti-dsRNA, and Hoescht 33342 or (B) anti-nsp15, antidsRNA, and Hoescht 33342. Surfaces for puncta were created based on dsRNA and nsp2/3
fluorescence, and fluorescence was measured within each surface. The foci from 25 images were
counted using IMARIS software program. (A) Images of subcellular localization of dsRNA and
nsp2/3 (Upper) and quantification of foci (Lower). (B) Images of subcellular localization of
dsRNA and nsp15 (Upper) and quantification of foci (Lower). Percent colocalization of nsp15
with dsRNA was calculated by dividing dsRNA+ nsp15+ foci by total dsRNA foci. Values were
analyzed by an unpaired t test and error bars represent the mean ± SEM, *P < 0.05; **P < 0.01;
***P < 0.001; n.s., not significant. Data are representative of two to three independent
experiments. (Scale bars, 5 μm.)
A previous study described that the CoV dsRNA signal disperses from replication
complexes late during infection (Becares et al., 2016). We therefore predicted that wild-type
MHV would have dispersed dsRNA similar to the EndoUmut at a later timepoint. We found that
the dispersal difference observed during EndoUmut infection is detected early during MHVinfection. As wild-type infection continues, the dsRNA also disperses from the replication
complexes (Fig. 14A). The dispersal of dsRNA at 12 hpi is similar between wild-type and
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EndoUmut MHV, leading to a similar number of total and free dsRNA foci during viral infection
(Fig. 14B). These data highlight that EndoU prevents an early dispersal of dsRNA from viral
replication complexes. This suggests that timing of the dispersal and detection of the dsRNA is
important in preventing immune activation and promoting viral replication.

Figure 14. Evaluating dsRNA Foci at 12 HPI in BMDMs. IFNAR-/- BMDMs were infected
with WT- or EndoUmut-MHV at an MOI of 0.1. Cells were fixed at 12 hpi and stained with antinsp2/3, anti-dsRNA, and Hoescht 33342. Surfaces for puncta were created based on dsRNA and
nsp2/3 fluorescence, and fluorescence was measured within each surface. The foci from 25
images were counted using IMARIS software program. (A) Images of subcellular localization of
dsRNA and nsp2/3. (B) Quantification of fluorescent total dsRNA, free dsRNA, and total nsp2/3
foci. Values were analyzed by an unpaired t test and error bars represent the mean, *P < 0.05;
**P < 0.01; ***P < 0.001; n.s., not significant. Data are representative of two to three
independent experiments. (Scale bars, 5 μm.)
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EndoU Activity Reduces the Accumulation of an Epitope Recognized by an Anti-dsRNA
Antibody in CoV-Infected Hepatocytes
To determine if this phenotype is present in a stable cell-line, we infected IFN-responsive
AML12 hepatocytes with wild-type or EndoUmut MHV and measured accumulation of
replication complexes (anti-nsp2/3) and K1 dsRNA foci at 8 hours post-infection (hpi) (Fig.
15A). We quantified the number of nsp2/3 foci and dsRNA foci from 50 individual cells. We
found that while the number of nsp2/3-labeled replication complexes were not significantly
different (Fig. 15B, right), the total number of dsRNA foci per cell was elevated in EndoUmutinfected cells (Fig. 15B, left). Median fluorescent intensity of the individual dsRNA foci was
also brighter in EndoUmut-infected cells (Fig. 15C). These results again indicate that EndoUmut
infection results in increased abundance of an epitope recognized by the K1 anti-dsRNA
antibody in multiple cell types.
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Figure 15. Evaluating the Accumulation of an Epitope Recognized by K1 antibody in
Virus-Infected AML12 Hepatocytes. AML12 hepatocytes were infected with WT- or
EndoUmut-MHV at an MOI of 0.1. Cells were fixed at 8 hpi and stained with K1 anti-dsRNA
antibody, anti-nsp2/3, and Hoescht 33342 nuclei stain. (A) Subcellular localization of dsRNA
and nsp2/3 foci was visualized. (B) Foci for dsRNA and nsp2/3 were quantified using Imaris
software from 50 individual cells. (C) The median fluorescent intensity was calculated for each
individual dsRNA foci and compared between WT- and EndoUmut-infections. Values were
analyzed by student T-tests. Data are representative of three independent experiments and
presented as individual cell points with mean ± standard deviation. n.s.: not significant
EndoU does not Alter Viral Replication Complex Structure or Formation
Since we observed a dispersal of dsRNA away from replication complexes, one
possibility for EndoU activity was that EndoU alters the formation of the viral DMVs which are
believed to sequester viral dsRNA during infection. To test this hypothesis, we performed
electron microscopy (EM) imaging on virally infected BMDMs. In both IFNAR-/- BMDMs (Fig.
16A) and C57Bl/6 BMDMs (Fig. 16B), we found that wild-type and EndoUmut viruses formed
DMVs and convoluted membranes. The DMVs during EndoUmut infection did not appear to be
deformed or decreased number, so we concluded that the viral replication complexes were not
altered by EndoU activity. These results are in line with a previous study that showed that only
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nsp3, nsp4, and nsp6 are necessary to form DMVs and convoluted membranes (Oudshoorn et al.,
2017).

Figure 16. Evaluating Replication Complexes using Electron Microscopy. BMDMs were
infected with WT- or EndoUmut-MHV at an MOI of 1. At 9 hpi, the cells were fixed, stained,
and imaged by electron microscopy. (A) IFNAR-/- BMDMs were infected and imaged by EM.
(B) C57Bl/6 BMDMs were infected and imaged by EM.
EndoUmut- and Wild-type Viruses have Similar Expression of Viral Proteins
Since viral replication is not altered by EndoU activity, we hypothesized that viral protein
production does not change between wild-type and EndoUmut infections. We found that
EndoUmut virus infection of both AML12 cells (Fig. 17A) and IFNAR-/- BMDMs (Fig. 17B)
produced similar levels of nsp1 and N protein compared to wild-type infection. The timing of
protein production also does not differ with N protein and Nsp1 becoming detectable at 6 hpi.
This data suggests that the formation of the dsRNA signal in the absence of EndoU does not alter
viral protein production, thus the viral replication does not differ between wild-type and
EndoUmut virus in the cells.
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Figure 17. Analysis of Viral Protein Production During EndoUmut Infection. (A) AML12
cells or (B) IFNAR-/- BMDMs were infected with WT- or EndoUmut-MHV at an MOI of 0.1.
Cellular protein lysate was collected at indicated timepoints and separated on a 10% SDS-PAGE
gel. After transfer, blots were stained with antibodies against N protein (J3.3), Nsp1 (anti-p28),
or host β-actin.
The Viral RNA Recognized by the K1 Antibody During CoV Infection is Negative-Sense
RNA
Since the dsRNA recognized by the K1 antibody accumulates in the absence of EndoU
activity, we sought to identify the dsRNA epitope. To this end, we sequenced the RNA
precipitated with the K1 anti-dsRNA antibody. We obtained ~30 million reads for each total
RNA sample and ~10 million reads for immunoprecipitated samples. Upon mapping the reads to
the mouse genome, we found similar read counts to host genes from both wild-type- and
EndoUmut-infected cells (data available at NCBI GEO database, GSE144886). We then mapped
the reads to the MHV-A59 genome (Genbank accession no. AY910861), and separated the viral
reads by strand specificity, expecting to identify complementary sequences from positive- and
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negative-sense RNA. Surprisingly, we found that the majority of reads from the
immunoprecipitated RNA sample mapped to negative-sense RNA (Fig. 18A). We discovered
that 99.8% of the reads from the input RNA sample mapped to positive-sense RNA. In contrast,
99.8% of the reads from the immunoprecipitated RNA mapped to negative-sense RNA. We
found that the reads from the input RNA sample mapped across the entire MHV genome, as
expected (Fig. 18B and D). Similarly, we found that the reads from the immunoprecipitated
RNA sample also mapped across the entire genome (Fig. 18C and E). We concluded that the K1
antibody immunoprecipitated full-length, negative-sense RNAs. When comparing the read
counts between wild-type virus- and EndoUmut virus-infected samples, we found an 8-fold
increase (6 x 105 read counts versus 4 x 106 read counts) in the abundance of the reads from the
EndoUmut virus-infected samples (Fig. 18A). These results are consistent with the increase in
dsRNA foci observed in EndoUmut-infected cells by immunofluorescence staining (Fig. 13).
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Figure 18. RNA-Seq Analysis of Input Viral RNA and RNA Immunoprecipitated with
Anti-dsRNA Antibody K1. IFNAR-/- BMDMs were infected with WT- or EndoUmut-virus at
an MOI of 1. At 6 hpi, RNA was purified, mixed with anti-dsRNA antibody, precipitated with
protein G beads, and purified off the beads. Input RNA and immunoprecipitated RNA samples
were evaluated by RNA-sequencing. (A) Summary of RNA reads mapped to MHV-A59
genome. Values in tables are the means of three biological triplicates. (B-E) Total reads mapped
to the viral genome. Reads were mapped to the positive-sense RNA from input RNA (B) and
immunoprecipitated RNA (C). Reads were mapped to the negative-sense RNA from input RNA
(D) and immunoprecipitated RNA (E). Read counts were quantified for each nucleotide of the
genome, then averaged into bins of 200 nucleotides for three biological triplicates. The black
(WT) and red (EndoUmut) lines represent the mean of each bin and shaded regions are the
standard deviation from the mean. Data are representative of two independent experiments.
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To determine the abundance of the dsRNA signal in other cell types, we infected
IFNAR-/- BMDMs, C57Bl/6 BMDMs, and AML12 cells with either wild-type or EndoUmut
virus, performed the anti-dsRNA immunoprecipitation, generated cDNA with random hexamers,
and evaluated the abundance of the captured viral RNA by qPCR. We consistently detected
elevated levels of viral RNA immunoprecipitated by the dsRNA antibody from EndoUmut virusinfected cells as compared to the levels detected in wild-type virus-infected cells (Fig. 19A). The
total input viral RNA was similar between wild-type- and EndoUmut-infected cells (Fig. 19B).
Overall, our sequencing and qPCR results suggest that EndoU reduces the accumulation of a
negative-sense viral RNA epitope that can be recognized by the anti-dsRNA antibody.

Figure 19. Quantifying Viral RNA Immunoprecipitated with Antibody K1. IFNAR-/BMDMs, C57Bl/6 BMDMs, and AML12 cells were infected with WT- or EndoUmut-virus
(EUmut) at an MOI of 1. At 6 hpi, RNA was collected and processed for dsRNA
immunoprecipitation (IP) with anti-dsRNA antibody or an isotype control. (A) CoV RNA
immunoprecipitated using K1 Ab was quantified using primers to the nucleocapsid (N) gene by
qPCR. (B) CoV RNA from input RNA was quantified by measuring the N gene expression.
Viral RNA was normalized to 18s rRNA and set relative to WT. Values were analyzed by
student T-tests. Data are representative of three independent experiments and presented as mean
± standard deviation. n.s.: not significant
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EndoU Activity Limits Abundance and Length of PUN RNAs
Previous studies showed that the 5’-end of the CoV negative-sense RNA contains polyU
extensions (Hofmann and Brian, 1991), and that EndoU cleaves at uridine residues (Bhardwaj et
al., 2008, 2006, 2004; Guarino et al., 2005; Ivanov et al., 2004; Kang et al., 2007). Therefore, we
considered the PolyU-containing, Negative-sense RNA, which we termed PUN RNA, as a
potential target for EndoU activity. We hypothesized that PUN RNAs accumulate in the absence
of EndoU activity. To quantitate the PUN RNAs, we generated cDNA from the negative-sense
RNA using a strand specific primer and performed a series of qPCRs with primers shown in
Figure 20A. Primer Set 1 flanks a taqman probe and provides a measurement of total negativesense RNA. Primer Set 2 measures the PUN RNA. By normalizing Set 2 to Set 1, we can
compare relative proportions of the negative-sense RNA that contain polyU sequences. To
control for potential “self-priming” of the viral RNA during cDNA synthesis, we performed
cDNA synthesis in the presence or absence of the (-) sense cDNA primer and quantified RNA
expression by qPCR (Fig. 20B). For both Set 1 and Set 2 qPCRs, we detected a significantly
higher signal with the (-) sense primer compared to no primer. When comparing wild-type- and
EndoUmut-infected cells, we detected a 10-fold increase in PUN RNAs from EndoUmutinfected cells as compared to wild-type virus-infected AML12 cells (Fig. 20C, left) and detected
a 60-fold increase in IFNAR-/- BMDMs (Fig. 20D, left). To determine if the polyA tail on the
positive-sense RNA was similarly reduced by EndoU activity, we used either random hexamers
or oligo-dT primers for reverse transcription and determined that the abundance of polyA tails on
positive-sense RNA does not differ between wild-type and EndoUmut infections (Fig. 20C and
D, middle and right). We concluded that EndoU activity reduces the abundance of negativesense RNA that contains polyU extensions.
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Figure 20. Quantifying PUN RNAs from Virus-Infected Cells. IFNAR-/- BMDMs and
AML12 cells were infected with WT- or EndoUmut-virus at an MOI of 1 and RNA was purified
from cell lysates. (A) Schematic of cDNA and qPCR design. cDNA was generated using cDNA
primers specific to the negative-sense RNA, random hexamers for total RNA, or oligo-dT
primers for positive-sense RNA. qPCR was performed with either primer set 1 or primer set 2 for
each polyU qPCR. Nucleotide number where (-) sense cDNA primer and probe bind to viral
RNA are labeled. (B) qPCR of cDNA synthesized with no primers or (-) sense cDNA primers.
(C) PolyU qPCR of negative-sense RNA (left) or PolyA qPCR primed with random hexamers
(middle) or oligo-dT primers (right) from AML12 cells at 8 hpi. (C) PolyU qPCR of negativesense RNA (left) or PolyA qPCR primed with random hexamers (middle) or oligo-dT primers
(right) from IFNAR-/- BMDMs at 6 hpi. Set 2 is normalized to Set 1 and are presented as mean ±
standard deviation. Values were analyzed by student T-tests. Data are representative of three
independent experiments. n.s.: not significant. nd: not detected.
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To determine if EndoU reduces the lengths of the polyU-extensions on the PUN RNA,
we completed a nested PCR reaction to obtain polyU-containing PCR products with a minimum
predicted size of ~ 100 bp (Fig. 21A). We detected PCR species of ~100 bp from both wild-typeand EndoUmut-infected cells, and detected a smear of larger PCR species unique to EndoUmut
virus-infected cells (Fig. 21B). To determine if the length of polyA tails on the positive-sense
RNA was affected by EndoU activity, we generated cDNA with oligo-dT primers to select for
polyA-containing RNAs and performed the nested PCR reactions. We found that the products
generated from positive-sense RNA were similar between wild-type and EndoUmut viruses,
consistent with our previous results indicating that the polyA tail is not cleaved by EndoU
activity (Fig. 21C). To determine if the smear of PCR amplicons represents extended polyU
sequences, we sequenced the amplicons with next generation sequencing and found that
EndoUmut PCR amplicons had an increase in the number of reads and proportion of products
with extended polyU sequences (Fig. 21D). The most striking feature of the sequencing results is
the bimodal distribution of the polyU extensions present in the EndoUmut-infected cell samples.
We found that the majority (65%) of the reads from wild-type virus infection contained 10
uridine residues. In contrast, only 35% of the reads from the EndoUmut virus-infected sample
contained 10 uridine residues. This was not due to a difference in the number of reads with 10
uridines, but an increase in longer polyU extensions detected in EndoUmut-infected cells. We
detected variability in the polyU extensions in the EndoUmut virus-infected sample, with 65% of
the reads containing from 11-17 uridine residues. We note that while PUN RNAs in EndoUmutinfected cells are only a few uridines longer than the PUN RNAs from wild-type virus-infected
cells, the PUN RNAs are 10-fold more abundant in EndoUmut virus-infected cells (Fig. 20).
Overall these experiments revealed that EndoU activity reduces the abundance and length of
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polyU extensions on PUN RNAs, consistent with our hypothesis that EndoU cleaves the PUN
RNAs during virus replication.

Figure 21. Evaluating the Length of PolyU Extensions on PUN RNA. AML12 cells were
infected with WT or EndoUmut virus at an MOI of 1. At 8 hpi, RNA was purified from cell
lysates and polyU nested PCR was performed. (A) Schematic of nested PCR. Briefly, cDNA was
generated with a strand-specific primer for negative-sense RNA or a oligo-dT-anchor primer for
positive-sense RNA, then nested PCR was performed. (B) PolyU or (C) PolyA pcr products
separated on a 10% polyacrylamide gel and stained with SYBR Green II. (D) PolyU PCR
products were purified from a polyacrylamide gel (B) and sequenced with MiSeq Next-Gen
Sequencing. (Left) Graph of read counts that contain a specific length of polyU extensions.
(Right) Graph of proportion of reads that contain a specific length of polyU extensions. Data are
representative of three independent experiments.
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Since EndoU is conserved among coronaviruses, we sought to determine if EndoU
reduces the abundance and length of the PUN RNAs in the alpha-coronavirus porcine epidemic
diarrhea virus (PEDV). Although the EndoU domains of MHV and PEDV exhibit only about
50% overall amino acid similarity, the catalytic histidines are 100% conserved (Deng and Baker,
2018). We showed that inactivation of EndoU in PEDV results in an increased type I and type III
IFN response during infection (Deng et al., 2019). To determine if EndoU limits the
accumulation of PUN RNAs during PEDV infection, we infected cells with either wild-type or
EndoUmut PEDV, isolated RNA and evaluated the levels of PUN RNAs. We found that, relative
to wild-type virus-infected cells, EndoUmut virus-infected cells contained abundant PUN RNAs
in PK1 (Fig. 22A) and Vero cells (Fig. 22B). Sequences of PCR products templated by PUN
RNA revealed that the length of the polyU extensions on the PUN RNAs was increased during
EndoUmut virus infection (Fig. 22C and E), with a similar bimodal distribution of polyU
extensions shown in Fig 22D. During PEDV infection, we did not observe a difference in polyAtail length (Fig. 22D). Taken together, these results indicate that PUN RNAs are generated
during alpha- and beta-CoV replication, and that the highly conserved EndoU activity targets the
polyU extensions in the PUN RNA.
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Figure 22. Evaluating the Abundance and Length of PUN RNA during PEDV Infection.
PK1 or Vero cells were infected with WT- or EndoUmut- PEDV at an MOI of 0.1. RNA was
purified at 24hpi. (A) PolyU qPCR quantified in PK1 cells. (B) PolyU qPCR quantified in Vero
cells. Set 2 is normalized to Set 1 and are presented as mean ± standard deviation. (C) PolyU or
(D) PolyA nested PCR products from PK1 Cells. (E) PolyU PCR products from PK1 cells were
purified from a polyacrylamide gel (C) and sequenced with MiSeq Next-Gen Sequencing. (Left)
Graph of read counts that contain a specific length of polyU extensions. (Right) Graph of
proportion of reads that contain a specific length of polyU extensions. Values were analyzed by a
student T-test. Data are representative of two independent experiments.
PUN RNA is a PAMP
Since EndoU both reduces PUN RNA abundance and suppresses host MDA5 activation,
we hypothesized that CoV PUN RNA is a PAMP. To directly test this hypothesis, we measured
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IFN stimulation following introduction of PUN RNAs into AML12 cells. PUN RNA was
synthesized by T7 in vitro transcription of digested plasmids that contained sequences
representing the 5’-end or 3’-end of the viral genome (Fig. 23A). The PUN RNA, designated N5,
and other coronavirus positive- and negative-sense RNA termini (P3, P5, N3) were transfected
into AML12 cells. Total cellular RNA was harvested at 8 hours post-transfection (hpt) and
subjected to qPCR for IFNβ1 mRNA expression. We found that the presence of PUN RNAs
increased IFNβ1 expression by 2,000-fold (Fig. 23B), which was 4-fold higher than any other in
vitro transcribed viral RNA, indicated that PUN RNA is a PAMP.
To determine if the polyU sequence contributed to the robust IFN stimulation of the PUN
RNA, we transcribed PUN RNA either containing 12 uridines (N5) or no uridines (N5.NoU) at
the 5’ end. We found that removing the 12 uridines from the PUN RNA significantly decreased
the ability of that RNA to induce IFNβ1 expression (Fig. 23C). Also, removing sections of the 3’
end of the PUN viral sequence (N5.180 and N5.100) resulted in a decrease in IFNβ1 expression,
suggesting the polyU sequence alone is not sufficient to induce the IFN response (Fig. 23C).
Shortening the polyU extension to 8 uridines (N5.8U) or 4 uridines (N5.4U) also diminished the
IFN activation by the PUN RNA (Fig. 23D). These results suggest that a polyU sequence of 12
U’s can enhance the IFN response to PUN RNA.
Previous studies documented that MHV-A59 infection induces IFN through MDA5
signaling (Deng et al., 2017; Roth-Cross et al., 2008). To determine if PUN RNA activates
MDA5, we generated MDA5 knock-down (MDA5-KD) AML12 cells by CRISPR-Cas9
transduction (Fig. 23E) and measured IFN activation by virus infection or RNA transfection.
Both viral infection and the transfection of the PUN RNA induces IFNβ1 expression in an
MDA5-dependent manner (Fig. 23F and G). During viral infection of MDA5-KD cells, both
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wild-type and EndoUmut virus infections had a significant reduction of IFNβ1 expression (Fig.
23F). IFNβ1 induction by in vitro transcribed PUN RNA also was significantly reduced in
MDA5-KD cells (Fig. 23G). Importantly, we found that a single-stranded, in vitro-transcribed
RNA activated MDA5, which was previously known to be activated by long complementary
dsRNA. Taken together, these data suggest that the PUN RNA can act as an MDA5-dependent,
viral PAMP.
EndoU Cleaves PUN RNA and Dampens Activation of IFN
To determine if EndoU activity can cleave the PUN RNA PAMP, we performed a series
of in vitro cleavage assays (Kang et al., 2007). We incubated EndoU with 5’-negative-sense
RNA containing a 12 U extension (RNA 1) or without the 12 U extension (RNA 2)(Fig 24A).
When either RNA 1 or RNA 2 is mixed with EndoU in the presence of MnCl2, the RNA is
degraded over time (Fig. 24B). This degradation is most likely due to the presence of multiple
uridines throughout RNA 1 and RNA 2, which is consistent with previous studies (Bhardwaj et
al., 2006). To determine if the polyU extension is cleaved, we substituted the viral sequence
uridines with adenosines and generated RNA 3 and RNA 4 (Fig. 24A). When mixed with EndoU
and MnCl2, the polyU extension of RNA 3 is cleaved, producing a cleavage product the size of
RNA 4 (Fig. 24C). RNA 4 was not cleaved, consistent with the requirement of uridine residues
for EndoU recognition and cleavage.
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Figure 23. Determining if PUN RNA is a MDA5-dependent PAMP. RNA was in vitro
transcribed from DNA constructs and transfected into AML12 cells. At 8 h post transfection
(hpt), RNA was purified from cell lysates and IFNβ1 gene expression was measured by qPCR.
(A) Schematic diagram of RNA products from in vitro transcription. (B) IFNβ1 gene expression
induced by coronaviral RNA termini. (C) IFNβ1 gene expression by PUN RNA constructs. (D)
IFNβ1 gene expression by PUN RNA constructs with varying polyU lengths. MDA5knockdown AML12 cells (MDA5-KD) were generated by CRISPR/Cas9 transduction. (E)
Western blot of WT and MDA5-KD AML12 cells for MDA5 and Actin. (F) WT and MDA5-KD
AML12 cells were infected with WT- or EndoUmut-MHV at an MOI of 1. IFNβ1 expression
was measured at 16 hpi. (G) In vitro transcribed PUN RNA was transfected into WT- or MDA5KD AML12 cells. IFNβ1 expression was measured at 8 hpt. IFNβ1 gene expression is
normalized to 18s rRNA and set relative to mock. Values were analyzed by student T-tests. Data
are representative of three independent experiments and presented as mean ± standard deviation.
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To determine if EndoU cleavage can decrease the ability of PUN RNA to stimulate IFN,
we cleaved the PUN RNA with EndoU (Fig. 24D). In the presence of EndoU and MnCl2, the
PUN RNA was degraded into smaller RNA fragments. After EndoU treatment, we transfected
the PUN RNAs into AML12 cells and measured IFN stimulation (Fig. 24E). We found
transfecting the RNA treated with EndoU decreased the IFN stimulation activity. We note that
the PUN RNA with MnCl2 migrated faster in the agarose gel, possibly due to a change in RNA
structure, but we do not observe a difference in IFN stimulation in the presence of MnCl2 alone.
Overall, EndoU is capable of cleaving and degrading PUN RNA, which then reduces the ability
of PUN RNA to stimulate IFN.
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Figure 24. Evaluating EndoU Activity on PUN RNA. RNA was cleaved by EndoU and
separated by gel electrophoresis. (A) Sequences and length of RNAs 1-4. (B) EndoU cleavage of
RNA 1 and RNA 2 performed for stated times and separated on a 10% polyacrylamide gel. (C)
EndoU cleavage of RNA 3 and RNA 4 for 30 min and separated on a 10% polyacrylamide gel.
(D) EndoU cleavage of in vitro transcribed PUN RNA (N5) for 45 min and separated on a 1%
agarose gel. (E) RNA treated by EndoU cleavage was transfected in AML12 cells and at 8 hpt,
RNA was purified from cell lysates and IFNβ1 gene expression was measured by qPCR. IFNβ1
gene expression is normalized to 18s rRNA and set relative to mock. Values were analyzed by
student T-tests. Data are representative of three independent experiments and presented as mean
± standard deviation.
Evaluating the Pathogenesis of EndoU-mutant Viruses in Mice
In this section, I discuss the role of EndoU as a virulence factor during MHV infection in
mice. Since EndoUmut viruses are attenuated in wild-type macrophages, I predict that
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EndoUmut viruses will be attenuated in vivo. I hypothesize that the IFN response generated
during the EndoUmut virus infection will stimulate an adaptive immune response and a memory
response that will protect the mice from challenge with wild-type virus. The experiments that
follow address the potential of using EndoUmut viruses as live-attenuated vaccine candidates.
EndoUmut Viruses are Attenuated In Vivo
Because EndoUmut viruses induces multiple host innate immune sensors, we
hypothesized that EndoUmut viruses will be attenuated compared to wild-type virus infection in
vivo. To test this, we first infected C57Bl/6 mice intraperitoneally (IP) with 6 x 104 PFUs of
wild-type or EndoUmut viruses. After 3- or 5-days post infection (dpi), we collected liver and
spleen tissue for viral pathogenesis analysis. Interestingly upon IP infection, we did not detect
infectious virus in the spleen or liver of EndoUmut virus infected mice at either 3- or 5-dpi,
while we detected wild-type MHV titers as high as 105 PFU/g of tissue (Figure 25A). We also
performed H&E staining of liver slices to evaluate the pathogenesis of the infections. Wild-type
infection induces plaque formation in the liver caused by immune cells infiltrating into the tissue
to control the viral infection. In contrast, we detected no evidence of disease or immune cell
infiltration in the liver during EndoUmut virus infections (Figure 25B).
A lethal challenge model of intracranial (IC) infection by MHV-A59 was also used to test
EndoUmut virus attenuation. Briefly, 600 PFU of wild-type or EndoUmut viruses were injected
into the mouse cranium and viral pathogenesis was measured by loss of body weight. Wild-type
MHV infection leads to weight loss, requiring euthanasia of the mice by 7-9 dpi. Comparatively,
all EndoUmut infected mice had transient weight loss and all mice recovered from the viral
infection, leading to 100% survival (Figure 25C and D). The attenuation of EndoUmut viruses is
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type I IFN-dependent, since infection of IFNAR-/- C57Bl/6 mice shows similar pathogenesis and
mortality in both wild-type and EndoUmut MHV infections (Figure 25E).

Figure 25. Evaluating the Pathogenesis of EndoUmut Infection in Mice. Six-week-old
C57BL/6 mice were intraperitoneally inoculated with 6.0 × 104 pfu of WT or EndoUmut viruses
(N15m1 and N15m3). (A) Liver and spleen were harvested at 3 and 5 dpi (DPI) and tested for
viral titer by plaque assay. Red dashed line indicates the limit of detection. (B) At 5 dpi, mouse
livers from A were harvested for pathology evaluation by H&E staining. Typical lesions of
MHV infection in liver were indicated by arrowheads. (Magnification, 40×.) (C and D) Mice
were inoculated by intracranial injection with 600 pfu of WT or mutant viruses. Viral
pathogenicity was evaluated by (C) bodyweight loss and (D) survival rate. Data are a pool of two
independent experiments. The P values of survival rate were calculated using a log-rank test. (E)
Twelve- to 14-wk-old IFNAR-/- mice were intraperitoneally inoculated with 50 pfu of virus and
monitored for mortality. The P values of survival rate were calculated using a log-rank test. WT
vs. N15m1, P = 0.0047; WT vs. N15m3, P = 0.0719; N15m1 vs. N15m3, P = 0.0145. Mouse
numbers (n) are indicated in parentheses. Data are a pool of two independent experiments. Error
bars in A, B, and D represent the mean ± SEM. These experiments were performed with Dr.
Xufang Deng and Dr. Robert Mettelman in the Baker Lab.
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EndoUmut Viruses Elicit a Protective Immune Response In Vivo
Because the EndoU mutant viruses are highly attenuated for virulence in vivo, we wanted
to determine if these viruses could elicit protective immunity against subsequent challenge with
wild-type virus. C57Bl/6 mice were infected intraperitoneally with 6 × 104 pfu of EndoUmut
viruses. Four weeks later, the same mice, as well as naïve, age-matched mice, were challenged
with 6 × 104 pfu of WT virus and viral burden and liver pathology were assessed at 5 dpi. In
contrast to naïve mice, mice that had been inoculated with EndoUmut viruses before challenge
with wild-type MHV produced undetectable viral titers in tested organs (Fig. 26A) and no
observable liver pathology (Fig. 26B). Even more striking were the results from intracranial
infection. Here we challenged mice that had been previously inoculated 7 wk prior with
EndoUmut or naïve mice with a 10-fold lethal dose of MHV-WT. We found that the immunized
mice experienced only minor weight loss and fully recovered from infection, whereas the agematched naïve mice succumbed to infection (Fig. 26C and D). This finding demonstrates that
immunization with EndoUmut viruses protects mice from a subsequent lethal challenge,
suggesting that EndoUmut viruses can elicit strong, protective immune memory in mice, which
highlights their potential as vaccine candidates.
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Figure 26. Evaluating if EndoUmut can Elicit a Protective Immune Response in Mice. Tenweek-old naïve C57BL/6 mice or mice immunized with mutant virus 4 wk prior (from Fig. 25A)
were intraperitoneally inoculated with 6.0 × 104 pfu of WT virus. At 5 dpi, organs were
harvested for (A) viral titration and (B) liver pathology. Red dashed line in A indicates limit of
detection. Images of liver sections in B are representative of four mice per group.
(Magnification, 40×.) Black arrowheads indicate the liver lesions caused by MHV infection. (C
and D) Thirteen-week-old naïve mice and mice immunized seven weeks prior with N15m1 (from
Fig. 7E) were challenged with 6.0 × 103 pfu WT virus by intracranial inoculation. Viral
pathogenicity was evaluated by (C) body weight loss and (D) percent survival. Mouse numbers
(n) are indicated in parentheses. The P values of survival rate were calculated using a log-rank
test. Data are a pool of two independent experiments. Error bars in A and C represent the mean ±
SEM. These experiments were performed with Dr. Xufang Deng and Dr. Robert Mettelman in
the Baker Lab.

CHAPTER 4
DISCUSSION
Summary.
Our studies sought to determine the role that the CoV endoribonuclease plays during viral
replication. Previous studies found that purified EndoU protein could cleave ssRNA and dsRNA
at uridine residues, but how this activity functioned during viral replication was unknown.
Previous researchers thought that EndoU activity was required for viral RNA synthesis, since
several attempts at generating EndoU-mutant CoVs were unsuccessful. Also, previous studies
found that overexpression of EndoU in cells can block multiple innate immune signaling
pathways, thus indicating that EndoU may be an immune antagonist and virulence factor during
viral infection. Our studies provided evidence for the role of EndoU activity in inhibiting innate
immune signaling and provided mechanistic details for how EndoU inhibits the detection of a
CoV pathogen-associated molecular pattern (PAMP).
We found that EndoU activity is not necessary for viral RNA production or viral
replication, but is necessary to prevent the activation of multiple host innate immune sensors. We
found that replication of EndoU mutant (EndoUmut)-MHV leads to an activation of multiple
host sensors in wild-type macrophages and eventual attenuation of viral replication compared to
wild-type virus infection. In IFN-signaling deficient macrophages (IFNAR-/- BMDMs),
EndoUmut viral replication is identical to wild-type MHV. EndoUmut viruses have increased
activation of the host PRRs that recognize viral dsRNA, including MDA5, PKR, and
OAS/RNAse L. MDA5 activation induces the production of IFN, PKR phosphorylates eIF2α to
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inhibit protein translation, and OAS1/2 activates RNAse L to degrade intracellular RNA. The activation
of multiple host sensors eventually leads to apoptosis in the macrophages and attenuation of

EndoUmut virus replication. Overall, we report that EndoUmut viruses activate multiple innate
immune sensors, driving macrophages to undergo apoptosis. This immune activation attenuates
viral replication and reduces the production of infectious virions (Fig. 27).

Figure 27. Diagram of Host dsRNA Sensor Activation by EndoUmut Viruses. Viral dsRNA
signals can activate host PRRS: MDA5, PKR, and OAS1/2. MDA5 activation leads to
expression of IFNs. PKR activation leads to the shutdown of host translation machinery. OAS
activation leads to RNAse L activation, which degrades host RNA. Overall, these responses lead
to apoptosis in macrophage. We found that EndoU activity plays a critical role in preventing the
activation of these sensors.
Since EndoU is an immune antagonist, we sought to determine if mutations in EndoU
could be used for generation of potential live-attenuated vaccines. To test whether EndoUmut
viruses are attenuated in vivo, we infected mice and determined if EndoUmut MHV caused
severe pathogenesis. Upon IP or IC infections in wild-type mice, we found that EndoUmut
viruses have attenuated viral replication and have decreased immunopathogenesis and mortality
compared to wild-type MHV. These results indicated that the EndoUmut viruses stimulated an
immune response and were effectively cleared by the mice without causing significant disease.
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Even though the EndoUmut virus is substantially attenuated in mice, the mutant virus still
elicited a protective immune response by protecting the EndoUmut-immunized mice from wildtype virus challenge. Therefore mutations in EndoU show potential as mutations for the
generation of live-attenuated vaccines for CoVs.
Since EndoUmut viruses showed promise as a vaccine candidate, we sought to determine
the mechanism for EndoU in inhibiting innate immune signaling. EndoU had previously been
shown to degrade dsRNA, which is the PAMP for the EndoUmut-activated PRRs. We therefore
hypothesized that EndoU would degrade the CoV-specific dsRNA PAMP during viral
replication. We found that cells infected with EndoUmut viruses exhibited an increase in dsRNA
signaling, but interestingly the dsRNA signal was formed by negative-sense viral RNA. Since
EndoU cleaves at uridine residues, we hypothesized that EndoU cleaved a uridine motif in the
negative-sense RNA. One feature that caught our attention was the poly-uridine (polyU) head of
the negative-sense RNA (Hofmann and Brian, 1991).
We hypothesized that during the synthesis of negative-sense RNA, the CoV RNAdependent RNA polymerase generated negative-sense RNAs with variable lengths of polyU
extensions. EndoU can recognize and cleave the polyU extensions, which limits the ability of the
negative-sense RNA to form a viral PAMP. In the absence of EndoU activity, the polyU
extension on the PUN RNA enhances the interactions of the PUN RNA with a complementary
region of the viral genome to form an epitope recognized by MDA5 and other host sensors,
signaling for activation of innate immunity.
Our studies reveal that CoV EndoU activity cleaves polyU-containing, negative-sense
RNA (termed PUN RNA), which acts as a viral PAMP. EndoU cleaves the poly-uridine
sequence on the PUN RNA, limiting the length and abundance of the polyU extension. We
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determined that EndoUmut-infected cells had significantly more PUN RNAs compared to wildtype infection. The increased PUN RNAs were also longer in EndoUmut virus infected cells
compared to wild-type MHV infected cells. To test if PUN RNA can activate host PRRs, we in
vitro-transcribed PUN RNA and found in fact that PUN RNA stimulates MDA5 to signal for an
IFN response in cells. Removal of the polyU extensions reduced the IFN stimulation by the PUN
RNA, indicating that removal of the polyU sequence by EndoU could reduce the IFN stimulation
by the PUN RNA. EndoU cleavage of in vitro-transcribed PUN RNA also reduced the immune
stimulation by the PUN RNA. Overall, our studies revealed that the PUN RNA is a PAMP and
that EndoU activity is essential for limiting the accumulation and length of PUN RNAs during
CoV infection (Fig. 28).
Our studies have determined a role for EndoU inhibiting innate immunity during CoV
replication. We have found that EndoU will prevent activation of dsRNA PRRs by cleaving the
PUN RNA. We also discovered that PUN RNA is a CoV PAMP, which can activate MDA5.
While we have determined the mechanism for EndoU to antagonize innate immunity, there are
many interesting questions regarding innate immune signaling and CoV replication that are still
unanswered. In the following sections, I will address these questions.

103

Figure 28. Model Depicting EndoU Cleavage of PUN RNAs. This model depicts how EndoU
activity limits the generation of PUN RNA, which can act as a PAMP. We found that PUN
RNAs with variable lengths of polyU sequences are generated in the absence of EndoU activity.
We predict that these PUN RNAs can fold back and generate stem-loop structures by hybridizing
with an A/G rich domain located within the PUN RNA or on adjacent RNAs. This stem-loop
structure may be recognized as dsRNA by host PRRs, thus stimulating the host innate immune
response. The function of EndoU during replication is to reduce the length of polyU sequences,
thus limiting the potential for generating PAMPs.
What RNAs are Activating MDA5 during CoV Infections?
Identifying viral PAMPs and the host PRRs that are activated by the PAMPs is critical
for developing strategies for treating viral infections. Previous studies implicated MDA5 as the
PRR important for macrophages to produce an IFN response against coronavirus infection (Deng
et al., 2017; Kindler et al., 2017; Roth-Cross et al., 2008). Consistent with these studies, we
report that the PUN RNA acts as a novel PAMP, recognized by MDA5 (Fig. 23). We show that
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PUN RNA can stimulate a type I IFN response and knocking down MDA5 by CRISPR-Cas9
limits the IFN stimulation by PUN RNA. The PUN RNA is then a novel PAMP that activates an
IFN signal through MDA5. The PUN RNA is a unique RNA PAMP that is generated during
CoV replication.
Canonically, MDA5 binds to long dsRNA species, such as poly I:C, to induce IFN
signaling (Kato et al., 2006). For most viruses, the leading hypothesis is that complement dsRNA
composed of positive- and negative-sense RNAs form the signal that activates host dsRNA
sensors. Contrary to this hypothesis, one previous study showed that viral RNA that activated
MDA5 formed a hybrid ssRNA/dsRNA structure (Pichlmair et al., 2009). In this study, the
researchers immunoprecipitated RNA from encephalomyocarditis virus (EMCV)-infected cells
with the K1 antibody and found that this RNA also bound to MDA5. Additionally, when this
RNA was separated on an agarose gel, there was not only a dsRNA band, but also a large amount
of RNA stuck in the well of the gel. When determining which of these RNAs activated MDA5, it
was the larger well RNAs, not the dsRNA, that activated IFN signaling. This study suggested
that the “normal” viral dsRNA was not the potent activator of IFN signaling, but instead a
higher-ordered structure that is composed of ssRNA and dsRNA stimulated MDA5.
In line with this previous study, our study suggests that the negative-sense RNA may
form a higher-order RNA structure that can bind and activate MDA5. While we have not yet
investigated the double-strandedness of the negative-sense RNA, our immunoprecipitation with
the dsRNA antibody yielded predominantly negative-sense RNA. This suggests the negativesense RNA can form a dsRNA epitope recognized by an anti-dsRNA antibody without the
presence of the complement positive-sense RNA. It would be interesting to determine if
immunoprecipitated CoV RNA is similar to the immunoprecipitated EMCV RNA with the
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formation of a higher-ordered RNA that possesses both ssRNA and dsRNA qualities. Future
studies should investigate the nature of K1-immunoprecipitated RNA for being either ssRNA or
dsRNA. Also, studies could focus on whether the polyU extensions and EndoU alter whether the
viral negative-sense RNA is ssRNA or dsRNA.
To investigate CoV PAMPS that are detected by MDA5, we transfected various CoV
RNA segments into cells and measured IFN stimulation. We found that PUN RNA stimulated
high levels of IFN and the removal of the polyU extensions of the PUN RNA dampened the IFN
stimulation. The PUN RNA IFN signal was mediated by MDA5. The looming question about
this result is how does the polyU extension enhance MDA5 activation? One possibility is that the
polyU’s stabilize an RNA secondary structure that is recognized by MDA5. The polyU sequence
could bind in cis with the upstream viral RNA sequence, either generating or locking in place a
unique RNA structure. Without the polyU extension, the negative-sense RNA could form an
RNA structure that is not recognized by MDA5. Another possibility is that the polyU sequence
binds in trans to other viral RNAs or potentially host RNAs that contain polyA sequences. The
binding in trans may produce a short dsRNA sequence with the polyU extension but may also
generate a higher-ordered, web-like RNA structure. This web-like structure of RNA would
contain both ssRNA and dsRNA that would then be immunostimulatory, akin to the Pichlmair
study (Pichlmair et al., 2009). Overall, future studies are needed to determine if the polyU
extensions drives RNA structure changes in the PUN RNAs, which could ultimately alter the
immune stimulation capabilities of the PUN RNA.
While PUN RNA from MHV-A59 is immunostimulatory, it has yet to be determined if
the PUN RNA from other coronaviruses have a similar phenotype. Interestingly, the sequence of
the 5’ UTR of the negative strand is not well conserved among coronaviruses. While SARS-CoV
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and SARS-CoV-2 share the highest similarity (89%), the other beta-CoVs share about 45% RNA
sequence similarity with MHV-A59 (Fig. 29). Future studies need to determine if other CoV
PUN RNAs have a similar immunostimulatory effect. The main questions driving these studies
would be to determine if polyU extensions enhance the immune stimulatory capabilities of all
CoV PUN RNAs.
If all PUN RNAs stimulate MDA5, then the recognition of MDA5 may not be a
sequence-dependent, but instead be RNA structure-dependent. This naturally leads back to the
question of what RNA structures the PUN RNAs form compared to positive-sense RNA. Many
studies have determined that the positive-sense RNA forms conserved RNA secondary
structures, including pseudoknots, that are necessary for viral RNA replication (Yang and
Leibowitz, 2015). Even though these structures are present in the positive-sense RNA, the
positive-sense RNAs is not as immunostimulatory compared to the negative-sense RNA (Fig.
23). This result suggests that the complement RNAs may form different RNA structures. CoVs
then may encode EndoU to combat the immune signaling stimulated by the PUN RNA.
One question is why did CoVs evolve to use EndoU to cleave the PUN RNA instead of
mutating the viral sequence to prevent an MDA5-recognized structure from forming. With the
positive-sense RNA structures being vital for RNA replication, any alterations to the positivesense structure or sequences may be detrimental to viral replication and attenuate the virus.
Therefore, the sequence of the complement negative-sense RNA cannot be altered, even though
the negative-sense RNA can stimulate IFN. Since the viral sequence cannot be changed, CoVs
may then use EndoU to combat the immune stimulation. EndoU will cleave the viral RNA thus
antagonizing the cellular immune responses without forcing selection of the genomic RNA
sequences.
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Figure 29. RNA Sequence Alignment of (-) Sense, 5’ UTRs of CoVs. Alignment of the first
500 nucleotides of the negative-sense 5’ UTR of multiple CoVs. Coronaviruses that are aligned
are MHV-A59 (AY910861), SARS-CoV (FJ882957.1), MERS-CoV (KJ614529.1), SARS-2CoV (MN985325.1), and PEDV-CoV (KF272920). Alignment was performed with Clustal
Omega, then visualized with ESPript3.
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Currently, many studies utilize nucleic acids as adjuvants to stimulate innate immune
responses (Temizoz et al., 2018). The theory is that by producing RNAs that will stimulate an
appropriate anti-viral response in conjunction with additional viral epitopes, then a robust
immune response will be mounted to these additional viral epitopes. With the PUN RNA
forming an MDA5-recognized structure, it would be interesting to determine if the PUN RNA
could act as an MDA5 adjuvant to elicit robust IFN responses during immunizations. The PUN
RNA could then be inserted into RNA vaccine constructs to act as an immune response boosting
RNA structure. The PUN RNA would activate MDA5 within cells containing the RNA vaccine
epitope, thus driving an appropriate anti-viral response to the viral epitopes.
What are the RNA Epitopes that the dsRNA Antibodies Recognize?
One of the surprising findings from our study was that antibody K1, which was
developed as an anti-dsRNA antibody (Schonborn et al., 1991), recognizes CoV negative-sense
RNA (Fig. 18). Our immunofluorescence studies showed that the epitope recognized by K1
accumulates in EndoUmut infected cells. Using RNA sequencing, we determined that the RNA
bound by K1 was negative-sense RNA. We speculate that coronavirus negative-sense RNA
forms a higher-order RNA structure recognized by the K1 antibody, and that this RNA is also
recognized by host sensors. Supporting this idea, a previous study showed that the viral RNA
immunoprecipitated by the K1 antibody during EMCV infection formed a higher-order RNA
structure and could activate MDA5 (Pichlmair et al., 2009). Our approach using RNA-seq
analysis of immunoprecipitated RNA could be widely used to determine if other unique dsRNA
epitopes are generated during viral infections. Schonborn et al developed four anti-dsRNA
antibodies: J2, J5, K1 and K2. These antibodies were generated against L-dsRNA from S.
cerevisiae and each antibody has unique binding specificities to different dsRNA species. For
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example, the K1 antibody was reported to be highly specific to poly I:C, whereas the J2 antibody
is specific to L-dsRNA (Schonborn et al., 1991; Sweeney et al., 1976). The differing specificities
suggest that each anti-dsRNA antibody recognizes unique dsRNA structures or sequences.
Ultimately, structural studies are needed to fully elucidate the higher-order RNA structures that
these dsRNA antibodies are recognizing during coronavirus infection.
Another interesting note about the dsRNA antibodies is that the antibodies do not detect
RNA from every virus. The J2 antibody can detect a dsRNA signal from CoV, reoviruses,
adenoviruses, herpes viruses, and vaccinia virus, so J2 can recognize RNA from both RNA and
DNA viruses. Interestingly, the J2 antibody will not detect any signal from Influenza A virus or
La Crosse fever viruses (Son et al., 2015; Weber et al., 2006). These studies bring up the idea
that not all viruses will produce the dsRNA antibody signal, even though they produce dsRNA
that can activate host dsRNA sensors (Kato et al., 2008; Pfaller et al., 2014). J2 recognizes
antigens with dsRNA at least 40bps and has a 10 times high affinity to poly A:U or mixed based
pairs than to poly I:C (Bonin et al., 2000). Although J2 will not recognize dsRNA during some
viral infections, other dsRNA antibodies may bind and recognize viral RNA during these
infections.
There are many unanswered questions about the binding specificities of these antibodies.
First, is one antibody better at recognizing viral dsRNA? Both K1 and J2 can recognize dsRNA
by immunofluorescence and immunoprecipitation, but they recognize different dsRNA species.
While MDA5 can be activated by K1 immunoprecipitated dsRNA, whether J2
immunoprecipitated RNA activates MDA5 is unknown. It may be that J2 immunoprecipitated
RNA will activate different RNA sensors, since it may recognize a different RNA epitope. The
current results indicate that for MDA5-activating viruses, K1 may be the better antibody to
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determine the dsRNA-activating epitopes. Further work is necessary to determine what the exact
epitopes these antibodies are recognizing during viral infection. Additionally, the question of
why certain viruses do not produce a dsRNA signal recognized by the antibodies needs to be
addressed.
Is the PUN RNA Cleavage Activity of EndoU Conserved Among Nidoviruses?
Since EndoU is conserved among all coronaviruses and arteriviruses, the function of
EndoU is hypothesized to be conserved among the viral family. We observed that EndoU from
both alpha- and beta-coronaviruses can control the length and abundance of PUN RNAs. While
the function of EndoU is conserved, the amino acid sequence conservation is only 40% between
PEDV and MHV (Fig. 30). While other human beta-coronaviruses, such as SARS-CoV, MERSCoV, and SARS-CoV-2, are more conserved to MHV than PEDV, the amino acid sequences are
still less than 50% conserved. One interesting feature of the MHV genome is a 33 amino acid
insert in the middle of EndoU. This inserted peptide actually forms a packaging signal for MHV
for the genomic RNA to be bound and packaged into the virion selectively over sgRNAs
(Athmer et al., 2017).
Although the overall amino acid sequence is not well conserved, the catalytic histidines
of all the CoVs is conserved. The histidines are indicated by the green arrows in Figure 30. With
conservation of catalytic histidines, mutations that remove EndoU activity should be able to be
applied to any known or recently emerged coronavirus. The structure of these endoribonucleases
also contain conserved secondary and tertiary protein structures (Nedialkova et al., 2009). This
indicates that anti-viral therapeutics targeting the EndoU catalytic pocket might inhibit a broad
spectrum of viruses in the nidovirus family. Interestingly, arteriviruses contain a nsp15 homolog,
named nsp11, that also encodes an endoribonuclease. This suggests that anti-viral therapeutics
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targeting EndoU activity may also be developed for arteriviruses, such as equine arteritis virus
(EAV) or porcine reproductive and respiratory system virus (PRRSV). Also live-attenuated
vaccines containing nsp11 catalytic mutations may also be developed. Further studies in
arteriviruses would also strengthen the conserved activity of EndoU and provide further
information for developing broad acting anti-virals or vaccines strategies. Overall, since the
catalytic histidines of EndoU are conserved in the nidovirus family, EndoU is a promising
candidate for the targeting of antiviral drugs and for generating live-attenuated vaccines.
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Figure 30. Protein Sequence Alignment of Nsp15/EndoU. Alignment of the protein sequence
of the endoribonuclease encoded by nsp15. Catalytic histidine residues are indicated by green
triangles. Coronaviruses that are aligned are MHV-A59 (AY910861), SARS-CoV (FJ882957.1),
MERS-CoV (KJ614529.1), SARS-2-CoV (MN985325.1), and PEDV-CoV (KF272920).
Alignment was performed with Clustal Omega, then visualized with ESPript3.
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Do Mutations in EndoU Reveal Unknown Mechanisms in CoV Replication?
Our study also raises interesting questions about CoV replication, particularly questions
associated with the formation and usage of the polyU extension during CoV RNA synthesis. The
first question is whether the polyU sequence is required for polyadenylation of the positive-sense
RNA. Studies from influenza virus revealed that a short polyU sequence within a unique RNA
stem loop mediates a stuttering mechanism used to polyadenylate the positive-sense RNA (Poon,
1999). In contrast, Peng et al implicate that CoVs utilize a non-canonical cytoplasmic
polyadenylation site to synthesize the positive-sense polyA tail (Peng et al., 2016). They
identified a conserved viral sequence on the positive sense RNA that could be bound by host
proteins including cytoplasmic polyadenylation element binding protein 1 (CPEB1)(Richter,
2007), a protein that mediates polyadenylation. In addition, CoV nsp8 has been demonstrated to
contain 3’ terminal adenylyltransferase (TAT) activity (Tvarogova et al., 2019). Nsp8 can
synthesize the polyA tail on the positive-sense RNA and having a complement negative-sense
RNA with a polyU extension greater than 5 U’s enhances the TAT activity. Since we observe
EndoU controlling the abundance of longer polyU sequences which stimulate IFN, it would be
interesting to determine if there is an “ideal length” of polyU sequences that lack immune
stimulation by MDA5 but promote TAT activity during addition of the polyA tail.
Another question arises about how the polyU tail is primed and generated. Our studies
reveals that the negative-sense RNA synthesis begins farther upstream within the polyA tail, thus
generating longer polyU extensions that are eventually cleaved by EndoU activity. In vitro
studies have shown that nsp8 and nsp7/8 complexes are capable of de novo initiation of RNA
synthesis. The hypothesis predicts that nsp7/8 either starts the RNA synthesis then allows the
nsp12 RdRp to finish the transcription or nsp7/8 generates RNA primers that are then utilized by
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nsp12 for RNA synthesis (Imbert et al., 2006; te Velthuis et al., 2012). Our data suggests that if a
primer is generated, it would most likely be a polyU sequence that would bind and interact with
the positive-sense polyA tail. This interaction would then prime the RNA for negative-sense
RNA synthesis. Another possibility is that a different primer or host miRNA is priming synthesis
inside the polyA tail, and EndoU activity removes this additional sequence. Since our RNAsequencing did not have sufficient reads over this region of the genome, it is unknown if there
are additional sequences attached to the polyU sequence in the absence of EndoU activity.
One caveat of the in vitro studies discussed above are that the assays are performed in the
absence of other viral replication complex proteins that may alter the binding, recognition, and
activity of the RNA processing proteins. Studies have shown protein-protein interactions
between nsp7, nsp8, nsp12, and nsp15, which may alter the activities of these proteins (Athmer
et al., 2017; Kirchdoerfer and Ward, 2019). While EndoU fully degrades PUN RNAs in vitro, the
cleavage activity may be more specific during viral infection due to interactions with other viral
proteins in the membrane-associated replicase complex (Gosert et al., 2002; Knoops et al., 2008).
While EndoU cleaves PUN RNA, there may also be other EndoU cleavage sites during CoV
infection that were not detected in this study. Further studies are needed to fully elucidate the
mechanisms CoVs use to alter and process viral RNAs.
Do Other Viruses Contain PolyU Sequences and Mechanisms to Prevent PolyU Detection?
Our studies raise the question of whether other viruses have mechanisms to limit polyUcontaining RNA from activating host PRRs. The Hepatitis C Virus (HCV) genome encodes a
long polyU stretch on the positive-sense RNA, but the polyU region is flanked by highly
structured RNA, which may limit immune stimulation (Schnell et al., 2012). This study found
that a 34 nucleotide polyU core sequence stimulates RIG-I signaling upon transfection of the
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RNA. This core sequence is part of the positive-sense 3’UTR and is a section of a polyU/UC
tract that is 100 nucleotides in length. The authors hypothesize that the polyU tract enhances
RIG-I binding to the RNA, but RIG-I must also bind with the triphosphate at the 5’-end of the
positive-sense RNA. This long-distance interaction may be possible though RNA folding and
secondary structure. Although HCV contains a long polyU region, the polyU is not located at the
terminal end of the RNA like the CoV polyU. Highly-structured RNA stem loops surround the
HCV polyU region, which may alter the polyU interactions with other RNAs and prevent
activation of dsRNA sensors by the polyU region (Adams et al., 2017). Furthermore, the HCV
replication complexes may hide and sequester the viral RNA from recognition by host sensors
(Neufeldt et al., 2016). So further studies are necessary to determine if the polyU region of the
HCV genome is immunostimulatory during viral infection.
Polioviruses prime replication of the negative-sense RNA with a polyU sequence
attached to VPg (Steil et al., 2010). The VPg protein is linked to a polyU sequence, which can
then act as a primer binding to the polyA tail to start RNA replication. After RNA transcription
and replication, the VPg linkage remains on the negative-sense RNA (Nomoto et al., 1977a),
leaving the virion RNA to be VPg-capped. The VPg-linkage may prevent the exposure of a
polyU structure to host sensors, thus preventing the polyU sequence from acting as a PAMP. The
polyU sequence attached to VPg is relatively short (< 5 nt), so it would be interesting to
determine if this polyU sequence is immunostimulatory. The positive-sense mRNA of PV also
contains a short polyU head, but lacks the VPg linkage (Nomoto et al., 1977b). A cleavage event
that removes the VPg linkage may be similar to EndoU cleavage of CoV polyU sequences and
prevent stimulation by the viral RNA.
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For influenza viruses, the polyU sequence on negative-sense RNA is essential for
polyadenylation because it is part of a unique stem-loop structure (Poon et al., 1999). This study
shows that the polyU sequence is necessary for influenza viruses to elongate the polyA tail on
the positive-sense RNA. The polyU stretch is not located at the terminal end of the 5’ UTR but is
located about 15 nucleotides from the 5’ end. The additional 15 nucleotides bind upstream of the
polyU tail forming a stem-loop structure that allows for the polyU stretch to be unpaired to act as
a ssRNA template. The additional RNA structure promoted by the 5’ terminal 15 nucleotides
may prevent the polyU sequence from influencing RNA secondary structure, thus preventing
immune activation by the RNA. Also it is worth noting that the negative-sense RNA is localized
to the nucleus and would not be exposed to cytoplasmic dsRNA sensors. These examples
illustrate that many viruses have polyU sequences that may potentially be PAMPs, and that each
virus may have evolved unique mechanisms or structures that limit their detection. Future work
would be necessary to determine if these polyU-containing sequences are in fact
immunostimulatory, particularly if you remove the different viral mechanisms that may alter the
polyU signal.
Does EndoU Function like Other Viral Ribonucleases?
Our study reveals that the coronavirus endoribonuclease activity is distinctly different
from three other previously documented viral ribonucleases. Influenza PA-X is an
endoribonuclease that selectively degrades host mRNA by hijacking host RNA splicing
machinery (Khaperskyy and McCormick, 2015). PA-X inhibits the translation of host proteins to
perturb the cell functions. PA-X selectively targets mRNA transcribed by RNA polymerase II in
the nucleus of the cell. Host exonuclease Xrn1 then completes the degradation of the mRNA to
prevent the mRNA from being translated into proteins. PA-X selectively targets specific host
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RNAs to promote the shutoff of host machinery, while allowing the cells to survive to produce
new virus particles.
Pestivirus RNAse E(rns) is an endoribonuclease that is secreted outside infected cells and
degrades extracellular viral RNAs to block innate immune activation (Mätzener et al., 2009).
This study determined that extracellular pestivirus dsRNA and ssRNA stimulates IFN signaling
in cells. RNAse E(rns) is a viral envelope glycoprotein that is secreted to degrade extracellular
RNAs, including the immunostimulatory pestivirus RNAs. Interestingly, viruses lacking RNAse
E enzymatic activity activate 5’-triphosphate IFN signaling, such as RIG-I. This result suggests
the RNA signal degraded by RNAse E differs from CoV EndoU as each virus activates a
different PRR in the absence of their endoribonuclease activity.
Lassa virus encodes an nucleoprotein (NP) with exonuclease activity that will specifically
degrade intracellular dsRNA (Hastie et al., 2011). The NP will block the activation of IRF3
signaling, which leads to IFN expression in the cells. The inhibition of IFN by NP has been
shown in overexpression studies, so further work is needed to determine the mechanism and
function of the NP exonuclease activity during viral infection.
While PA-X cleaves host RNAs to shut down the host cell functions, both RNAse E(rns)
and Lassa virus NP cleave viral RNAs that are hypothesized to be PAMPs. Our study reveals an
additional mechanism for a viral endoribonuclease to degrade a viral PAMP. Since the functions
of the viral nucleases are distinct, the development or evolution of these nucleases probably
occurred in distinct, separate events.
Are there any Antivirals that Target EndoU?
Although EndoU appears to be a promising target for inhibition of CoV replication, there
are no approved anti-viral drugs developed. One study has developed drugs targeting the
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enzymatic pocket of structurally similar endoribonucleases, XendoU and human PP11
endoribonucleases (Ragno et al., 2011). The small molecule inhibitors can block
endoribonuclease activity during in vitro cleavage assays, but it has yet to be determined if these
inhibitors are toxic in cell culture and could inhibit CoV EndoU activity. Ideally, these small
molecule inhibitors would block EndoU activity without blocking host ribonucleases. Since
Ragno et al. use structure-based drug screening, the specificity of the drugs to the XendoU
family may prevent off target effects in cells. Another study sought to determine if RNAse A
inhibitors would also inhibit EndoU activity in vitro and during viral infection (Ortiz-Alcantara
et al., 2010). They ultimately determined that some of these compounds could inhibit infectious
virus production, but also could have potential off-target effects due to the binding of these
compounds to host nucleases. One potential avenue may be to find polyU analogs that could
block EndoU activity. This could work as a competitive inhibitor for EndoU activity and
therefore induce an antiviral IFN response during wild-type CoV infection. Overall, future
studies are needed to investigate the efficacy of these XendoU drugs against CoV infections and
specifically EndoU activity. Future work may also use these identified small molecule inhibitors
as a base molecule in a drug development screen. The identified molecules would be modified to
better fit the CoV EndoU catalytic pocket to increase specificity and decrease off-target side
effects.
Can EndoU-Mutant Viruses be Used as Live-Attenuated Vaccines?
There are some studies that suggest that live-attenuated vaccines may be more efficacious
than inactivated or subunit vaccines (Buchan et al., 2018; Kwong et al., 2015). While many of
these vaccines are currently under development for CoVs, I hypothesize that a live-attenuated
vaccine may be the most effective for CoVs. One benefit for live-attenuated vaccines is that most
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do not require immune adjuvants. The viral replication stimulates a robust anti-viral immune
response, which promotes a long-lasting memory response. Another benefit for live-attenuated
vaccines is that active viral replication can produce viral quasi-species. Viral quasi-species are
virus populations that contain multiple diverse and unique mutations in the viral genome that
may alter protein sequences, particularly structural protein sequences (Toro et al., 2012;
Viehweger et al., 2019). The mutations in viral structural proteins may provide additional
epitopes for the stimulation of adaptive immune responses. While CoV quasi-species are viewed
as a mechanism for CoVs to evolve and escape neutralizing antibodies, a vaccine strain that
contained additional quasi-species epitopes would enhance the diversity of the host antibody
repertoire, thus stimulating a more diverse vaccine response. One shortcoming of live-attenuated
vaccines is that the vaccine must be maintained in a cold chain from production to delivery to
allow for the vaccine strain to infect and immunize the patient. Also, mutating the virus to
attenuate the virus in vivo may produce defects in viral replication. Replication defects would
produce vaccine strains that would be difficult to mass produce and distribute. EndoUmut CoVs
can replicate similar to wild-type virus in the absence of IFN signaling, therefore CoV vaccine
strains containing EndoU mutations should be able to be mass produced.
One issue that might arise during vaccination is the potential for lack of long-term
immunity generated by a CoV vaccine. Interestingly, wild-type CoV infections do not generate
robust adaptive memory B-cell responses in humans (Tang et al., 2011). When SARS-CoV
patients were analyzed 3 years post-infection, studies found that a majority of the patients lacked
neutralizing antibodies specific for SARS-CoV (Liu et al., 2011). The reasons for why wild-type
CoVs do not generate sustained immune memory responses are currently unknown. One
possibility is that the subversion of the early innate immune system by CoVs alters the adaptive
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immune responses. The early IFN induction seen during EndoU mutant virus infections could
then promote an appropriate anti-viral immune response and stimulate long-term immunity after
vaccination. Studies are needed to determine if CoV vaccines can sufficiently prime and
stimulate an effective immune response to properly immunize a population.
While the EndoUmut virus used in these studies contains one catalytic site mutation
(H262A), generating a live-attenuated mutant virus with only one mutation is not ideal.
Reversion mutations either in the catalytic site or satellite sites may convert the attenuated
mutant virus back into a virulent strain. In order to combat reversion, we can generate vaccine
strains that contain multiple mutations in multiple immune antagonists. EndoU has two catalytic
histidines, so mutating both catalytic histidine sites to alanine residues would decrease the
likelihood of the virus regaining EndoU activity. Additionally, Menachery et al have shown that
combining different IFN antagonist mutations can produce a reversion resistant CoV strain
(Menachery et al., 2018). This study compared the pathogenesis of an nsp16-mutant SARS-CoV
with a SAR-CoV mutant virus that contained a combination of mutations in nsp14 and nsp16.
The SARS-CoV that contained multiple mutations in IFN antagonists had enhanced attenuation
of viral replication and decreased pathogenesis in vivo compared to the nsp16 mutant virus.
Ideally, the goal is to develop a vaccine strategy in which multiple conserved immune
antagonists can be mutated to generate a vaccine strain. Since the mutations are conserved across
the CoV family, so the strategy could be applied to any CoV. Future studies are needed to
identify the constellation of IFN antagonists that should be targeted to generate the best vaccine.
Our study emphasizes that EndoU catalytic mutations should be included in these vaccine
strategies.
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Another potential problem with live-attenuated vaccines is RNA recombination with
another coronavirus that would allow a virus to regain virulence. Since CoVs are a relatively
large RNA genome (~30kb), CoV strains recombine viral genomes with other CoV strains
during in vivo co-infection. To make a stable live-attenuated vaccine, the virus should not be able
to recombine with other viruses. One study described a vaccine platform approach that generated
recombination-resistant coronaviruses (Graham et al., 2018). This platform takes advantage of
the multiple TRS locations of CoVs. By mutating each TRS sequence of SARS-CoV to a new
sequence, the mutant viruses were unable to recombine with wild-type SARS-CoV in vivo. Only
viruses that contained an entire set of matching TRSs could replicate, which prevents the vaccine
strain from gaining any genes from wild-type CoVs through recombination and producing a
viable virus.
Overall, mutations in EndoU present ideal mutations to be included in a set of mutations
for generating live-attenuated vaccines against CoVs. The EndoU sequence and function is
conserved among CoVs, so this vaccine strategy could be applied to any known and recently
emerged CoV. EndoUmut viruses can replicate similar to wild-type CoV in cell culture, but are
attenuated in vivo and provide a protective immune response.
Do CoVs have a Hierarchy of IFN Antagonists?
One interesting aspect of these studies is that EndoUmut viruses are attenuated during
infection of macrophages and in vivo, even though CoVs contain multiple IFN antagonists and
innate immune antagonists that are still intact. One theory is that CoVs have a hierarchy of IFN
antagonists. EndoU would be a vital IFN antagonist, since the virus lacking EndoU activity
cannot grow in IFN-response cells. Our data suggests that EndoU prevents the initial dsRNA
signal from forming and being detected by host sensors. Other IFN antagonists block pathways
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downstream of the dsRNA detection. EndoU may dampen the initial dsRNA signal before other
IFN antagonists have been effectively translated. This would grant the virus an advantage on
blocking the immune signaling pathways and keep the initial dsRNA signal at a minimum.
Another possibility is that the other IFN antagonists block different pathways. While EndoU
blocks one dsRNA signal that is detected by MDA5, other viral proteins will inhibit different
signals or pathways that will ultimately signal for an IFN response in the cells. Other IFN
antagonists may be necessary to completely shutoff IFN signaling early in infection. Even with
EndoU, wild-type MHV produces a low level of PUN RNAs, which may be necessary for viral
replication. EndoU may inhibit a significant portion of the signal but may not block all of the
dsRNA signal that activates host sensors. Then additional viral proteins are needed to block the
remaining dsRNA signaling or downstream IFN signaling that is stimulated in those cells.
Another hypothesis is that each IFN antagonist is necessary in specific cell types. We
have studied EndoU in macrophages and hepatocytes, showing the importance of EndoU activity
for IFN antagonism in these cells. In other cell types, such as lung or intestinal epithelial cells,
EndoU may play a lesser role and other IFN antagonists may be more crucial for inhibiting the
innate immune response. It would be interesting to determine if all EndoU inhibits IFN
expression in all infectable cell types or if other viral antagonists have a more profound effect in
other cell types, particularly the respiratory epithelium.
To study the potential hierarchy of IFN antagonists, studies should determine the function
of each IFN antagonist in combination with EndoU catalytic mutations. One hypothesis is that
EndoU inhibits the dsRNA signal that is necessary for activation of the immune pathways
modulated by other viral proteins. With a robust activation of host dsRNA sensors during
EndoUmut infections, we could study the effect of other CoV proteins on these pathways.
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What are the Potential Consequences of CoV Outbreaks?
The current outbreak of SARS-CoV-2 reveals the constant threat of the emergence of
CoVs from animal populations. Multiple studies have discovered many SARS-Like and MERSLike CoVs that exist in bats and other mammalian species around the world (Corman et al.,
2014; Hon et al., 2008; Lau et al., 2005; Menachery et al., 2015; Woo et al., 2018). These CoVs
have the potential to bind to human receptors and infect human cells (Wan et al., 2020). SARSCoV-2 is an example of one of these bat viruses emerging into humans. The current outbreak of
SARS-CoV-2 has a mortality rate of ~2%, highlighting the deadliness of this virus (Huang et al.,
2020; Munster et al., 2020; Zhou et al., 2020). The presence of similar CoVs that are lurking in
animal reservoirs leads to the potential for CoV pandemics to occur regularly. CoVs also have
the potential to spread quickly through respiratory transmission. The ever-looming threat of new
strains of CoVs to infect humans emphasizes the need for broadly acting anti-virals and
strategies to quickly generate vaccines.
The potential for CoV outbreaks is not limited to the human population. Multiple CoVs
have emerged in pigs and generated billions of dollars of annual loss in the porcine industry
(Langel et al., 2016). TGEV and PEDV emerged in the porcine population early in the 1990s, but
recently porcine delta coronavirus (PDCoV) caused a pandemic outbreak in 2012 among pig
farms in China and the USA (Zhang, 2016). More recently, researchers found that swine acute
diarrhea syndrome coronavirus (SADS-CoV) emerged from bats to infect pigs in China, again
causing significant loss in the pork industry (Cui et al., 2019). These outbreaks in the pig
populations highlight that CoVs have potential for pandemics to occur in multiple species, easily
jumping between host populations. Overall, the SARS-CoV-2 outbreak is the most recent CoV
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pandemic, but unfortunately many other CoVs are poised to shift into the human population and
cause significant disease.
Final Remarks
In summary, my work provides evidence for a novel mechanism used by the coronavirus
EndoU to cleave a viral RNA PAMP, which would otherwise be recognized by MDA5. These
studies identify a novel CoV PAMP, which we termed PUN RNA. EndoU cleaves the polyU
extension of the PUN RNA, which can decrease the ability of MDA5 to activate and stimulate
IFN signaling in cells. By removing EndoU activity, we can generate vaccine strains of CoVs
that can replicate in the absence of IFN signaling but will be severely attenuated in vivo. EndoU
therefore is a highly conserved virulence factor and a potential target for antiviral and vaccine
strategies.

REFERENCE LIST
Abraham, S., Kienzle, T.E., Lapps, W., Brian, D.A., 1990. Deduced sequence of the bovine
coronavirus spike protein and identification of the internal proteolytic cleavage site.
Virology 176, 296–301. https://doi.org/10.1016/0042-6822(90)90257-r
Adams, R.L., Pirakitikulr, N., Pyle, A.M., 2017. Functional RNA structures throughout the
Hepatitis C Virus genome. Curr. Opin. Virol. 24, 79–86.
https://doi.org/10.1016/j.coviro.2017.04.007
Angelini, M.M., Akhlaghpour, M., Neuman, B.W., Buchmeier, M.J., 2013. Severe acute
respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce doublemembrane vesicles. MBio 4, e00524-13. https://doi.org/10.1128/mBio.00524-13
Athmer, J., Fehr, A.R., Grunewald, M., Smith, E.C., Denison, M.R., Perlman, S., 2017. In Situ
Tagged nsp15 Reveals Interactions with Coronavirus Replication/Transcription ComplexAssociated Proteins. MBio 8. https://doi.org/10.1128/mBio.02320-16
Athmer, J., Fehr, A.R., Grunewald, M.E., Qu, W., Wheeler, D.L., Graepel, K.W.,
Channappanavar, R., Sekine, A., Aldabeeb, D.S., Gale Jr, M., Denison, M.R., Perlman, S.,
2018. Selective Packaging in Murine Coronavirus Promotes Virulence by Limiting Type I
Interferon Responses. MBio 9, e00272-18. https://doi.org/10.1128/mBio.00272-18
Baker, S.C., Shieh, C.K., Soe, L.H., Chang, M.F., Vannier, D.M., Lai, M.M., 1989. Identification
of a domain required for autoproteolytic cleavage of murine coronavirus gene A
polyprotein. J. Virol. 63, 3693–3699.
Baker, S.C., Yokomori, K., Dong, S., Carlisle, R., Gorbalenya, A.E., Koonin, E. V, Lai, M.M.,
1993. Identification of the catalytic sites of a papain-like cysteine proteinase of murine
coronavirus. J. Virol. 67, 6056–6063.
Bárcena, M., Oostergetel, G.T., Bartelink, W., Faas, F.G.A., Verkleij, A., Rottier, P.J.M., Koster,
A.J., Bosch, B.J., 2009. Cryo-electron tomography of mouse hepatitis virus: Insights into
the structure of the coronavirion. Proc. Natl. Acad. Sci. U. S. A. 106, 582–587.
https://doi.org/10.1073/pnas.0805270106
Baric, R.S., Stohlman, S.A., Lai, M.M., 1983. Characterization of replicative intermediate RNA
of mouse hepatitis virus: presence of leader RNA sequences on nascent chains. J. Virol. 48,
633–640.

125

126

Becares, M., Pascual-Iglesias, A., Nogales, A., Sola, I., Enjuanes, L., Zuñiga, S., 2016.
Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate
Immune Response. J. Virol. 90, 5399–414. https://doi.org/10.1128/JVI.03259-15
Belouzard, S., Chu, V.C., Whittaker, G.R., 2009. Activation of the SARS coronavirus spike
protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. U. S.
A. 106, 5871–5876. https://doi.org/10.1073/pnas.0809524106
Belouzard, S., Millet, J.K., Licitra, B.N., Whittaker, G.R., 2012. Mechanisms of coronavirus cell
entry mediated by the viral spike protein. Viruses 4, 1011–1033.
https://doi.org/10.3390/v4061011
Bhardwaj, K., Guarino, L., Kao, C.C., 2004. The Severe Acute Respiratory Syndrome
Coronavirus Nsp15 Protein Is an Endoribonuclease That Prefers Manganese as a Cofactor.
J. Virol. 78, 12218–12224. https://doi.org/10.1128/JVI.78.22.12218-12224.2004
Bhardwaj, K., Liu, P., Leibowitz, J.L., Kao, C.C., 2012. The Coronavirus Endoribonuclease
Nsp15 Interacts with Retinoblastoma Tumor Suppressor Protein. J. Virol. 86, 4294–4304.
https://doi.org/10.1128/JVI.07012-11
Bhardwaj, K., Palaninathan, S., Alcantara, J.M.O., Li Yi, L., Guarino, L., Sacchettini, J.C., Kao,
C.C., 2008. Structural and Functional Analyses of the Severe Acute Respiratory Syndrome
Coronavirus Endoribonuclease Nsp15. J. Biol. Chem. 283, 3655–3664.
https://doi.org/10.1074/jbc.M708375200
Bhardwaj, K., Sun, J., Holzenburg, A., Guarino, L.A., Kao, C.C., 2006. RNA Recognition and
Cleavage by the SARS Coronavirus Endoribonuclease. J. Mol. Biol. 361, 243–256.
https://doi.org/10.1016/j.jmb.2006.06.021
Bonin, M., Oberstrass, J., Lukacs, N., Ewert, K., Oesterschulze, E., Kassing, R., Nellen, W.,
2000. Determination of preferential binding sites for anti-dsRNA antibodies on doublestranded RNA by scanning force microscopy. RNA 6, 563–570.
https://doi.org/10.1017/s1355838200992318
Boscarino, J.A., Logan, H.L., Lacny, J.J., Gallagher, T.M., 2008. Envelope protein
palmitoylations are crucial for murine coronavirus assembly. J. Virol. 82, 2989–2999.
https://doi.org/10.1128/JVI.01906-07
Bosch, B.J., van der Zee, R., de Haan, C.A.M., Rottier, P.J.M., 2003. The coronavirus spike
protein is a class I virus fusion protein: structural and functional characterization of the
fusion core complex. J. Virol. 77, 8801–8811. https://doi.org/10.1128/jvi.77.16.88018811.2003

127

Bouvet, M., Lugari, A., Posthuma, C.C., Zevenhoven, J.C., Bernard, S., Betzi, S., Imbert, I.,
Canard, B., Guillemot, J.-C., Lécine, P., Pfefferle, S., Drosten, C., Snijder, E.J., Decroly,
E., Morelli, X., 2014. Coronavirus Nsp10, a critical co-factor for activation of multiple
replicative enzymes. J. Biol. Chem. 289, 25783–25796.
https://doi.org/10.1074/jbc.M114.577353
Bredenbeek, P.J., Pachuk, C.J., Noten, A.F., Charité, J., Luytjes, W., Weiss, S.R., Spaan, W.J.,
1990. The primary structure and expression of the second open reading frame of the
polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is
expressed by an efficient ribosomal frameshifting mechanism. Nucleic Acids Res. 18,
1825–1832. https://doi.org/10.1093/nar/18.7.1825
Brierley, I., Boursnell, M.E., Binns, M.M., Bilimoria, B., Blok, V.C., Brown, T.D., Inglis, S.C.,
1987. An efficient ribosomal frame-shifting signal in the polymerase-encoding region of
the coronavirus IBV. EMBO J. 6, 3779–3785.
Brocard, M., Ruggieri, A., Locker, N., 2017. m6A RNA methylation, a new hallmark in virushost interactions. J. Gen. Virol. 98, 2207–2214. https://doi.org/10.1099/jgv.0.000910
Brockway, S.M., Clay, C.T., Lu, X.T., Denison, M.R., 2003. Characterization of the expression,
intracellular localization, and replication complex association of the putative mouse
hepatitis virus RNA-dependent RNA polymerase. J. Virol. 77, 10515–10527.
https://doi.org/10.1128/jvi.77.19.10515-10527.2003
Brown, C.G., Nixon, K.S., Senanayake, S.D., Brian, D.A., 2007. An RNA stem-loop within the
bovine coronavirus nsp1 coding region is a cis-acting element in defective interfering RNA
replication. J. Virol. 81, 7716–7724. https://doi.org/10.1128/JVI.00549-07
Bruns, A.M., Leser, G.P., Lamb, R.A., Horvath, C.M., 2014. The innate immune sensor LGP2
activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly.
Mol. Cell 55, 771–781. https://doi.org/10.1016/j.molcel.2014.07.003
Buchan, S.A., Booth, S., Scott, A.N., Simmonds, K.A., Svenson, L.W., Drews, S.J., Russell,
M.L., Crowcroft, N.S., Loeb, M., Warshawsky, B.F., Kwong, J.C., 2018. Effectiveness of
Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013
Through 2015-2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization
Research Network (CIRN) Study. JAMA Pediatr. 172, e181514–e181514.
https://doi.org/10.1001/jamapediatrics.2018.1514
Budzilowicz, C.J., Wilczynski, S.P., Weiss, S.R., 1985. Three intergenic regions of coronavirus
mouse hepatitis virus strain A59 genome RNA contain a common nucleotide sequence that
is homologous to the 3’ end of the viral mRNA leader sequence. J. Virol. 53, 834–840.

128

Cao, J., Wu, C.-C., Lin, T.L., 2008. Turkey coronavirus non-structure protein NSP15--an
endoribonuclease. Intervirology 51, 342–351. https://doi.org/10.1159/000175837
Case, J.B., Li, Y., Elliott, R., Lu, X., Graepel, K.W., Sexton, N.R., Smith, E.C., Weiss, S.R.,
Denison, M.R., 2017. Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required
for Resistance to Innate Immunity. J. Virol. 92, e01531-17.
https://doi.org/10.1128/JVI.01531-17
Cervantes-Barragán, L., Kalinke, U., Züst, R., König, M., Reizis, B., López-Macías, C., Thiel,
V., Ludewig, B., 2009. Type I IFN-mediated protection of macrophages and dendritic cells
secures control of murine coronavirus infection. J. Immunol. 182, 1099–1106.
https://doi.org/10.4049/jimmunol.182.2.1099
Chang, C., Sue, S.-C., Yu, T., Hsieh, C.-M., Tsai, C.-K., Chiang, Y.-C., Lee, S., Hsiao, H., Wu,
W.-J., Chang, W.-L., Lin, C.-H., Huang, T., 2006. Modular organization of SARS
coronavirus nucleocapsid protein. J. Biomed. Sci. 13, 59–72.
https://doi.org/10.1007/s11373-005-9035-9
Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K., Perlman, S.,
2016. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses
Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19, 181–193.
https://doi.org/10.1016/j.chom.2016.01.007
Channappanavar, R., Fehr, A.R., Zheng, J., Wohlford-Lenane, C., Abrahante, J.E., Mack, M.,
Sompallae, R., McCray, P.B., Meyerholz, D.K., Perlman, S., 2019. IFN-I response timing
relative to virus replication determines MERS coronavirus infection outcomes. J. Clin.
Invest. 129, 3625–3639. https://doi.org/10.1172/JCI126363
Channappanavar, R., Perlman, S., 2020. Evaluation of Activation and Inflammatory Activity of
Myeloid Cells During Pathogenic Human Coronavirus Infection. Methods Mol. Biol. 2099,
195–204. https://doi.org/10.1007/978-1-0716-0211-9_15
Channappanavar, R., Perlman, S., 2017. Pathogenic human coronavirus infections: causes and
consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–
539. https://doi.org/10.1007/s00281-017-0629-x
Chatterjee, A., Johnson, M.A., Serrano, P., Pedrini, B., Joseph, J.S., Neuman, B.W., Saikatendu,
K., Buchmeier, M.J., Kuhn, P., Wüthrich, K., 2009. Nuclear magnetic resonance structure
shows that the severe acute respiratory syndrome coronavirus-unique domain contains a
macrodomain fold. J. Virol. 83, 1823–1836. https://doi.org/10.1128/JVI.01781-08
Chen, Y., Guo, D., 2016. Molecular mechanisms of coronavirus RNA capping and methylation.
Virol. Sin. 31, 3–11. https://doi.org/10.1007/s12250-016-3726-4

129

Chen, Y., Su, C., Ke, M., Jin, X., Xu, L., Zhang, Z., Wu, A., Sun, Y., Yang, Z., Tien, P., Ahola,
T., Liang, Y., Liu, X., Guo, D., 2011. Biochemical and structural insights into the
mechanisms of SARS coronavirus RNA ribose 2’-O-methylation by nsp16/nsp10 protein
complex. PLoS Pathog. 7, e1002294. https://doi.org/10.1371/journal.ppat.1002294
Clementz, M.A., Chen, Z., Banach, B.S., Wang, Y., Sun, L., Ratia, K., Baez-Santos, Y.M.,
Wang, J., Takayama, J., Ghosh, A.K., Li, K., Mesecar, A.D., Baker, S.C., 2010.
Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases.
J. Virol. 84, 4619–4629. https://doi.org/10.1128/JVI.02406-09
Clementz, M.A., Kanjanahaluethai, A., O’Brien, T.E., Baker, S.C., 2008. Mutation in murine
coronavirus replication protein nsp4 alters assembly of double membrane vesicles.
Virology 375, 118–129. https://doi.org/10.1016/j.virol.2008.01.018
Collins, A.R., Knobler, R.L., Powell, H., Buchmeier, M.J., 1982. Monoclonal antibodies to
murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for
attachment and cell--cell fusion. Virology 119, 358–371. https://doi.org/10.1016/00426822(82)90095-2
Comar, C.E., Goldstein, S.A., Li, Y., Yount, B., Baric, R.S., Weiss, S.R., 2019. Antagonism of
dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during
MERS Coronavirus Infection. MBio 10. https://doi.org/10.1128/mBio.00319-19
Corman, V.M., Ithete, N.L., Richards, L.R., Schoeman, M.C., Preiser, W., Drosten, C., Drexler,
J.F., 2014. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus
by characterization of a conspecific virus from an African bat. J. Virol. 88, 11297–11303.
https://doi.org/10.1128/JVI.01498-14
Cornelissen, L.A., Wierda, C.M., van der Meer, F.J., Herrewegh, A.A., Horzinek, M.C.,
Egberink, H.F., de Groot, R.J., 1997. Hemagglutinin-esterase, a novel structural protein of
torovirus. J. Virol. 71, 5277–5286.
Cornillez-Ty, C.T., Liao, L., Yates, J.R. 3rd, Kuhn, P., Buchmeier, M.J., 2009. Severe acute
respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein
complex involved in mitochondrial biogenesis and intracellular signaling. J. Virol. 83,
10314–10318. https://doi.org/10.1128/JVI.00842-09
Corse, E., Machamer, C.E., 2000. Infectious bronchitis virus E protein is targeted to the Golgi
complex and directs release of virus-like particles. J. Virol. 74, 4319–4326.
https://doi.org/10.1128/jvi.74.9.4319-4326.2000
Cruz, J.L.G., Becares, M., Sola, I., Oliveros, J.C., Enjuanes, L., Zúñiga, S., 2013.
Alphacoronavirus protein 7 modulates host innate immune response. J. Virol. 87, 9754–
9767. https://doi.org/10.1128/JVI.01032-13

130

Cruz, J.L.G., Sola, I., Becares, M., Alberca, B., Plana, J., Enjuanes, L., Zuñiga, S., 2011.
Coronavirus gene 7 counteracts host defenses and modulates virus virulence. PLoS Pathog.
7, e1002090–e1002090. https://doi.org/10.1371/journal.ppat.1002090
Cui, J., Li, F., Shi, Z.-L., 2019. Origin and evolution of pathogenic coronaviruses. Nat. Rev.
Microbiol. 17, 181–192. https://doi.org/10.1038/s41579-018-0118-9
de Haan, C.A.M., Rottier, P.J.M., 2005. Molecular interactions in the assembly of coronaviruses.
Adv. Virus Res. 64, 165–230. https://doi.org/10.1016/S0065-3527(05)64006-7
de Weerd, N.A., Nguyen, T., 2012. The interferons and their receptors--distribution and
regulation. Immunol. Cell Biol. 90, 483–491. https://doi.org/10.1038/icb.2012.9
Decroly, E., Debarnot, C., Ferron, F., Bouvet, M., Coutard, B., Imbert, I., Gluais, L.,
Papageorgiou, N., Sharff, A., Bricogne, G., Ortiz-Lombardia, M., Lescar, J., Canard, B.,
2011. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2’-Omethyltransferase nsp10/nsp16 complex. PLoS Pathog. 7, e1002059.
https://doi.org/10.1371/journal.ppat.1002059
Decroly, E., Imbert, I., Coutard, B., Bouvet, M., Selisko, B., Alvarez, K., Gorbalenya, A.E.,
Snijder, E.J., Canard, B., 2008. Coronavirus nonstructural protein 16 is a cap-0 binding
enzyme possessing (nucleoside-2’O)-methyltransferase activity. J. Virol. 82, 8071–8084.
https://doi.org/10.1128/JVI.00407-08
Dedeurwaerder, A., Olyslaegers, D.A.J., Desmarets, L.M.B., Roukaerts, I.D.M., Theuns, S.,
Nauwynck, H.J., 2014. ORF7-encoded accessory protein 7a of feline infectious peritonitis
virus as a counteragent against IFN-α-induced antiviral response. J. Gen. Virol. 95, 393–
402. https://doi.org/10.1099/vir.0.058743-0
Deng, X., Baker, S.C., 2018. An “Old” protein with a new story: Coronavirus endoribonuclease
is important for evading host antiviral defenses. Virology 517, 157–163.
https://doi.org/10.1016/j.virol.2017.12.024
Deng, X., Hackbart, M., Mettelman, R.C., O’Brien, A., Mielech, A.M., Yi, G., Kao, C.C., Baker,
S.C., 2017. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and
limits apoptosis in macrophages. Proc. Natl. Acad. Sci. U. S. A. 114.
https://doi.org/10.1073/pnas.1618310114
Deng, X., Mettelman, R.C., O’Brien, A., Thompson, J.A., O’Brien, T.E., Baker, S.C., 2019a.
Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the
Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis. J. Virol.
93, e02140-18. https://doi.org/10.1128/JVI.02140-18

131

Deng, X., van Geelen, A., Buckley, A.C., O’Brien, A., Pillatzki, A., Lager, K.M., Faaberg, K.S.,
Baker, S.C., 2019b. Coronavirus Endoribonuclease Activity in Porcine Epidemic Diarrhea
Virus Suppresses Type I and Type III Interferon Responses. J. Virol. 93, 1–15.
https://doi.org/10.1128/jvi.02000-18
Denison, M.R., Graham, R.L., Donaldson, E.F., Eckerle, L.D., Baric, R.S., 2011. Coronaviruses:
an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. 8,
270–279. https://doi.org/10.4161/rna.8.2.15013
Dong, B., Silverman, R.H., 1995. 2-5A-dependent RNase molecules dimerize during activation
by 2-5A. J. Biol. Chem. 270, 4133–4137. https://doi.org/10.1074/jbc.270.8.4133
Earnest, J.T., Hantak, M.P., Li, K., McCray Jr, P.B., Perlman, S., Gallagher, T., 2017. The
tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and
proteases. PLoS Pathog. 13, e1006546–e1006546.
https://doi.org/10.1371/journal.ppat.1006546
Eckerle, L.D., Lu, X., Sperry, S.M., Choi, L., Denison, M.R., 2007. High fidelity of murine
hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J. Virol. 81,
12135–12144. https://doi.org/10.1128/JVI.01296-07
Egloff, M.-P., Ferron, F., Campanacci, V., Longhi, S., Rancurel, C., Dutartre, H., Snijder, E.J.,
Gorbalenya, A.E., Cambillau, C., Canard, B., 2004. The severe acute respiratory syndromecoronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in
the RNA virus world. Proc. Natl. Acad. Sci. U. S. A. 101, 3792–3796.
https://doi.org/10.1073/pnas.0307877101
Fehr, A.R., Athmer, J., Channappanavar, R., Phillips, J.M., Meyerholz, D.K., Perlman, S., 2015.
The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis.
J. Virol. 89, 1523–1536. https://doi.org/10.1128/JVI.02596-14
Fehr, A.R., Perlman, S., 2015. Coronaviruses: an overview of their replication and pathogenesis.
Methods Mol. Biol. 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
Fischer, F., Stegen, C.F., Masters, P.S., Samsonoff, W.A., 1998. Analysis of constructed E gene
mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus
assembly. J. Virol. 72, 7885–7894.
Freundt, E.C., Yu, L., Park, E., Lenardo, M.J., Xu, X.-N., 2009. Molecular determinants for
subcellular localization of the severe acute respiratory syndrome coronavirus open reading
frame 3b protein. J. Virol. 83, 6631–6640. https://doi.org/10.1128/JVI.00367-09
Frieman, M., Ratia, K., Johnston, R.E., Mesecar, A.D., Baric, R.S., 2009. Severe acute
respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic
domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 83, 6689–705.
https://doi.org/10.1128/JVI.02220-08

132

Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P., Baric, R.S., 2007.
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by
sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane.
J. Virol. 81, 9812–24. https://doi.org/10.1128/JVI.01012-07
Gadlage, M.J., Sparks, J.S., Beachboard, D.C., Cox, R.G., Doyle, J.D., Stobart, C.C., Denison,
M.R., 2010. Murine hepatitis virus nonstructural protein 4 regulates virus-induced
membrane modifications and replication complex function. J. Virol. 84, 280–290.
https://doi.org/10.1128/JVI.01772-09
Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., Rosenblum, K., 2019. PKR: A Kinase to Remember.
Front. Mol. Neurosci. 11, 480. https://doi.org/10.3389/fnmol.2018.00480
Gallagher, T.M., Buchmeier, M.J., 2001. Coronavirus spike proteins in viral entry and
pathogenesis. Virology 279, 371–374. https://doi.org/10.1006/viro.2000.0757
García, M.A., Meurs, E.F., Esteban, M., 2007. The dsRNA protein kinase PKR: virus and cell
control. Biochimie 89, 799–811. https://doi.org/10.1016/j.biochi.2007.03.001
Glowacka, I., Bertram, S., Müller, M.A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I.,
Tsegaye, T.S., He, Y., Gnirss, K., Niemeyer, D., Schneider, H., Drosten, C., Pöhlmann, S.,
2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus
spike protein for membrane fusion and reduces viral control by the humoral immune
response. J. Virol. 85, 4122–4134. https://doi.org/10.1128/JVI.02232-10
Goebel, S.J., Hsue, B., Dombrowski, T.F., Masters, P.S., 2004a. Characterization of the RNA
components of a putative molecular switch in the 3’ untranslated region of the murine
coronavirus genome. J. Virol. 78, 669–682. https://doi.org/10.1128/jvi.78.2.669-682.2004
Goebel, S.J., Taylor, J., Masters, P.S., 2004b. The 3’ cis-acting genomic replication element of
the severe acute respiratory syndrome coronavirus can function in the murine coronavirus
genome. J. Virol. 78, 7846–7851. https://doi.org/10.1128/JVI.78.14.7846-7851.2004
Gorbalenya, A.E., Koonin, E. V, Donchenko, A.P., Blinov, V.M., 1989. Coronavirus genome:
prediction of putative functional domains in the non-structural polyprotein by comparative
amino acid sequence analysis. Nucleic Acids Res. 17, 4847–4861.
https://doi.org/10.1093/nar/17.12.4847
Gosert, R., Kanjanahaluethai, A., Egger, D., Bienz, K., Baker, S.C., 2002. RNA replication of
mouse hepatitis virus takes place at double-membrane vesicles. J. Virol. 76, 3697–708.
Graham, R.L., Deming, D.J., Deming, M.E., Yount, B.L., Baric, R.S., 2018. Evaluation of a
recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine
platform. Commun. Biol. 1, 179. https://doi.org/10.1038/s42003-018-0175-7

133

Graham, R.L., Sims, A.C., Brockway, S.M., Baric, R.S., Denison, M.R., 2005. The nsp2
replicase proteins of murine hepatitis virus and severe acute respiratory syndrome
coronavirus are dispensable for viral replication. J. Virol. 79, 13399–13411.
https://doi.org/10.1128/JVI.79.21.13399-13411.2005
Guan, B.-J., Wu, H.-Y., Brian, D.A., 2011. An optimal cis-replication stem-loop IV in the 5’
untranslated region of the mouse coronavirus genome extends 16 nucleotides into open
reading frame 1. J. Virol. 85, 5593–5605. https://doi.org/10.1128/JVI.00263-11
Guarino, L.A., Bhardwaj, K., Dong, W., Sun, J., Holzenburg, A., Kao, C., 2005. Mutational
Analysis of the SARS Virus Nsp15 Endoribonuclease: Identification of Residues Affecting
Hexamer Formation. J. Mol. Biol. 353, 1106–1117.
https://doi.org/10.1016/j.jmb.2005.09.007
Haddad, F., Qin, A.X., Giger, J.M., Guo, H., Baldwin, K.M., 2007. Potential pitfalls in the
accuracy of analysis of natural sense-antisense RNA pairs by reverse transcription-PCR.
BMC Biotechnol. 7, 21. https://doi.org/10.1186/1472-6750-7-21
Hantak, M.P., Qing, E., Earnest, J.T., Gallagher, T., 2019. Tetraspanins: Architects of Viral
Entry and Exit Platforms. J. Virol. 93, e01429-17. https://doi.org/10.1128/JVI.01429-17
Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., Saphire, E.O., 2011. Structure of
the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity
essential for immune suppression. Proc. Natl. Acad. Sci. U. S. A. 108, 2396–401.
https://doi.org/10.1073/pnas.1016404108
Heusipp, G., Grotzinger, C., Herold, J., Siddell, S.G., Ziebuhr, J., 1997. Identification and
subcellular localization of a 41 kDa, polyprotein 1ab processing product in human
coronavirus 229E-infected cells. J. Gen. Virol. 78 ( Pt 11, 2789–2794.
https://doi.org/10.1099/0022-1317-78-11-2789
Hoang, H.-D., Graber, T.E., Alain, T., 2018. Battling for Ribosomes: Translational Control at the
Forefront of the Antiviral Response. J. Mol. Biol. 430, 1965–1992.
https://doi.org/10.1016/j.jmb.2018.04.040
Hofmann, M.A., Brian, D.A., 1991. The 5’ end of coronavirus minus-strand RNAs contains a
short poly(U) tract. J Virol 65, 6331–6333.
Holmes, K. V, Williams, R.K., Cardellichio, C.B., Compton, S.R., Stephensen, C.B., Snyder,
S.W., Frana, M.F., Jiang, G.S., Smith, A., Knobler, R.L., 1990. Is the 110K glycoprotein
the only receptor for MHV and does its expression determine species specificity? Adv.
Exp. Med. Biol. 276, 37–44. https://doi.org/10.1007/978-1-4684-5823-7_6

134

Hon, C.-C., Lam, T.-Y., Shi, Z.-L., Drummond, A.J., Yip, C.-W., Zeng, F., Lam, P.-Y., Leung,
F.C.-C., 2008. Evidence of the recombinant origin of a bat severe acute respiratory
syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS
coronavirus. J. Virol. 82, 1819–1826. https://doi.org/10.1128/JVI.01926-07
Hou, Y., Ke, H., Kim, J., Yoo, D., Su, Y., Boley, P., Chepngeno, J., Vlasova, A.N., Saif, L.J.,
Wang, Q., 2019. Engineering a Live Attenuated Porcine Epidemic Diarrhea Virus Vaccine
Candidate via Inactivation of the Viral 2’-O-Methyltransferase and the Endocytosis Signal
of the Spike Protein. J. Virol. 93, e00406-19. https://doi.org/10.1128/JVI.00406-19
Huang, C., Lokugamage, K.G., Rozovics, J.M., Narayanan, K., Semler, B.L., Makino, S., 2011.
SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of
mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 7,
e1002433. https://doi.org/10.1371/journal.ppat.1002433
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020.
Articles Clinical features of patients infected with 2019 novel coronavirus in Wuhan ,
China 6736, 1–10. https://doi.org/10.1016/S0140-6736(20)30183-5
Hurst, K.R., Koetzner, C.A., Masters, P.S., 2009. Identification of in vivo-interacting domains of
the murine coronavirus nucleocapsid protein. J. Virol. 83, 7221–7234.
https://doi.org/10.1128/JVI.00440-09
Hussain, S., Gallagher, T., 2010. SARS-coronavirus protein 6 conformations required to impede
protein import into the nucleus. Virus Res. 153, 299–304.
https://doi.org/10.1016/j.virusres.2010.08.017
Imbert, I., Guillemot, J.-C., Bourhis, J.-M., Bussetta, C., Coutard, B., Egloff, M.-P., Ferron, F.,
Gorbalenya, A.E., Canard, B., 2006. A second, non-canonical RNA-dependent RNA
polymerase in SARS coronavirus. EMBO J. 25, 4933–4942.
https://doi.org/10.1038/sj.emboj.7601368
Isaacs, A., Lindenmann, J., 1957. Virus Interference I . The. Proc R Soc L. B Biol Sci 147, 258–
267.
Isaacs, A., Lindenmann, J., Valentine, R.C., 1957. Virus Interference II. Some Properties of
Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 268-273. Proc R Soc L. B Biol Sci 147,
268–273.
Ivanov, K. A., Hertzig, T., Rozanov, M., Bayer, S., Thiel, V., Gorbalenya, A.E., Ziebuhr, J.,
2004. Major genetic marker of nidoviruses encodes a replicative endoribonuclease. Proc.
Natl. Acad. Sci. 101, 12694–12699. https://doi.org/10.1073/pnas.0403127101
Ivanov, Konstantin A, Thiel, V., Dobbe, J.C., van der Meer, Y., Snijder, E.J., Ziebuhr, J., 2004.
Multiple enzymatic activities associated with severe acute respiratory syndrome
coronavirus helicase. J. Virol. 78, 5619–5632. https://doi.org/10.1128/JVI.78.11.56195632.2004

135

Ivanov, K.A., Ziebuhr, J., 2004. Human coronavirus 229E nonstructural protein 13:
characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5’triphosphatase activities. J. Virol. 78, 7833–7838. https://doi.org/10.1128/JVI.78.14.78337838.2004
Ivashkiv, L.B., Donlin, L.T., 2014. Regulation of type I interferon responses. Nat. Rev.
Immunol. 14, 36–49. https://doi.org/10.1038/nri3581
Joseph, J.S., Saikatendu, K.S., Subramanian, V., Neuman, B.W., Buchmeier, M.J., Stevens, R.C.,
Kuhn, P., 2007. Crystal structure of a monomeric form of severe acute respiratory
syndrome coronavirus endonuclease nsp15 suggests a role for hexamerization as an
allosteric switch. J. Virol. 81, 6700–8. https://doi.org/10.1128/JVI.02817-06
Kamitani, W., Huang, C., Narayanan, K., Lokugamage, K.G., Makino, S., 2009. A two-pronged
strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct.
Mol. Biol. 16, 1134–1140. https://doi.org/10.1038/nsmb.1680
Kamitani, W., Narayanan, K., Huang, C., Lokugamage, K., Ikegami, T., Ito, N., Kubo, H.,
Makino, S., 2006. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses
host gene expression by promoting host mRNA degradation. Proc. Natl. Acad. Sci. U. S. A.
103, 12885–12890. https://doi.org/10.1073/pnas.0603144103
Kang, H., Bhardwaj, K., Li, Y., Palaninathan, S., Sacchettini, J., Guarino, L., Leibowitz, J.L.,
Kao, C.C., 2007. Biochemical and Genetic Analyses of Murine Hepatitis Virus Nsp15
Endoribonuclease. J. Virol. 81, 13587–13597. https://doi.org/10.1128/JVI.00547-07
Kanjanahaluethai, A., Jukneliene, D., Baker, S.C., 2003. Identification of the murine coronavirus
MP1 cleavage site recognized by papain-like proteinase 2. J. Virol. 77, 7376–7382.
https://doi.org/10.1128/jvi.77.13.7376-7382.2003
Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A.,
Dermody, T.S., Fujita, T., Akira, S., 2008. Length-dependent recognition of doublestranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiationassociated gene 5. J. Exp. Med. 205, 1601–1610. https://doi.org/10.1084/jem.20080091
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung,
A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis E Sousa,
C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I
helicases in the recognition of RNA viruses. Nature 441, 101–105.
https://doi.org/10.1038/nature04734
Kazi, L., Lissenberg, A., Watson, R., de Groot, R.J., Weiss, S.R., 2005. Expression of
hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances
neurovirulence. J. Virol. 79, 15064–15073. https://doi.org/10.1128/JVI.79.24.1506415073.2005

136

Khaperskyy, D.A., McCormick, C., 2015. Timing Is Everything: Coordinated Control of Host
Shutoff by Influenza A Virus NS1 and PA-X Proteins. J. Virol. 89, 6528–6531.
https://doi.org/10.1128/jvi.00386-15
Kindler, E., Gil-Cruz, C., Spanier, J., Li, Y., Wilhelm, J., Rabouw, H.H., Z?st, R., Hwang, M.,
V?kovski, P., Stalder, H., Marti, S., Habjan, M., Cervantes-Barragan, L., Elliot, R., Karl,
N., Gaughan, C., van Kuppeveld, F.J.M., Silverman, R.H., Keller, M., Ludewig, B.,
Bergmann, C.C., Ziebuhr, J., Weiss, S.R., Kalinke, U., Thiel, V., 2017. Early
endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication.
PLOS Pathog. 13, e1006195. https://doi.org/10.1371/journal.ppat.1006195
Kindler, E., Thiel, V., 2014. To sense or not to sense viral RNA-essentials of coronavirus innate
immune evasion. Curr. Opin. Microbiol. 20, 69–75.
https://doi.org/10.1016/j.mib.2014.05.005
King, B., Potts, B.J., Brian, D.A., 1985. Bovine coronavirus hemagglutinin protein. Virus Res. 2,
53–59. https://doi.org/10.1016/0168-1702(85)90059-0
Kirchdoerfer, R.N., Ward, A.B., 2019. Structure of the SARS-CoV nsp12 polymerase bound to
nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342. https://doi.org/10.1038/s41467-01910280-3
Klausegger, A., Strobl, B., Regl, G., Kaser, A., Luytjes, W., Vlasak, R., 1999. Identification of a
coronavirus hemagglutinin-esterase with a substrate specificity different from those of
influenza C virus and bovine coronavirus. J. Virol. 73, 3737–3743.
Knoops, K., Kikkert, M., Worm, S.H.E. van den, Zevenhoven-Dobbe, J.C., van der Meer, Y.,
Koster, A.J., Mommaas, A.M., Snijder, E.J., 2008. SARS-Coronavirus Replication Is
Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum. PLoS
Biol. 6, e226. https://doi.org/10.1371/journal.pbio.0060226
Koetzner, C.A., Kuo, L., Goebel, S.J., Dean, A.B., Parker, M.M., Masters, P.S., 2010. Accessory
protein 5a is a major antagonist of the antiviral action of interferon against murine
coronavirus. J. Virol. 84, 8262–8274. https://doi.org/10.1128/JVI.00385-10
Kopecky-Bromberg, S.A., Martínez-Sobrido, L., Frieman, M., Baric, R.A., Palese, P., 2007.
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and
nucleocapsid proteins function as interferon antagonists. J. Virol. 81, 548–557.
https://doi.org/10.1128/JVI.01782-06
Krahling, V., Stein, D.A., Spiegel, M., Weber, F., Muhlberger, E., 2009. Severe Acute
Respiratory Syndrome Coronavirus Triggers Apoptosis via Protein Kinase R but Is
Resistant to Its Antiviral Activity. J. Virol. 83, 2298–2309.
https://doi.org/10.1128/jvi.01245-08

137

Krijnse-Locker, J., Ericsson, M., Rottier, P.J., Griffiths, G., 1994. Characterization of the
budding compartment of mouse hepatitis virus: evidence that transport from the RER to the
Golgi complex requires only one vesicular transport step. J. Cell Biol. 124, 55–70.
https://doi.org/10.1083/jcb.124.1.55
Kuhen, K.L., Samuel, C.E., 1997. Isolation of the interferon-inducible RNA-dependent protein
kinase Pkr promoter and identification of a novel DNA element within the 5’-flanking
region of human and mouse Pkr genes. Virology 227, 119–130.
https://doi.org/10.1006/viro.1996.8306
Kwong, J.C., Pereira, J.A., Quach, S., Pellizzari, R., Dusome, E., Russell, M.L., Hamid, J.S.,
Feinberg, Y., Winter, A.-L., Gubbay, J.B., Sirtonski, B., Moher, D., Sider, D., Finkelstein,
M., Loeb, M., Group, P.H.A. of C.I. of H.R.I.R.N. (PCIRN) P.D. and E., 2015.
Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools
(RELATIVES) cluster randomized trial: Pilot results from a household surveillance study
to assess direct and indirect protection from influenza vaccination. Vaccine 33, 4910–4915.
https://doi.org/10.1016/j.vaccine.2015.07.044
Lai, M.M., Baric, R.S., Brayton, P.R., Stohlman, S.A., 1984. Characterization of leader RNA
sequences on the virion and mRNAs of mouse hepatitis virus, a cytoplasmic RNA virus.
Proc. Natl. Acad. Sci. U. S. A. 81, 3626–3630. https://doi.org/10.1073/pnas.81.12.3626
Lai, M.M., Liao, C.L., Lin, Y.J., Zhang, X., 1994. Coronavirus: how a large RNA viral genome
is replicated and transcribed. Infect. Agents Dis. 3, 98–105.
Lai, M.M., Patton, C.D., Baric, R.S., Stohlman, S.A., 1983. Presence of leader sequences in the
mRNA of mouse hepatitis virus. J. Virol. 46, 1027–1033.
Lai, M.M., Patton, C.D., Stohlman, S.A., 1982. Replication of mouse hepatitis virus: negativestranded RNA and replicative form RNA are of genome length. J. Virol. 44, 487–492.
Laneve, P., Altieri, F., Fiori, M.E., Scaloni, A., Bozzoni, I., Caffarelli, E., 2003. Purification,
cloning, and characterization of XendoU, a novel endoribonuclease involved in processing
of intron-encoded small nucleolar RNAs in Xenopus laevis. J. Biol. Chem. 278, 13026–
13032. https://doi.org/10.1074/jbc.M211937200
Langel, S.N., Paim, F.C., Lager, K.M., Vlasova, A.N., Saif, L.J., 2016. Lactogenic immunity and
vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts.
Virus Res. 226, 93–107. https://doi.org/10.1016/j.virusres.2016.05.016
Lau, S.K.P., Woo, P.C.Y., Li, K.S.M., Huang, Y., Tsoi, H.-W., Wong, B.H.L., Wong, S.S.Y.,
Leung, S.-Y., Chan, K.-H., Yuen, K.-Y., 2005. Severe acute respiratory syndrome
coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102,
14040–14045. https://doi.org/10.1073/pnas.0506735102

138

Lauber, C., Ziebuhr, J., Junglen, S., Drosten, C., Zirkel, F., Nga, P.T., Morita, K., Snijder, E.J.,
Gorbalenya, A.E., 2012. Mesoniviridae: a proposed new family in the order Nidovirales
formed by a single species of mosquito-borne viruses. Arch. Virol. 157, 1623–1628.
https://doi.org/10.1007/s00705-012-1295-x
Lefkowitz, E.J., Dempsey, D.M., Hendrickson, R.C., Orton, R.J., Siddell, S.G., Smith, D.B.,
2018. Virus taxonomy: the database of the International Committee on Taxonomy of
Viruses (ICTV). Nucleic Acids Res. 46, D708–D717. https://doi.org/10.1093/nar/gkx932
Lei, Y., Moore, C.B., Liesman, R.M., O’Connor, B.P., Bergstralh, D.T., Chen, Z.J., Pickles, R.J.,
Ting, J.P.-Y., 2009. MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS
One 4, e5466–e5466. https://doi.org/10.1371/journal.pone.0005466
Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., Somasundaran, M.,
Sullivan, J.L., Luzuriaga, K., Greenough, T.C., Choe, H., Farzan, M., 2003. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–
454. https://doi.org/10.1038/nature02145
Lissenberg, A., Vrolijk, M.M., van Vliet, A.L.W., Langereis, M.A., de Groot-Mijnes, J.D.F.,
Rottier, P.J.M., de Groot, R.J., 2005. Luxury at a cost? Recombinant mouse hepatitis
viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in
vitro. J. Virol. 79, 15054–15063. https://doi.org/10.1128/JVI.79.24.15054-15063.2005
Liu, X., Fang, P., Fang, L., Hong, Y., Zhu, X., Wang, D., Peng, G., Xiao, S., 2019. Porcine
deltacoronavirus nsp15 antagonizes interferon-β production independently of its
endoribonuclease activity. Mol. Immunol. 114, 100–107.
https://doi.org/10.1016/j.molimm.2019.07.003
Liu, L., Xie, J., Sun, J., Han, Y., Zhang, C., Fan, H., Liu, Z., Qiu, Z., He, Y., Li, T., 2011.
Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory
syndrome coronavirus components and neutralizing activities in recovered patients. Scand.
J. Infect. Dis. 43, 515–521. https://doi.org/10.3109/00365548.2011.560184
Lu, Y., Lu, X., Denison, M.R., 1995. Identification and characterization of a serine-like
proteinase of the murine coronavirus MHV-A59. J. Virol. 69, 3554–3559.
Luytjes, W., Sturman, L.S., Bredenbeek, P.J., Charite, J., van der Zeijst, B.A., Horzinek, M.C.,
Spaan, W.J., 1987. Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and
identification of the trypsin cleavage site. Virology 161, 479–487.
https://doi.org/10.1016/0042-6822(87)90142-5
Masters, P.S., 2006. The Molecular Biology of Coronaviruses, in: Advances in Virus Research.
pp. 193–292. https://doi.org/10.1016/S0065-3527(06)66005-3

139

Mätzener, P., Magkouras, I., Rümenapf, T., Peterhans, E., Schweizer, M., 2009. The viral RNase
Erns prevents IFN type-I triggering by pestiviral single- and double-stranded RNAs. Virus
Res. 140, 15–23. https://doi.org/10.1016/j.virusres.2008.10.015
Menachery, V.D., Eisfeld, A.J., Schäfer, A., Josset, L., Sims, A.C., Proll, S., Fan, S., Li, C.,
Neumann, G., Tilton, S.C., Chang, J., Gralinski, L.E., Long, C., Green, R., Williams, C.M.,
Weiss, J., Matzke, M.M., Webb-Robertson, B.J., Schepmoes, A.A., Shukla, A.K., Metz,
T.O., Smith, R.D., Waters, K.M., Katze, M.G., Kawaoka, Y., Baric, R.S., 2014. Pathogenic
influenza viruses and coronaviruses utilize similar and contrasting approaches to control
interferon-stimulated gene responses. MBio 5, 1–11. https://doi.org/10.1128/mBio.0117414
Menachery, V.D., Gralinski, L.E., Mitchell, H.D., Dinnon, K.H., Leist, S.R., Yount, B.L.,
Graham, R.L., McAnarney, E.T., Stratton, K.G., Cockrell, A.S., Debbink, K., Sims, A.C.,
Waters, K.M., Baric, R.S., 2017. Middle East Respiratory Syndrome Coronavirus
Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis.
mSphere 2, e00346-17. https://doi.org/10.1128/mSphere.00346-17
Menachery, V.D., Gralinski, L.E., Mitchell, H.D., Dinnon, K.H., Leist, S.R., Yount, B.L.,
McAnarney, E.T., Graham, R.L., Waters, K.M., Baric, R.S., 2018. Combination attenuation
offers strategy for live-attenuated coronavirus vaccines. J. Virol. 92, e00710-18.
https://doi.org/10.1128/JVI.00710-18
Menachery, V.D., Yount Jr, B.L., Debbink, K., Agnihothram, S., Gralinski, L.E., Plante, J.A.,
Graham, R.L., Scobey, T., Ge, X.-Y., Donaldson, E.F., Randell, S.H., Lanzavecchia, A.,
Marasco, W.A., Shi, Z.-L., Baric, R.S., 2015. A SARS-like cluster of circulating bat
coronaviruses shows potential for human emergence. Nat. Med. 21, 1508–1513.
https://doi.org/10.1038/nm.3985
Mielech, A.M., Deng, X., Chen, Y., Kindler, E., Wheeler, D.L., Mesecar, A.D., Thiel, V.,
Perlman, S., Baker, S.C., 2015. Murine coronavirus ubiquitin-like domain is important for
papain-like protease stability and viral pathogenesis. J. Virol. 89, 4907–4917.
https://doi.org/10.1128/JVI.00338-15
Mielech, A.M., Kilianski, A., Baez-Santos, Y.M., Mesecar, A.D., Baker, S.C., 2014. MERSCoV papain-like protease has deISGylating and deubiquitinating activities. Virology 450–
451, 64–70. https://doi.org/10.1016/j.virol.2013.11.040
Millet, J.K., Whittaker, G.R., 2015. Host cell proteases: Critical determinants of coronavirus
tropism and pathogenesis. Virus Res. 202, 120–134.
https://doi.org/10.1016/j.virusres.2014.11.021
Minakshi, R., Padhan, K., Rani, M., Khan, N., Ahmad, F., Jameel, S., 2009. The SARS
Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligandindependent downregulation of the type 1 interferon receptor. PLoS One 4, e8342–e8342.
https://doi.org/10.1371/journal.pone.0008342

140

Minskaia, E., Hertzig, T., Gorbalenya, A.E., Campanacci, V., Cambillau, C., Canard, B.,
Ziebuhr, J., 2006. Discovery of an RNA virus 3’->5’ exoribonuclease that is critically
involved in coronavirus RNA synthesis. Proc. Natl. Acad. Sci. U. S. A. 103, 5108–5113.
https://doi.org/10.1073/pnas.0508200103
Molenkamp, R., Spaan, W.J., 1997. Identification of a specific interaction between the
coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal.
Virology 239, 78–86. https://doi.org/10.1006/viro.1997.8867
Müller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M., Aguet, M.,
1994. Functional role of type I and type II interferons in antiviral defense. Science 264,
1918–1921. https://doi.org/10.1126/science.8009221
Munster, V.J., Koopmans, M., van Doremalen, N., van Riel, D., de Wit, E., 2020. A Novel
Coronavirus Emerging in China - Key Questions for Impact Assessment. N. Engl. J. Med.
10.1056/NEJMp2000929. https://doi.org/10.1056/NEJMp2000929
Nedialkova, D.D., Ulferts, R., van den Born, E., Lauber, C., Gorbalenya, A.E., Ziebuhr, J.,
Snijder, E.J., 2009. Biochemical Characterization of Arterivirus Nonstructural Protein 11
Reveals the Nidovirus-Wide Conservation of a Replicative Endoribonuclease. J. Virol. 83,
5671–5682. https://doi.org/10.1128/jvi.00261-09
Neufeldt, C.J., Joyce, M.A., Van Buuren, N., Levin, A., Kirkegaard, K., Gale, M., Tyrrell,
D.L.J., Wozniak, R.W., 2016. The Hepatitis C Virus-Induced Membranous Web and
Associated Nuclear Transport Machinery Limit Access of Pattern Recognition Receptors to
Viral Replication Sites. PLoS Pathog. 12, 1–28.
https://doi.org/10.1371/journal.ppat.1005428
Neuman, B.W., Adair, B.D., Yoshioka, C., Quispe, J.D., Milligan, R.A., Yeager, M., Buchmeier,
M.J., 2006. Ultrastructure of SARS-CoV, FIPV, and MHV revealed by electron
cryomicroscopy. Adv. Exp. Med. Biol. 581, 181–185. https://doi.org/10.1007/978-0-38733012-9_31
Neuman, B.W., Chamberlain, P., Bowden, F., Joseph, J., 2014. Atlas of coronavirus replicase
structure. Virus Res. 194, 49–66. https://doi.org/10.1016/j.virusres.2013.12.004
Neuman, B.W., Kiss, G., Kunding, A.H., Bhella, D., Baksh, M.F., Connelly, S., Droese, B.,
Klaus, J.P., Makino, S., Sawicki, S.G., Siddell, S.G., Stamou, D.G., Wilson, I.A., Kuhn, P.,
Buchmeier, M.J., 2011. A structural analysis of M protein in coronavirus assembly and
morphology. J. Struct. Biol. 174, 11–22. https://doi.org/10.1016/j.jsb.2010.11.021
Nga, P.T., Parquet, M. del C., Lauber, C., Parida, M., Nabeshima, T., Yu, F., Thuy, N.T., Inoue,
S., Ito, T., Okamoto, K., Ichinose, A., Snijder, E.J., Morita, K., Gorbalenya, A.E., 2011.
Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the
largest RNA virus genomes. PLoS Pathog. 7, e1002215.
https://doi.org/10.1371/journal.ppat.1002215

141

Niemeyer, D., Mösbauer, K., Klein, E.M., Sieberg, A., Mettelman, R.C., Mielech, A.M.,
Dijkman, R., Baker, S.C., Drosten, C., Müller, M.A., 2018. The papain-like protease
determines a virulence trait that varies among members of the SARS-coronavirus species.
PLOS Pathog. 14, e1007296. https://doi.org/10.1371/journal.ppat.1007296
Niemeyer, D., Zillinger, T., Muth, D., Zielecki, F., Horvath, G., Suliman, T., Barchet, W.,
Weber, F., Drosten, C., Müller, M.A., 2013. Middle East respiratory syndrome coronavirus
accessory protein 4a is a type I interferon antagonist. J. Virol. 87, 12489–12495.
https://doi.org/10.1128/JVI.01845-13
Nieto-Torres, J.L., DeDiego, M.L., Verdiá-Báguena, C., Jimenez-Guardeño, J.M., Regla-Nava,
J.A., Fernandez-Delgado, R., Castaño-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella,
V.M., Enjuanes, L., 2014. Severe acute respiratory syndrome coronavirus envelope protein
ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 10, e1004077–
e1004077. https://doi.org/10.1371/journal.ppat.1004077
Nomoto, A., Detjen, B., Pozzatti, R., Wimmer, E., 1977a. The location of the polio genome
protein in viral RNAs and its implication for RNA synthesis. Nature 268, 208–213.
https://doi.org/10.1038/268208a0
Nomoto, A., Kitamura, N., Golini, F., Wimmer, E., 1977b. The 5’-terminal structures of
poliovirion RNA and poliovirus mRNA differ only in the genome-linked protein VPg.
Proc. Natl. Acad. Sci. U. S. A. 74, 5345–5349. https://doi.org/10.1073/pnas.74.12.5345
Ogden, K.M., Hu, L., Jha, B.K., Sankaran, B., Weiss, S.R., Silverman, R.H., Patton, J.T., Prasad,
B.V.V., 2015. Structural basis for 2’-5’-oligoadenylate binding and enzyme activity of a
viral RNase L antagonist. J. Virol. 89, 6633–6645. https://doi.org/10.1128/JVI.00701-15
Oostra, M., Hagemeijer, M.C., van Gent, M., Bekker, C.P.J., te Lintelo, E.G., Rottier, P.J.M., de
Haan, C.A.M., 2008. Topology and membrane anchoring of the coronavirus replication
complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning. J. Virol.
82, 12392–12405. https://doi.org/10.1128/JVI.01219-08
Ortiz-Alcantara, J., Bhardwaj, K., Palaninathan, S., Frieman, M., Baric, R.S., Kao, C.C., 2010.
Small molecule inhibitors of the SARS-CoV Nsp15 endoribonuclease. Virus Adapt. Treat.
2, 125–133. https://doi.org/10.2147/VAAT.S12733
Oudshoorn, D., Rijs, K., Limpens, R.W.A.L., Groen, K., Koster, A.J., Snijder, E.J., Kikkert, M.,
Bárcena, M., 2017. Expression and Cleavage of Middle East Respiratory Syndrome
Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That
Mimic Those Associated with Coronaviral RNA Replication. MBio 8, e01658-17.
https://doi.org/10.1128/mBio.01658-17
Park, J.-E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray Jr, P.B., Gallagher, T., 2016.
Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands
virus tropism. Proc. Natl. Acad. Sci. U. S. A. 113, 12262–12267.
https://doi.org/10.1073/pnas.1608147113

142

Pedersen, I.M., Cheng, G., Wieland, S., Volinia, S., Croce, C.M., Chisari, F. V, David, M., 2007.
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919–
922. https://doi.org/10.1038/nature06205
Peng, Y.H., Lin, C.H., Lin, C.N., Lo, C.Y., Tsai, T.L., Wu, H.Y., 2016. Characterization of the
role of hexamer AGUAAA and poly(A) tail in coronavirus polyadenylation. PLoS One 11,
7–13. https://doi.org/10.1371/journal.pone.0165077
Pfaller, C.K., Radeke, M.J., Cattaneo, R., Samuel, C.E., 2014. Measles virus C protein impairs
production of defective copyback double-stranded viral RNA and activation of protein
kinase R. J. Virol. 88, 456–468. https://doi.org/10.1128/JVI.02572-13
Pichlmair, A., Schulz, O., Tan, C.-P., Rehwinkel, J., Kato, H., Takeuchi, O., Akira, S., Way, M.,
Schiavo, G., Reis e Sousa, C., 2009. Activation of MDA5 Requires Higher-Order RNA
Structures Generated during Virus Infection. J. Virol. 83, 10761–10769.
https://doi.org/10.1128/jvi.00770-09
Poon, L.L., Pritlove, D.C., Fodor, E., Brownlee, G.G., 1999. Direct evidence that the poly(A) tail
of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion
RNA template. J. Virol. 73, 3473–6.
Posthuma, C.C., Nedialkova, D.D., Zevenhoven-Dobbe, J.C., Blokhuis, J.H., Gorbalenya, A.E.,
Snijder, E.J., 2006. Site-directed mutagenesis of the Nidovirus replicative endoribonuclease
NendoU exerts pleiotropic effects on the arterivirus life cycle. J. Virol. 80, 1653–1661.
https://doi.org/10.1128/JVI.80.4.1653-1661.2006
Prentice, E., McAuliffe, J., Lu, X., Subbarao, K., Denison, M.R., 2004. Identification and
Characterization of Severe Acute Respiratory Syndrome Coronavirus Replicase Proteins. J.
Virol. 78, 9977–9986. https://doi.org/10.1128/JVI.78.18.9977-9986.2004
Qing, E., Hantak, M., Perlman, S., Gallagher, T., 2020. Distinct Roles for Sialoside and Protein
Receptors in Coronavirus Infection. MBio 11, e02764-19.
https://doi.org/10.1128/mBio.02764-19
Raamsman, M.J., Locker, J.K., de Hooge, A., de Vries, A.A., Griffiths, G., Vennema, H.,
Rottier, P.J., 2000. Characterization of the coronavirus mouse hepatitis virus strain A59
small membrane protein E. J. Virol. 74, 2333–2342. https://doi.org/10.1128/jvi.74.5.23332342.2000
Rabouw, H.H., Langereis, M.A., Knaap, R.C.M., Dalebout, T.J., Canton, J., Sola, I., Enjuanes,
L., Bredenbeek, P.J., Kikkert, M., de Groot, R.J., van Kuppeveld, F.J.M., 2016. Middle
East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress
Responses. PLoS Pathog. 12, 1–26. https://doi.org/10.1371/journal.ppat.1005982

143

Ragno, R., Gioia, U., Laneve, P., Bozzoni, I., Mai, A., Caffarelli, E., 2011. Identification of
small-molecule inhibitors of the XendoU endoribonucleases family. ChemMedChem 6,
1797–1805. https://doi.org/10.1002/cmdc.201100281
Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H.W., Müller, M.A., Dijkman, R., Muth, D.,
Demmers, J.A.A., Zaki, A., Fouchier, R.A.M., Thiel, V., Drosten, C., Rottier, P.J.M.,
Osterhaus, A.D.M.E., Bosch, B.J., Haagmans, B.L., 2013. Dipeptidyl peptidase 4 is a
functional receptor for the emerging human coronavirus-EMC. Nature 495, 251–254.
https://doi.org/10.1038/nature12005
Ramanathan, A., Robb, G.B., Chan, S.-H., 2016. mRNA capping: biological functions and
applications. Nucleic Acids Res. 44, 7511–7526. https://doi.org/10.1093/nar/gkw551
Rebouillat, D., Marié, I., Hovanessian, A.G., 1998. Molecular cloning and characterization of
two related and interferon-induced 56-kDa and 30-kDa proteins highly similar to 2’-5’
oligoadenylate synthetase. Eur. J. Biochem. 257, 319–330. https://doi.org/10.1046/j.14321327.1998.2570319.x
Reikine, S., Nguyen, J.B., Modis, Y., 2014. Pattern Recognition and Signaling Mechanisms of
RIG-I and MDA5. Front. Immunol. 5, 342. https://doi.org/10.3389/fimmu.2014.00342
Ricagno, S., Egloff, M.P., Ulferts, R., Coutard, B., Nurizzo, D., Campanacci, V., Cambillau, C.,
Ziebuhr, J., Canard, B., 2006. Crystal structure and mechanistic determinants of SARS
coronavirus nonstructural protein 15 define an endoribonuclease family. Proc. Natl. Acad.
Sci. U. S. A. 103, 11892–11897. https://doi.org/10.1073/pnas.0601708103
Richter, J.D., 2007. CPEB: a life in translation. Trends Biochem. Sci. 32, 279–285.
https://doi.org/10.1016/j.tibs.2007.04.004
Roth-Cross, J.K., Bender, S.J., Weiss, S.R., 2008. Murine Coronavirus Mouse Hepatitis Virus Is
Recognized by MDA5 and Induces Type I Interferon in Brain Macrophages/Microglia. J.
Virol. 82, 9829–9838. https://doi.org/10.1128/jvi.01199-08
Sadler, A.J., Williams, B.R.G., 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol.
8, 559–568. https://doi.org/10.1038/nri2314
Saito, T., Gale Jr, M., 2008. Differential recognition of double-stranded RNA by RIG-I-like
receptors in antiviral immunity. J. Exp. Med. 205, 1523–1527.
https://doi.org/10.1084/jem.20081210
Sawicki, S.G., Sawicki, D.L., Siddell, S.G., 2007. A contemporary view of coronavirus
transcription. J. Virol. 81, 20–29. https://doi.org/10.1128/JVI.01358-06
Schickli, J.H., Zelus, B.D., Wentworth, D.E., Sawicki, S.G., Holmes, K. V, 1997. The murine
coronavirus mouse hepatitis virus strain A59 from persistently infected murine cells
exhibits an extended host range. J. Virol. 71, 9499–9507.

144

Schiller, J.J., Kanjanahaluethai, A., Baker, S.C., 1998. Processing of the coronavirus MHV-JHM
polymerase polyprotein: Identification of precursors and proteolytic products spanning 400
kilodaltons of ORF1a. Virology 242, 288–302. https://doi.org/10.1006/viro.1997.9010
Schnell, G., Loo, Y.M., Marcotrigiano, J., Gale, M., 2012. Uridine Composition of the PolyU/UC Tract of HCV RNA Defines Non-Self Recognition by RIG-I. PLoS Pathog. 8.
https://doi.org/10.1371/journal.ppat.1002839
Schonborn, J., Oberstraß, J., Breyel, E., Tittgen, J., Schumacher, J., Lukacs, N., 1991.
Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude
nucleic acid extracts. Nucleic Acids Res. 19, 2993–3000.
https://doi.org/10.1093/nar/19.11.2993
Sethna, P.B., Hofmann, M.A., Brian, D.A., 1991. Minus-strand copies of replicating coronavirus
mRNAs contain antileaders. J. Virol. 65, 320–5.
Shi, S.T., Schiller, J.J., Kanjanahaluethai, A., Baker, S.C., Oh, J.W., Lai, M.M., 1999.
Colocalization and membrane association of murine hepatitis virus gene 1 products and De
novo-synthesized viral RNA in infected cells. J. Virol. 73, 5957–69.
Silverman, R.H., 2007. Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L
during the interferon antiviral response. J. Virol. 81, 12720–12729.
https://doi.org/10.1128/JVI.01471-07
Silverman, R.H., Weiss, S.R., 2014. Viral phosphodiesterases that antagonize double-stranded
RNA signaling to RNase L by degrading 2-5A. J. Interferon Cytokine Res. 34, 455–463.
https://doi.org/10.1089/jir.2014.0007
Snijder, E.J., Bredenbeek, P.J., Dobbe, J.C., Thiel, V., Ziebuhr, J., Poon, L.L.M., Guan, Y.,
Rozanov, M., Spaan, W.J.M., Gorbalenya, A.E., 2003. Unique and conserved features of
genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group
2 lineage. J. Mol. Biol. 331, 991–1004. https://doi.org/10.1016/S0022-2836(03)00865-9
Sola, I., Almazan, F., Zuniga, S., Enjuanes, L., 2015. Continuous and Discontinuous RNA
Synthesis in Coronaviruses. Annu. Rev. Virol. 2, 265–288.
https://doi.org/10.1146/annurev-virology-100114-055218
Son, K.-N., Liang, Z., Lipton, H.L., 2015. Double-Stranded RNA Is Detected by
Immunofluorescence Analysis in RNA and DNA Virus Infections, Including Those by
Negative-Stranded RNA Viruses. J. Virol. 89, 9383–9392.
https://doi.org/10.1128/JVI.01299-15
Steil, B.P., Kempf, B.J., Barton, D.J., 2010. Poly(A) at the 3’ End of Positive-Strand RNA and
VPg-Linked Poly(U) at the 5’ End of Negative-Strand RNA Are Reciprocal Templates
during Replication of Poliovirus RNA. J. Virol. 84, 2843–2858.
https://doi.org/10.1128/jvi.02620-08

145

Stohlman, S.A., Baric, R.S., Nelson, G.N., Soe, L.H., Welter, L.M., Deans, R.J., 1988. Specific
interaction between coronavirus leader RNA and nucleocapsid protein. J. Virol. 62, 4288–
4295.
Stohlman, S.A., Lai, M.M., 1979. Phosphoproteins of murine hepatitis viruses. J. Virol. 32, 672–
675.
Sturman, L.S., Holmes, K. V, Behnke, J., 1980. Isolation of coronavirus envelope glycoproteins
and interaction with the viral nucleocapsid. J. Virol. 33, 449–462.
Sun, L., Xing, Y., Chen, X., Zheng, Y., Yang, Y., Nichols, D.B., Clementz, M.A., Banach, B.S.,
Li, K., Baker, S.C., Chen, Z., 2012. Coronavirus papain-like proteases negatively regulate
antiviral innate immune response through disruption of STING-mediated signaling. PLoS
One 7, e30802–e30802. https://doi.org/10.1371/journal.pone.0030802
Sun, Y., Ke, H., Han, M., Chen, N., Fang, W., Yoo, D., 2016. Nonstructural Protein 11 of
Porcine Reproductive and Respiratory Syndrome Virus Suppresses Both MAVS and RIG-I
Expression as One of the Mechanisms to Antagonize Type I Interferon Production. PLoS
One 11, e0168314. https://doi.org/10.1371/journal.pone.0168314
Sweeney, T.K., Tate, A., Fink, G.R., 1976. A study of the transmission and structure of double
stranded RNAs associated with the killer phenomenon in Saccharomyces cerevisiae.
Genetics 84, 27–42.
Tanaka, T., Kamitani, W., DeDiego, M.L., Enjuanes, L., Matsuura, Y., 2012. Severe acute
respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a
specific translational shutoff of host mRNA. J. Virol. 86, 11128–11137.
https://doi.org/10.1128/JVI.01700-12
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H.,
Richardus, J.H., Liu, W., Cao, W.-C., 2011. Lack of peripheral memory B cell responses in
recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J.
Immunol. 186, 7264–7268. https://doi.org/10.4049/jimmunol.0903490
Taylor, D.R., Tian, B., Romano, P.R., Hinnebusch, A.G., Lai, M.M., Mathews, M.B., 2001.
Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with
autophosphorylation sites in the RNA-binding domain. J. Virol. 75, 1265–1273.
https://doi.org/10.1128/JVI.75.3.1265-1273.2001
te Velthuis, A.J.W., van den Worm, S.H.E., Snijder, E.J., 2012. The SARS-coronavirus
nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo
initiation and primer extension. Nucleic Acids Res. 40, 1737–1747.
https://doi.org/10.1093/nar/gkr893

146

Temizoz, B., Kuroda, E., Ishii, K.J., 2018. Combination and inducible adjuvants targeting
nucleic acid sensors. Curr. Opin. Pharmacol. 41, 104–113.
https://doi.org/10.1016/j.coph.2018.05.003
Tooze, J., Tooze, S., Warren, G., 1984. Replication of coronavirus MHV-A59 in sac- cells:
determination of the first site of budding of progeny virions. Eur. J. Cell Biol. 33, 281–293.
Toro, H., van Santen, V.L., Jackwood, M.W., 2012. Genetic diversity and selection regulates
evolution of infectious bronchitis virus. Avian Dis. 56, 449–455.
https://doi.org/10.1637/10072-020212-Review.1
Tortorici, M.A., Veesler, D., 2019. Structural insights into coronavirus entry. Adv. Virus Res.
105, 93–116. https://doi.org/10.1016/bs.aivir.2019.08.002
Totura, A.L., Baric, R.S., 2012. SARS coronavirus pathogenesis: host innate immune responses
and viral antagonism of interferon. Curr. Opin. Virol. 2, 264–75.
https://doi.org/10.1016/j.coviro.2012.04.004
Trinchieri, G., 2010. Type I interferon: friend or foe? J. Exp. Med. 207, 2053–2063.
https://doi.org/10.1084/jem.20101664
Tvarogova, J., Madhugiri, R., Bylapudi, G., Ferguson, L.J., Karl, N., Ziebuhr, J., 2019.
Identification and Characterization of a Human Coronavirus 229E Nonstructural Protein 8Associated RNA 3’-Terminal Adenylyltransferase Activity. J. Virol. 93.
https://doi.org/10.1128/JVI.00291-19
Uchikawa, E., Lethier, M., Malet, H., Brunel, J., Gerlier, D., Cusack, S., 2016. Structural
Analysis of dsRNA Binding to Anti-viral Pattern Recognition Receptors LGP2 and MDA5.
Mol. Cell 62, 586–602. https://doi.org/10.1016/j.molcel.2016.04.021
van der Hoeven, B., Oudshoorn, D., Koster, A.J., Snijder, E.J., Kikkert, M., Bárcena, M., 2016.
Biogenesis and architecture of arterivirus replication organelles. Virus Res. 220, 70–90.
https://doi.org/10.1016/j.virusres.2016.04.001
van der Meer, Y., Snijder, E.J., Dobbe, J.C., Schleich, S., Denison, M.R., Spaan, W.J., Locker,
J.K., 1999. Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis
indicates a role for late endosomes in viral replication. J. Virol. 73, 7641–7657.
Verdiá-Báguena, C., Nieto-Torres, J.L., Alcaraz, A., DeDiego, M.L., Torres, J., Aguilella, V.M.,
Enjuanes, L., 2012. Coronavirus E protein forms ion channels with functionally and
structurally-involved membrane lipids. Virology 432, 485–494.
https://doi.org/10.1016/j.virol.2012.07.005

147

Viehweger, A., Krautwurst, S., Lamkiewicz, K., Madhugiri, R., Ziebuhr, J., Hölzer, M., Marz,
M., 2019. Direct RNA nanopore sequencing of full-length coronavirus genomes provides
novel insights into structural variants and enables modification analysis. Genome Res. 29,
1545–1554. https://doi.org/10.1101/gr.247064.118
Walls, A.C., Xiong, X., Park, Y.-J., Tortorici, M.A., Snijder, J., Quispe, J., Cameroni, E., Gopal,
R., Dai, M., Lanzavecchia, A., Zambon, M., Rey, F.A., Corti, D., Veesler, D., 2019.
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion.
Cell 176, 1026-1039.e15. https://doi.org/10.1016/j.cell.2018.12.028
Wan, Y., Shang, J., Graham, R., Baric, R.S., Li, F., 2020. Receptor recognition by novel
coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J.
Virol. JVI.00127-20. https://doi.org/10.1128/JVI.00127-20
Wathelet, M.G., Orr, M., Frieman, M.B., Baric, R.S., 2007. Severe acute respiratory syndrome
coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated
strain. J. Virol. 81, 11620–11633. https://doi.org/10.1128/JVI.00702-07
Weber, F., Wagner, V., Rasmussen, S.B., Hartmann, R., Paludan, S.R., 2006. Double-stranded
RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable
amounts by negative-strand RNA viruses. J. Virol. 80, 5059–5064.
https://doi.org/10.1128/JVI.80.10.5059-5064.2006
Weischenfeldt, J., Porse, B., 2008. Bone Marrow-Derived Macrophages (BMM): Isolation and
Applications. CSH Protoc. 2008, pdb.prot5080-pdb.prot5080.
https://doi.org/10.1101/pdb.prot5080
Woo, P.C.Y., Lau, S.K.P., Chen, Y., Wong, E.Y.M., Chan, K.-H., Chen, H., Zhang, L., Xia, N.,
Yuen, K.-Y., 2018. Rapid detection of MERS coronavirus-like viruses in bats: pote1ntial
for tracking MERS coronavirus transmission and animal origin. Emerg. Microbes Infect. 7,
18. https://doi.org/10.1038/s41426-017-0016-7
Xu, X., Zhai, Y., Sun, F., Lou, Z., Su, D., Xu, Y., Zhang, R., Joachimiak, A., Zhang, X.C.,
Bartlam, M., Rao, Z., 2006. New Antiviral Target Revealed by the Hexameric Structure of
Mouse Hepatitis Virus Nonstructural Protein nsp15. J. Virol. 80, 7909–7917.
https://doi.org/10.1128/jvi.00525-06
Yang, D., Leibowitz, J.L., 2015. The structure and functions of coronavirus genomic 3’ and 5’
ends. Virus Res. 206, 120–133. https://doi.org/10.1016/j.virusres.2015.02.025
Yang, X., Chen, X., Bian, G., Tu, J., Xing, Y., Wang, Y., Chen, Z., 2014. Proteolytic processing,
deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome
coronavirus papain-like protease. J. Gen. Virol. 95, 614–626.
https://doi.org/10.1099/vir.0.059014-0

148

Ye, Y., Hogue, B.G., 2007. Role of the coronavirus E viroporin protein transmembrane domain
in virus assembly. J. Virol. 81, 3597–3607. https://doi.org/10.1128/JVI.01472-06
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira,
K., Akira, S., Fujita, T., 2004. The RNA helicase RIG-I has an essential function in doublestranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730–737.
https://doi.org/10.1038/ni1087
Zhai, Y., Sun, F., Li, X., Pang, H., Xu, X., Bartlam, M., Rao, Z., 2005. Insights into SARS-CoV
transcription and replication from the structure of the nsp7-nsp8 hexadecamer. Nat. Struct.
Mol. Biol. 12, 980–986. https://doi.org/10.1038/nsmb999
Zhang, J., 2016. Porcine deltacoronavirus: Overview of infection dynamics, diagnostic methods,
prevalence and genetic evolution. Virus Res. 226, 71–84.
https://doi.org/10.1016/j.virusres.2016.05.028
Zhang, L., Li, L., Yan, L., Ming, Z., Jia, Z., Lou, Z., Rao, Z., 2018. Structural and Biochemical
Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory
Syndrome Coronavirus. J. Virol. 92, e00893-18. https://doi.org/10.1128/JVI.00893-18
Zhao, L., Jha, B.K., Wu, A., Elliott, R., Ziebuhr, J., Gorbalenya, A.E., Silverman, R.H., Weiss,
S.R., 2012. Antagonism of the interferon-induced OAS-RNase L pathway by murine
coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host
Microbe 11, 607–16. https://doi.org/10.1016/j.chom.2012.04.011
Zhou, H., Zhao, J., Perlman, S., 2010. Autocrine interferon priming in macrophages but not
dendritic cells results in enhanced cytokine and chemokine production after coronavirus
infection. MBio 1, e00219-10. https://doi.org/10.1128/mBio.00219-10
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B.,
Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y.,
Shen, X.-R., Wang, X., Zheng, X.-S., Zhao, K., Chen, Q.-J., Deng, F., Liu, L.-L., Yan, B.,
Zhan, F.-X., Wang, Y.-Y., Xiao, G.-F., Shi, Z.-L., 2020. A pneumonia outbreak associated
with a new coronavirus of probable bat origin. Nature 10.1038/s41586-020-2012–7.
https://doi.org/10.1038/s41586-020-2012-7
Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B.W., Ziebuhr, J., Szretter,
K.J., Baker, S.C., Barchet, W., Diamond, M.S., Siddell, S.G., Ludewig, B., Thiel, V., 2011.
Ribose 2’-O-methylation provides a molecular signature for the distinction of self and nonself mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12, 137–143.
https://doi.org/10.1038/ni.1979

VITA
Matthew Steven Hackbart was born in Woodstock, Illinois on June 25th, 1989 to Robert
and Patricia Hackbart. He attended Beloit College in Beloit, Wisconsin, where he earned a
Bachelor of Science degree in Biochemistry and Psychology in May 2012. During his
undergraduate studies, Matthew worked with John Jungck, Ph.D. designing teaching programs
for mathematical biology. Upon graduation, Matthew worked as a Microbiology I at Now Foods
Inc. in Glen Elyn, Illinois until 2014.
In August 2014, Matthew enrolled into the Interdisciplinary Program in Biomedical
Sciences at Loyola University and joined the Department of Microbiology and Immunology. He
completed his doctoral work in the laboratory of Susan C. Baker, Ph.D., where he focused on
determining the mechanisms for a coronavirus endoribonuclease to antagonize innate immune
signaling. Matthew’s work was supported by an NIH RO1 awarded to SC Baker, Ph.D. and an
NIH T32 Training Grant in Experimental Immunology awarded to KL Knight, Ph.D. Matthew
will continue his research endeavors as a Postdoctoral Fellow in the laboratory of CB Lopez,
Ph.D. at Washington University in St. Louis, Missouri. There Matthew will study the interactions
of innate immune pathways and respiratory virus RNAs.

149

